



Cancer in South Australia 2017

with projections to 2020

February 2020

South Australian Cancer Registry,
Wellbeing SA



Government
of South Australia

Wellbeing SA

Published February 2020
© Wellbeing SA

ISSN 0819-3835

Suggested citation: Cancer in South Australia 2017 – with projections to 2020. Adelaide: South Australian Cancer Registry, Prevention and Population Health Directorate, Wellbeing SA, Government of South Australia, 2020.

Acknowledgements

The South Australian Cancer Registry (SACR), operating within the Prevention and Population Health Directorate of Wellbeing SA, relies on the cooperation of a large number of agencies and clinicians to provide it with the vital information required to succeed.

The SACR would like to thank the health information managers, clinicians, hospitals, radiotherapy centres and pathology laboratories for their continued support of the registry. The valued support of the Registrar of Births, Deaths and Marriages is also appreciated. The interactions between the registry and its stakeholders are very positive and greatly appreciated.

The dedicated work of the staff in the registry is gratefully acknowledged:

Rhonda Pfeiffer - Registrar

Cancer Registry officers:

Sonya Clarke

Elizabeth Jarosz

Lesley Milliken

Teresa Molik

Kylie Parrott

Anna-Liisa Skene

Debra Whyatt

Cathy Wiesner

Stephen Corns – Information Systems Coordinator

Iordan Kostadinov - Epidemiologist

Britt Catcheside – Epidemiologist

Ben Krumeich – Epidemiologist

Suresh Joshi – Epidemiologist

Dr Rebecca Nolan - Manager, Population Health Survey

Rosie Meng – Epidemiologist

Kamalesh Venugopal – Head Statistician

Helen Thomas – Manager, Data Warehouse

Professor Katina D'Onise – Director, Prevention and Population Health

Table of Contents

Acknowledgements.....	5
Table of Contents	6
List of Tables	7
List of Figures	7
Executive Summary.....	8
1. Introduction.....	9
1.1 Annual Report.....	9
1.2 The Collection.....	9
1.3 Data Sources	10
1.4 Quality Assurance.....	11
1.5 The Report.....	11
2. Most Common Cancers in 2017	12
2.1 Incidence.....	12
2.2 Mortality	18
3. Trends in Cancer Incidence and Mortality.....	24
3.1 Incidence.....	24
3.2 Mortality	25
3.3 Projections	25
3.4 Most Common Cancers.....	27
Appendix 1 Methods and Terminology	32
Appendix 2 List of Site-Specific Tables	35
Appendix 3 Quality Measures	65

List of Tables

Table 2.1	South Australian persons: incidence, age-standardised rates, lifetime risk, leading cancer types, 2017	14
Table 2.2	South Australian males: incidence, age-standardised rates, lifetime risk, leading cancer types, 2017	15
Table 2.3	South Australian females: incidence, age-standardised rates, lifetime risk, leading cancer types, 2017	16
Table 2.4	South Australian persons: mortality, age-standardised rates, lifetime risk, leading cancer types, 2017	20
Table 2.5	South Australian males: mortality, age-standardised rates, lifetime risk, leading cancer types, 2017	21
Table 2.6	South Australian females: mortality, age-standardised rates, lifetime risk, leading cancer types, 2017	22
Table 3.1	Male cancer incidence, mortality rates (2017) and projections (2018-2020), South Australia	26
Table 3.2	Female cancer incidence, mortality rates (2017) and projections (2018-2020), South Australia	26
Table A3.1	Indices of data quality – male cancers, 2017	65
Table A3.2	Indices of data quality – female cancers, 2017	66

List of Figures

Figure 2.1	Most common cancers in South Australia 2017 – Males	12
Figure 2.2	Most common cancers in South Australia 2017 – Females	13
Figure 2.3	Most common cancers in South Australia 2017, by age group	17
Figure 2.4	Most common cancer deaths in South Australia 2017 – Males	18
Figure 2.5	Most common cancer deaths in South Australia 2017 – Females	19
Figure 2.6	Most common cancer deaths in South Australia 2017, by age group	23
Figure 3.1	Trends in cancer incidence - numbers and rates, South Australia, 1977-2017	24
Figure 3.2	Trends in cancer mortality - numbers and rates, South Australia, 1977-2017	25
Figure 3.3	Breast cancer incidence and mortality, South Australia, 1977-2017 with projections to 2020	27
Figure 3.4	Prostate cancer incidence and mortality, South Australia, 1977-2017 with projections to 2020	28
Figure 3.5	Lung cancer incidence and mortality, South Australia, 1977-2017 with projections to 2020	29
Figure 3.6	Colorectal cancer incidence and mortality, South Australia, 1977-2017 with projections to 2020	30
Figure 3.7	Melanoma incidence and mortality, South Australia, 1977-2017 with projections to 2020	31

Executive Summary

In 2017 there were 10,514 new cases of cancer diagnosed in South Australia (age standardised rate 516.6 per 100,000 population), while there were 3,713 cancer deaths (173.4 per 100,000 population).

Between 2013 and 2017 male incidence rates decreased by 2.0% per annum, while female rates remained steady with a slight 0.2% decrease over the same period. Mortality rates in males have shown a decrease of 1.8% per annum between 2013 and 2017, while female mortality rates decreased by 1.2% per annum over the same period.

In 2017 the most common cancers for males were prostate cancer, which accounted for 28.5% of all male cancers, colorectal cancer (10.6%) and lung cancer (9.1%). The most common cancers for females in 2017 were breast cancer, which accounted for 29.2% of all female cancers, colorectal cancer (12.0%) and lung cancer (9.8%).

Lung cancer remained the leading cause of cancer death among South Australian males (21.1%), followed by prostate cancer (12.0%) and colorectal cancer (11.0%). Lung cancer (18.3%), breast cancer (12.4%) and colorectal cancer (10.9%) were the leading causes of cancer deaths among females in South Australia during 2017.

Lung cancer incidence for both men and women increased in 2017, as did male lung cancer mortality rates while female lung cancer mortality rates remained stable (Figure 3.5, Table A2.19).

Cancer was a disease predominantly affecting the older population. In South Australia in 2017 people aged over 65 accounted for 62.7% of all cancers and 78.9% of all cancer deaths. The lifetime risk of being diagnosed with cancer in South Australia (calculated to age 75) was 1 in 3 for males and 1 in 4 for females. Colorectal cancer was the most common cancer death among 15-44 year olds, although the numbers are low (Figure 2.6). Previously breast cancer had been the leading cause of death in this age group.

Despite there being a sharp rise in prostate cancer incidence from 140.1 per 100,000 population in 2016 to 163.8 per 100,000 population in 2017 (Figure 3.4, Table A2.38), incidence rates of prostate cancer decreased 1.7% per annum between 2013 and 2017, and mortality rates decreased by 3.6% per annum over the same period.

Melanoma incidence and mortality decreased from 2016 to 2017 for both males and females (Figure 3.7, Table A2.23).

1. Introduction

1.1 Annual Report

The South Australian Cancer Registry (SACR) has been collecting data on cancer incidence and mortality since 1977. Information on new cancers and cancer related deaths are notified under the *Health Care Act 2008*. Pathology laboratories and health care institutions are required to notify the SACR of any cancer diagnosed at their facility. The Cancer in South Australia 2017 report presents the cancer data for 2017, describes the trends in cancer in South Australia over the years 2013-2017, and projects incidence and mortality rates from 2018 to 2020.

The collection is a rich source of data that has many uses to support the control of cancer. Data are used to describe trends in cancer incidence and death in South Australia. They inform cancer service planning, health policy and also help evaluate cancer prevention, screening and treatment services, as well as identifying issues for population-specific groups. The SACR enables surveillance of trends in cancer incidence, mortality and survival within South Australia by cancer type and by age, sex, geographic area of residence and diagnostic period. It also allows comparison nationally and internationally using agreed standards, by providing South Australian cancer data to the Australian Institute of Health and Welfare's Australian Cancer Database, and to the International Agency for Research on Cancer.

Continuous monitoring permits a prompt response to public concerns about clusters of cancers or regional elevations. This has been an area of increased activity for SACR staff in recent years.

South Australia also has a separate clinical cancer registry, which collects more detailed information including stage, grade, initial course of treatment, and a range of prognostic factors for specific tumour sites. The clinical registry allows clinicians to add information on stage of progression of disease at diagnosis, other prognostic indicators, initial round of treatment, and initial response to care. The clinical cancer registry is used by clinicians to monitor changing patterns of care and effects of these changes on survival rates and other case outcomes. The data are used to support clinical epidemiological studies where more detailed information is required.

The SACR is working towards inclusion of stage at diagnosis in the collection across the population. The *Health Care (Reporting of Cancer) Regulations* under the *Health Care Act 2008* were amended in June 2017 to include reporting of stage at diagnosis and non-malignant tumours of the Central Nervous System as new items for cancers diagnosed from June 2017 onwards. These items will be assessed for quality and reported for cancer diagnoses from 2018 onwards.

1.2 The Collection

The SACR collects information on all invasive cancers. Non-melanoma skin cancers are only collected for squamous cell carcinoma of the lip and for skin of genitalia and perineum and for basal cell carcinoma of the skin of genitalia and perineum.

The SACR collects a minimum data set for each cancer case, including such elements as place of residence, sex, date of birth, date of diagnosis, cancer site and morphology, means of diagnosis,

whether there were multiple primary sites of cancer, Aboriginal status, country of birth, and date, place and cause of death, where applicable.

The primary site and morphology of South Australian cancer incidence are coded using the third edition of the International Classification of Diseases for Oncology (ICD-O-3). For most ICD-O-3 sites reported here, topography codes were used, except for a small number of sites including haematological malignancies when a combination of morphology and topography codes was used. For ease of reference a list of all sites and their ICD-O-3 codes have been summarised in Appendix 2. In reports prior to 2008, the primary sites of cancers diagnosed in South Australia were coded using the International Classification of Diseases, Ninth Edition (ICD-9-CM Australian version). The morphologies were coded according to the Systematised Nomenclature of Medicine and Modifications (SNOMED). In published reports from 2011 – 2014 cause of death was coded in ICD-10-AM, 7th Edition. From the 2015 report onwards, deaths were coded and tabulated using ICD-O-3.

The SACR has used the Surveillance, Epidemiology and End Results Program (SEER) Multiple Primary Rules for all cases diagnosed from 2011 onwards (the rules can be found at: <http://seer.cancer.gov/tools/mphrules/>). These rules are based on site and histology and guide registration of multiple primaries per individual in a standardised way. These rules have the effect of increasing the number of cases registered, as cancers that would previously not be recorded, for example a second case of breast cancer in an individual, could now be recorded according to the SEER Multiple Primary rules.

In order to ensure ongoing comparability of the cancer data over time, the information presented for 2017 has been reduced to a single primary according to the specifications of the International Association of Cancer Registries (see at: http://www.iacr.com.fr/images/doc/MPrules_july2004.pdf). This will also have the effect of making the SACR cancer report comparable with other jurisdictions in Australia that use the same process to reduce cancer registrations to a single primary.

1.3 Data Sources

Primary sources of information include pathology laboratories, hospitals, radiotherapy departments and the Registrar of Births, Deaths and Marriages (BDM). Notifications are mandated by the *Health Care (Reporting of Cancer) Regulations* under the *Health Care Act 2008*. The information is refined through contact with the primary health-care sector and with other cancer registries, resulting in near 100% ascertainment.

Over the past five years the SACR has focussed on increasing the proportion of electronic notifications. These changes have increased the efficiency of coding and data processing, but have also increased the ascertainment of cases by automating notification to a greater degree. For cancers diagnosed in 2017 it is estimated that the SACR received 90% of all notifications electronically.

1.4 Quality Assurance

The SACR has a number of processes that enhance the quality of the data collected. Notification from multiple sources for a given case of cancer increases the likelihood that the case will be recorded. An attempt is made with all notified cases to trace pathology if it is missing as the definitive source to record the detail of the cancer. The SACR undertakes an annual internal de-duplication procedure to ensure there are no duplicate individuals on the database. In addition, a number of quality assurance checks are run over the cancer data to ensure that the high quality data within the registry is maintained. A new suite of quality assurance checks were implemented for cases diagnosed in 2016 onwards that query the SACR database in real time, allowing more timely quality assurance activities to be undertaken by coding staff.

The Registry Plus software system that is used by the SACR also has a number of features inbuilt to enhance the quality of data entered. Electronic notification reduces the risk of error by erroneous keying in of information. There are a series of validation checks that report in real time possibly inconsistent information such as certain sex/cancer combinations, morphology/topography combinations, age/cancer combinations so that they may be corrected before the case reaches the database. Additionally, prior to reporting the data, a series of internal checks are undertaken looking for possible errors and these are reviewed and corrected if necessary.

The SACR supports standardised coding through development and implementation of coding manuals and regular internal coding meetings to discuss any difficulties on classifying a notified cancer.

1.5 The Report

The SACR database is continually updated with the most recent available information. Accordingly, numbers in this report for earlier years may vary slightly from those in previous publications, with some South Australian cases eventually found to have been diagnosed elsewhere or diagnosed in earlier years. Death certificate information can reveal information about a person's cancer history and often leads to investigation which can also affect case numbers. As an example, in the 2015 SACR annual report there were 10,008 new cancers reported, and our currently reported total for 2015 cancers is 10,196.

Chapters 2 and 3 are regular chapters in the report. Chapter 2 covers the most common cancers in terms of incidence, mortality, age and sex differences, and distribution by age. Chapter 3 examines trends in cancer incidence and mortality for each major cancer site, with projections to 2020.

Appendix 1 outlines the methods used in the report. Appendix 2 outlines the topography/morphology codes that were used to create the report categories and Appendix 3 presents quality measures for the SACR. This includes the proportion of Death Certificate Only cases among other measures.

2. Most Common Cancers in 2017


There are many types of cancer, varying by site of origin (primary site) and by tumour type (histology). This section describes the patterns of the most common invasive cancers by primary site in South Australia for 2017, examining incidence (new cases) and mortality (deaths), by both sex and age groups.

2.1 Incidence

In 2017, there were 10,514 new diagnoses of cancer in South Australia (Table 2.1). There were 5,733 cancers diagnosed in males (ASR 594.0 per 100,000) and 4,781 in females (ASR 452.3 per 100,000) resulting in an age-adjusted male-female ratio of 1.31. (Table 2.2 and 2.3). Cancers in males accounted for 54.5% of all cases, with 1 in 3 males and 1 in 4 females being diagnosed with cancer in their lifetime (calculated to age 75, see Methods and Terminology).


Prostate cancer was the most commonly reported cancer in males, accounting for 28.5% of all cancers. Colorectal cancer (10.6%), lung cancer (9.1%), melanoma of skin (7.8%), and Non-Hodgkin Lymphoma (5.0%) were the next most common cancers among males. These five cancers accounted for 61.1% of all newly diagnosed cancers among males in 2017 (Figure 2.1 and Table 2.2).

Figure 2.1 Most common cancers in South Australia 2017 – Males



Breast cancer remained the most commonly reported cancer in females, accounting for 29.2% of all cancers, followed by colorectal cancer (12.0%), lung cancer (9.8%), melanoma of skin (6.8%) and uterine cancers (4.8%). These five cancers accounted for 62.7% of all cancers diagnosed among females in 2017 (Figure 2.2 and Table 2.3).

Figure 2.2 Most common cancers in South Australia 2017 – Females



Cancer was predominantly a disease of the elderly in South Australia with 62.7% occurring in the 65 years and over age group (6,592 cases, Table A2.61).

In children under the age of 15 years, there were 51 cases of cancer diagnosed in 2017, 25 males and 26 females (Table A2.61). The most common childhood cancers were leukaemia (21 cases), brain cancer (6 cases), cancer of the kidney (4 cases) and thyroid cancer (3 cases, Figure 2.3).

For people in the 15 to 44 year age group there were 609 cancers diagnosed in 2017, 266 males and 343 females (Table A2.61). The most common cancers in this age group were female breast cancer (110 cases), melanoma of skin (75 cases), colorectal cancer (61 cases), testicular cancer (54 cases) and thyroid cancer (51 cases, Figure 2.3).

In the 45 to 64 year age group there were 3,262 cancers diagnosed in 2017 – 1,668 males and 1,594 females (Table A2.61). The most common cancers in this age group were female breast cancer (625 cases), prostate cancer (478 cases) colorectal cancer (329 cases), melanoma of skin and lung cancer (both 255 cases, Figure 2.3). Below the age of 55, female cases for all cancers (1,031 cases) outnumber male cases (751 cases). This trend reverses from 55 years of age, when male cases predominate (57.1% of cases). This is due largely to female breast cancer cases in the 35 to 54 age group and prostate and lung cancer in the over 55 year male age group (Tables A2.19, A2.28 and A2.38).

In those aged 65 years and over there were 6,592 cancers diagnosed in 2017 – 3,774 male cancers and 2,818 female cancers (Table A2.61). The most common cancers in this age group were prostate cancer (1154 cases), colorectal cancer (791 cancers), lung cancer (728 cases), female breast cancer (661 cases) and melanoma of skin (445 cases, Figure 2.3). Colorectal cancer is traditionally diagnosed in older patients although the South Australian data for 2017 show that incidence is beginning from age 15 years, increasing steadily to age 85 years and over (Table A2.12).

Table 2.1 South Australian persons: incidence, age-standardised rates, lifetime risk, leading cancer types, 2017

Site Name	Incidence				
	New Cases	ASR (A)	ASR (W)	Risk (1 in n)	% of All Cancer
Prostate	1,635	77.5	50.7	1 in 16	15.6
Female breast	1,396	71.6	52.3	1 in 18	13.3
Colon and rectum	1,181	57.4	37.5	1 in 27	11.2
Trachea, bronchus and lung	994	46.9	29.1	1 in 32	9.5
Melanoma of skin	775	38.9	27.2	1 in 36	7.4
Non-Hodgkin lymphoma	468	22.9	15.4	1 in 65	4.5
Kidney	297	14.9	10.5	1 in 85	2.8
All leukaemias	293	14.6	10.7	1 in 103	2.8
Other and unspecified sites	292	14.0	8.6	1 in 137	2.8
Pancreas	276	13.2	8.2	1 in 133	2.6
Bladder	258	12.0	6.9	1 in 174	2.5
Body of the uterus	229	11.3	7.7	1 in 117	2.2
Stomach	184	9.0	5.8	1 in 184	1.8
Liver and intrahepatic bile ducts	170	8.4	5.6	1 in 165	1.6
Thyroid gland	164	9.1	7.6	1 in 146	1.6
Multiple myeloma/Plasma cell tumours	164	7.9	5.0	1 in 189	1.6
Brain	149	7.7	5.9	1 in 169	1.4
Oesophagus	131	6.2	3.9	1 in 229	1.2
Connective and other soft tissue	109	5.1	3.3	1 in 313	1.0
Myelodysplastic syndromes	97	4.4	2.4	1 in 524	0.9
Ovary	96	4.7	3.2	1 in 290	0.9
Gallbladder and bile ducts	83	3.9	2.3	1 in 523	0.8
Tongue	77	3.8	2.6	1 in 307	0.7
Small intestine	63	3.1	2.0	1 in 516	0.6
Cervix uteri	63	3.7	3.2	1 in 400	0.6
Oropharynx	61	3.2	2.3	1 in 418	0.6
Heart, mediastinum and pleura	59	2.8	1.6	1 in 690	0.6
Testis	58	3.7	3.8	1 in 385	0.6
Larynx	54	2.6	1.6	1 in 545	0.5
Other chronic myeloproliferative and haematological disorders	54	2.5	1.6	1 in 579	0.5
Lip	51	2.6	1.9	1 in 530	0.5
Skin of lip	48	2.3	1.5	1 in 690	0.5
Hodgkin lymphoma	47	2.7	2.4	1 in 523	0.4
Mouth	41	2.0	1.4	1 in 576	0.4
Anus, anal canal, anorectum	38	1.9	1.3	1 in 647	0.4
Vulva	37	1.8	1.1	1 in 867	0.4
Renal pelvis, other and unspecified urinary organs	36	1.6	0.9	1 in 1,532	0.3
Salivary gland	32	1.6	1.2	1 in 1,059	0.3
Other and unspecified female genitalia	30	1.5	1.1	1 in 938	0.3
Eye	28	1.5	1.2	1 in 902	0.3
Retroperitoneum and peritoneum	27	1.3	0.9	1 in 1,222	0.3
Bone, joints and articular cartilage	21	1.2	1.1	1 in 1,089	0.2
Polycythaemia vera	21	1.1	0.8	1 in 1,412	0.2
Penis	16	0.8	0.6	1 in 2,051	0.2
Thymus	14	0.7	0.5	1 in 1,605	0.1
Other lymphomas	14	0.7	0.4	1 in 2,007	0.1
Nose, nasal cavities, middle ear and accessory sinuses	11	0.6	0.4	1 in 2,596	0.1
Vagina	11	0.6	0.4	1 in 2,560	0.1
Male breast	9	0.4	0.3	1 in 2,993	0.1
Immunoproliferative neoplasms	8	0.4	0.2	1 in 6,515	0.1
Other endocrine glands	7	0.4	0.4	1 in 3,497	0.1
Nasopharynx	6	0.3	0.3	1 in 3,762	0.1
Hypopharynx	6	0.3	0.2	1 in 3,136	0.1
Unspecified sites - lip, oral cavity and pharynx	5	0.2	0.1	1 in 9,859	0.0
Skin of anus (including perineum, perianal skin)	5	0.2	0.2	1 in 4,764	0.0
Cranial nerves, spinal cord, meninges etc.	5	0.3	0.2	1 in 7,404	0.0
Malignancy of histiocytes and accessory lymphoid cells	5	0.3	0.3	1 in 4,067	0.0
Other male genital organs	4	0.2	0.1	1 in 10,005	0.0
Placenta	1	0.1	0.1	1 in 23,213	0.0
All cancers	10,514	516.6	350.5	1 in 3	100.0

Notes: See Appendix 2 for ICD-O-3 coding ranges

Other coding groups of interest (eg Mesothelioma, Leukaemias, Melanomas etc) can be found in Tables A2.62-A2.82

Age-standardised rates are expressed per 100,000 and standardised to the Australian 2011 population ASR (A)

Age-standardised rates are expressed per 100,000 and standardised to the new World standard population 2011 ASR (W)

Lifetime risk is calculated to age 75. Where risk marked N/A not calculated due to unreliable calculation.

Table 2.2 South Australian males: incidence, age-standardised rates, lifetime risk, leading cancer types, 2017

Site Name	Incidence				
	New Cases	ASR (A)	ASR (W)	Risk (1 in n)	% of All Cancer
Prostate	1,635	163.8	106.1	1 in 8	28.5
Colon and rectum	605	63.2	40.3	1 in 25	10.6
Trachea, bronchus and lung	524	53.5	32.3	1 in 30	9.1
Melanoma of skin	450	47.6	32.6	1 in 31	7.8
Non-Hodgkin lymphoma	289	30.1	20.1	1 in 49	5.0
Kidney	206	21.7	15.5	1 in 59	3.6
Bladder	202	21.0	11.9	1 in 107	3.5
All leukaemias	181	19.1	13.4	1 in 80	3.2
Other and unspecified sites	155	16.6	10.4	1 in 117	2.7
Pancreas	132	13.6	8.4	1 in 129	2.3
Stomach	128	13.4	8.5	1 in 124	2.2
Liver and intrahepatic bile ducts	122	12.7	8.6	1 in 108	2.1
Oesophagus	99	10.1	6.3	1 in 143	1.7
Multiple myeloma/Plasma cell tumours	95	9.8	6.2	1 in 156	1.7
Brain	89	9.6	7.5	1 in 140	1.6
Connective and other soft tissue	66	6.8	4.1	1 in 253	1.2
Testis	58	7.4	7.6	1 in 193	1.0
Myelodysplastic syndromes	58	6.1	3.2	1 in 403	1.0
Thyroid gland	53	6.1	5.0	1 in 219	0.9
Oropharynx	52	5.6	4.1	1 in 233	0.9
Larynx	48	5.0	3.1	1 in 300	0.8
Heart, mediastinum and pleura	48	5.0	2.7	1 in 427	0.8
Tongue	46	4.6	3.2	1 in 238	0.8
Lip	39	4.3	3.3	1 in 310	0.7
Other chronic myeloproliferative and haematological disorders	34	3.3	2.1	1 in 423	0.6
Gallbladder and bile ducts	33	3.4	2.1	1 in 577	0.6
Small intestine	31	3.2	2.0	1 in 596	0.5
Skin of lip	31	3.3	2.3	1 in 465	0.5
Hodgkin lymphoma	28	3.2	2.7	1 in 471	0.5
Mouth	24	2.5	1.8	1 in 396	0.4
Salivary gland	22	2.4	1.7	1 in 785	0.4
Eye	20	2.2	1.9	1 in 635	0.3
Penis	16	1.8	1.3	1 in 1,007	0.3
Renal pelvis, other and unspecified urinary organs	15	1.5	0.8	1 in 1,109	0.3
Anus, anal canal, anorectum	11	1.1	0.8	1 in 1,051	0.2
Polycythaemia vera	11	1.2	0.8	1 in 1,611	0.2
Bone, joints and articular cartilage	10	1.1	1.0	1 in 1,120	0.2
Male breast	9	0.9	0.5	1 in 1,451	0.2
Retroperitoneum and peritoneum	8	0.8	0.5	1 in 3,260	0.1
Immunoproliferative neoplasms	7	0.7	0.4	1 in 4,466	0.1
Hypopharynx	6	0.6	0.4	1 in 1,525	0.1
Thymus	6	0.6	0.5	1 in 1,805	0.1
Nose, nasal cavities, middle ear and accessory sinuses	5	0.6	0.4	1 in 3,646	0.1
Other lymphomas	5	0.4	0.3	1 in 1,618	0.1
Nasopharynx	4	0.5	0.4	1 in 2,767	0.1
Unspecified sites - lip, oral cavity and pharynx	4	0.4	0.2	1 in 4,793	0.1
Other male genital organs	4	0.4	0.3	1 in 4,934	0.1
Cranial nerves, spinal cord, meninges etc.	4	0.5	0.4	1 in 3,715	0.1
Malignancy of histiocytes and accessory lymphoid cells	3	0.4	0.4	1 in 3,515	0.1
Skin of anus (including perineum, perianal skin)	1	0.1	0.1	1 in 11,131	0.0
Other endocrine glands	1	0.1	0.1	1 in 9,983	0.0
All cancers	5,733	594.0	390.7	1 in 3	100.0

Notes: See Appendix 2 for ICD-O-3 coding ranges

Other coding groups of interest (eg Mesothelioma, Leukaemias, Melanomas etc) can be found in Tables A2.62-A2.82

Age-standardised rates are expressed per 100,000 and standardised to the Australian 2011 population ASR (A)

Age-standardised rates are expressed per 100,000 and standardised to the new World standard population 2011 ASR (W)

Lifetime risk is calculated to age 75. Where risk marked N/A not calculated due to unreliable calculation.

Table 2.3 South Australian females: incidence, age-standardised rates, lifetime risk, leading cancer types, 2017

Site Name	Incidence				
	New Cases	ASR (A)	ASR (W)	Risk (1 in n)	% of All Cancer
Female breast	1,396	138.4	101.7	1 in 10	29.2
Colon and rectum	576	52.5	35.2	1 in 29	12.0
Trachea, bronchus and lung	470	41.8	26.6	1 in 35	9.8
Melanoma of skin	325	31.4	22.5	1 in 44	6.8
Body of the uterus	229	21.6	14.9	1 in 60	4.8
Non-Hodgkin lymphoma	179	16.5	11.1	1 in 95	3.7
Pancreas	144	12.8	8.1	1 in 137	3.0
Other and unspecified sites	137	11.7	6.9	1 in 165	2.9
All leukaemias	112	10.6	8.2	1 in 142	2.3
Thyroid gland	111	12.1	10.1	1 in 111	2.3
Ovary	96	8.9	6.2	1 in 148	2.0
Kidney	91	8.5	5.8	1 in 152	1.9
Multiple myeloma/Plasma cell tumours	69	6.3	4.1	1 in 238	1.4
Cervix uteri	63	7.2	6.3	1 in 202	1.3
Brain	60	5.9	4.5	1 in 212	1.3
Stomach	56	5.2	3.4	1 in 338	1.2
Bladder	56	4.7	2.6	1 in 429	1.2
Gallbladder and bile ducts	50	4.3	2.5	1 in 481	1.0
Liver and intrahepatic bile ducts	48	4.4	2.8	1 in 332	1.0
Connective and other soft tissue	43	3.8	2.5	1 in 405	0.9
Myelodysplastic syndromes	39	3.2	1.8	1 in 731	0.8
Vulva	37	3.3	2.2	1 in 445	0.8
Oesophagus	32	2.8	1.7	1 in 537	0.7
Small intestine	32	3.1	2.1	1 in 457	0.7
Tongue	31	3.0	2.0	1 in 422	0.6
Other and unspecified female genitalia	30	2.9	2.0	1 in 480	0.6
Anus, anal canal, anorectum	27	2.6	1.9	1 in 473	0.6
Renal pelvis, other and unspecified urinary organs	21	1.7	0.9	1 in 2,364	0.4
Other chronic myeloproliferative and haematological disorders	20	1.8	1.2	1 in 880	0.4
Retroperitoneum and peritoneum	19	1.8	1.2	1 in 767	0.4
Hodgkin lymphoma	19	2.2	2.1	1 in 586	0.4
Mouth	17	1.5	1.0	1 in 1,009	0.4
Skin of lip	17	1.4	0.8	1 in 1,303	0.4
Lip	12	1.1	0.7	1 in 1,689	0.3
Heart, mediastinum and pleura	11	1.0	0.7	1 in 1,629	0.2
Bone, joints and articular cartilage	11	1.2	1.2	1 in 1,049	0.2
Vagina	11	1.1	0.8	1 in 1,309	0.2
Salivary gland	10	0.9	0.7	1 in 1,600	0.2
Polycythaemia vera	10	1.0	0.7	1 in 1,269	0.2
Oropharynx	9	0.9	0.6	1 in 1,724	0.2
Other lymphomas	9	0.8	0.5	1 in 2,558	0.2
Thymus	8	0.8	0.6	1 in 1,449	0.2
Eye	8	0.8	0.6	1 in 1,547	0.2
Nose, nasal cavities, middle ear and accessory sinuses	6	0.6	0.4	1 in 2,048	0.1
Larynx	6	0.5	0.3	1 in 2,395	0.1
Other endocrine glands	6	0.7	0.7	1 in 2,107	0.1
Skin of anus (including perineum, perianal skin)	4	0.3	0.2	1 in 3,108	0.1
Nasopharynx	2	0.2	0.2	1 in 5,817	0.0
Malignancy of histiocytes and accessory lymphoid cells	2	0.2	0.2	1 in 4,913	0.0
Unspecified sites - lip, oral cavity and pharynx	1	0.1	0.1	N/A	0.0
Placenta	1	0.1	0.1	1 in 11,676	0.0
Cranial nerves, spinal cord, meninges etc.	1	0.1	0.0	N/A	0.0
Immunoproliferative neoplasms	1	0.1	0.1	1 in 11,375	0.0
All cancers	4,781	452.3	316.3	1 in 4	100.0

Notes: See Appendix 2 for ICD-O-3 coding ranges

Other coding groups of interest (eg Mesothelioma, Leukaemias, Melanomas etc) can be found in Tables A2.62-A2.82


Age-standardised rates are expressed per 100,000 and standardised to the Australian 2011 population ASR (A)

Age-standardised rates are expressed per 100,000 and standardised to the new World standard population 2011 ASR (W)


Lifetime risk is calculated to age 75. Where risk marked N/A not calculated due to unreliable calculation.

Figure 2.3 Most common cancers in South Australia 2017, by age group


Ages 0 - 14 years (n=51)




Ages 15 - 44 years (n=609)



Ages 45 - 64 years (n=3,262)




Ages 65 years + (n=6,592)



2.2 Mortality


In 2017, there were 3,713 cancer deaths in South Australia (Table A2.61). There were 2,038 cancer deaths in males (ASR 211.8 per 100,000) and 1,675 in females (ASR 143.6 per 100,000, Table A2.61). Lung cancer was the most commonly reported cancer cause of death in males, accounting for 21.1% of all male cancer deaths. Prostate cancer (12.0%), colorectal cancer (11.0%), cancer of unspecified site (5.6%) and pancreatic cancer (5.3%) were the next most common cancer causes of death among males (Figure 2.4).

Figure 2.4 Most common cancer deaths in South Australia 2017 – Males



Lung cancer was also the most commonly reported cancer cause of death in females, accounting for 18.3% of all female cancer deaths. Female breast cancer (12.4%), colorectal cancer (10.9%), pancreatic cancer (7.8%), and cancer of unspecified site (6.3%) were the next most common cancer causes of death among females (Figure 2.5).

Figure 2.5 Most common cancer deaths in South Australia 2017 – Females



Cancer deaths were very rare in the 0-14 age group (4 cases, Table A2.61).

For people in the 15 to 44 year age group there were 62 cancer deaths in 2017 - 34 male and 28 female deaths (Table A2.61). The most common cancer deaths in this age group were colorectal cancer (11 deaths), female breast and brain cancer (both 7 deaths), cervical cancer (6 deaths), and cancers of unspecified site (5 deaths, Figure 2.6).

In the 45 to 64 year age group there were 716 cancer deaths in 2017 – 379 male and 337 female deaths (Table A2.61). The most common cancer deaths in this age group were lung cancer (143 deaths), colorectal cancer (79 deaths), female breast cancer (78 deaths), liver cancer (49 deaths) and pancreatic cancer (44 deaths, Figure 2.6).

In those aged 65 years and over there were 2,931 deaths caused by cancer in 2017 – 1,623 male and 1,308 female deaths (Table A2.61). The most common cancers in this age group were lung cancer (592 deaths), colorectal cancer (317 deaths), prostate cancer (232 deaths), pancreatic cancer (195 deaths) and cancers of unspecified site (172 cases, Figure 2.6).

Deaths from cancer generally increase with age for both sexes, with the majority of cancer deaths occurring from the age of 65 (78.9%). The likelihood of dying from cancer was similar for males and females up to and including the age of 59 years. However, after the age of 60 years the rate of male deaths was higher and increased more steeply than in females (Table A2.61).

Table 2.4 South Australian persons: mortality, age-standardised rates, lifetime risk, leading cancer types, 2017

Site Name	Mortality				
	Deaths	ASR (A)	ASR (W)	Risk (1 in n)	% of All Cancer
Trachea, bronchus and lung	736	33.9	19.7	1 in 51	19.8
Colon and rectum	407	19.2	11.0	1 in 112	11.0
Prostate	244	10.8	5.4	1 in 259	6.6
Pancreas	239	11.2	6.5	1 in 172	6.4
Other and unspecified sites	220	10.2	5.8	1 in 205	5.9
Female breast	208	10.3	6.8	1 in 147	5.6
All leukaemias	141	6.6	3.7	1 in 378	3.8
Non-Hodgkin lymphoma	138	6.4	3.7	1 in 298	3.7
Liver and intrahepatic bile ducts	122	5.9	3.8	1 in 238	3.3
Stomach	110	5.1	3.0	1 in 390	3.0
Bladder	110	5.0	2.7	1 in 462	3.0
Brain	109	5.4	3.8	1 in 263	2.9
Multiple myeloma/Plasma cell tumours	87	4.1	2.4	1 in 496	2.3
Oesophagus	79	3.7	2.2	1 in 524	2.1
Kidney	70	3.3	1.9	1 in 610	1.9
Gallbladder and bile ducts	67	3.1	1.7	1 in 699	1.8
Ovary	65	3.0	1.8	1 in 626	1.8
Myelodysplastic syndromes	65	2.9	1.5	1 in 1,473	1.8
Melanoma of skin	56	2.6	1.5	1 in 667	1.5
Heart, mediastinum and pleura	54	2.5	1.3	1 in 1,106	1.5
Body of the uterus	50	2.3	1.3	1 in 934	1.3
Connective and other soft tissue	43	2.1	1.2	1 in 1,540	1.2
Renal pelvis, other and unspecified urinary organs	27	1.2	0.6	1 in 2,551	0.7
Cervix uteri	26	1.3	1.0	1 in 1,039	0.7
Retroperitoneum and peritoneum	24	1.1	0.7	1 in 1,880	0.6
Small intestine	18	0.8	0.5	1 in 2,114	0.5
Other chronic myeloproliferative and haematological disorders	17	0.8	0.5	1 in 2,747	0.5
Thyroid gland	16	0.7	0.5	1 in 2,239	0.4
Tongue	15	0.7	0.5	1 in 1,625	0.4
Oropharynx	14	0.7	0.4	1 in 3,191	0.4
Other and unspecified female genitalia	14	0.7	0.4	1 in 2,743	0.4
Larynx	12	0.6	0.4	1 in 2,606	0.3
Mouth	11	0.5	0.3	1 in 2,456	0.3
Anus, anal canal, anorectum	9	0.4	0.3	1 in 3,344	0.2
Nose, nasal cavities, middle ear and accessory sinuses	9	0.4	0.2	1 in 3,743	0.2
Other lymphomas	8	0.3	0.1	1 in 7,761	0.2
Bone, joints and articular cartilage	7	0.4	0.3	1 in 7,424	0.2
Vulva	7	0.3	0.1	1 in 18,956	0.2
Cranial nerves, spinal cord, meninges etc.	6	0.3	0.2	1 in 4,887	0.2
Hodgkin lymphoma	6	0.3	0.2	1 in 9,178	0.2
Unspecified sites - lip, oral cavity and pharynx	5	0.2	0.1	1 in 9,859	0.1
Eye	5	0.2	0.1	1 in 7,761	0.1
Hypopharynx	4	0.2	0.1	1 in 4,513	0.1
Thymus	4	0.2	0.1	1 in 9,217	0.1
Male breast	4	0.2	0.1	1 in 8,534	0.1
Polycythaemia vera	4	0.2	0.1	N/A	0.1
Salivary gland	3	0.2	0.1	1 in 10,279	0.1
Skin of lip	3	0.1	0.1	1 in 9,859	0.1
Testis	3	0.2	0.2	1 in 7,273	0.1
Nasopharynx	2	0.1	0.1	1 in 10,729	0.1
Skin of anus (including perineum, perianal skin)	2	0.1	0.0	N/A	0.1
Vagina	2	0.1	0.1	N/A	0.1
Penis	2	0.1	0.0	N/A	0.1
Other endocrine glands	2	0.1	0.1	1 in 22,457	0.1
Mast cell tumours	1	0.0	0.0	N/A	0.0
Immunoproliferative neoplasms	1	0.0	0.0	N/A	0.0
All cancers	3,713	173.4	101.2	1 in 12	100.0

Notes: See Appendix 2 for ICD-O-3 coding ranges

Other coding groups of interest (eg Mesothelioma, Leukaemias, Melanomas etc) can be found in Tables A2.62-A2.82

Age-standardised rates are expressed per 100,000 and standardised to the Australian 2011 population ASR (A)

Age-standardised rates are expressed per 100,000 and standardised to the new World standard population 2011 ASR (W)

Lifetime risk is calculated to age 75. Where risk marked N/A not calculated due to unreliable calculation.

Table 2.5 South Australian males: mortality, age-standardised rates, lifetime risk, leading cancer types, 2017

Site Name	Mortality				
	Deaths	ASR (A)	ASR (W)	Risk (1 in n)	% of All Cancer
Trachea, bronchus and lung	430	44.0	25.0	1 in 43	21.1
Prostate	244	25.3	12.3	1 in 125	12.0
Colon and rectum	224	23.6	13.8	1 in 84	11.0
Other and unspecified sites	114	11.8	7.0	1 in 160	5.6
Pancreas	108	11.3	6.6	1 in 183	5.3
All leukaemias	87	9.1	4.9	1 in 293	4.3
Liver and intrahepatic bile ducts	86	9.0	5.9	1 in 155	4.2
Bladder	78	8.2	4.2	1 in 315	3.8
Non-Hodgkin lymphoma	74	7.7	4.4	1 in 233	3.6
Stomach	70	7.2	4.4	1 in 254	3.4
Brain	61	6.5	4.6	1 in 223	3.0
Oesophagus	55	5.7	3.5	1 in 307	2.7
Multiple myeloma/Plasma cell tumours	51	5.3	3.1	1 in 401	2.5
Heart, mediastinum and pleura	45	4.7	2.4	1 in 695	2.2
Kidney	44	4.6	2.7	1 in 395	2.2
Melanoma of skin	43	4.3	2.5	1 in 373	2.1
Myelodysplastic syndromes	41	4.3	2.1	1 in 974	2.0
Gallbladder and bile ducts	27	2.8	1.6	1 in 746	1.3
Connective and other soft tissue	22	2.3	1.3	1 in 1,287	1.1
Oropharynx	12	1.3	0.8	1 in 1,962	0.6
Larynx	10	1.1	0.7	1 in 1,709	0.5
Renal pelvis, other and unspecified urinary organs	10	1.0	0.5	1 in 2,661	0.5
Other chronic myeloproliferative and haematological disorders	10	1.0	0.6	1 in 1,879	0.5
Tongue	8	0.7	0.5	1 in 1,056	0.4
Small intestine	8	0.8	0.4	1 in 2,138	0.4
Mouth	7	0.6	0.4	1 in 1,189	0.3
Nose, nasal cavities, middle ear and accessory sinuses	7	0.7	0.4	1 in 2,269	0.3
Thyroid gland	6	0.6	0.4	1 in 2,387	0.3
Bone, joints and articular cartilage	5	0.6	0.4	1 in 5,846	0.2
Hodgkin lymphoma	5	0.6	0.3	1 in 11,083	0.2
Hypopharynx	4	0.4	0.3	1 in 2,187	0.2
Unspecified sites - lip, oral cavity and pharynx	4	0.4	0.2	1 in 4,793	0.2
Retroperitoneum and peritoneum	4	0.4	0.3	1 in 3,413	0.2
Male breast	4	0.4	0.2	1 in 4,130	0.2
Other lymphomas	4	0.4	0.2	1 in 3,740	0.2
Polycythaemia vera	4	0.4	0.2	N/A	0.2
Salivary gland	3	0.3	0.2	1 in 5,033	0.1
Testis	3	0.4	0.4	1 in 3,637	0.1
Cranial nerves, spinal cord, meninges etc.	3	0.3	0.2	1 in 4,384	0.1
Nasopharynx	2	0.2	0.2	1 in 5,252	0.1
Anus, anal canal, anorectum	2	0.2	0.1	1 in 9,983	0.1
Thymus	2	0.2	0.1	1 in 7,480	0.1
Penis	2	0.2	0.1	N/A	0.1
Skin of lip	1	0.1	0.1	1 in 9,219	0.0
Eye	1	0.1	0.1	N/A	0.0
Other endocrine glands	1	0.1	0.1	1 in 11,083	0.0
Mast cell tumours	1	0.1	0.1	N/A	0.0
Immunoproliferative neoplasms	1	0.1	0.0	N/A	0.0
All cancers	2,038	211.8	120.7	1 in 10	100.0

Notes: See Appendix 2 for ICD-O-3 coding ranges

Other coding groups of interest (eg Mesothelioma, Leukaemias, Melanomas etc) can be found in Tables A2.62-A2.82

Age-standardised rates are expressed per 100,000 and standardised to the Australian 2011 population ASR (A)

Age-standardised rates are expressed per 100,000 and standardised to the new World standard population 2011 ASR (W)

Lifetime risk is calculated to age 75. Where risk marked N/A not calculated due to unreliable calculation.

Table 2.6 South Australian females: mortality, age-standardised rates, lifetime risk, leading cancer types, 2017

Site Name	Mortality				
	Deaths	ASR (A)	ASR (W)	Risk (1 in n)	% of All Cancer
Trachea, bronchus and lung	306	25.9	15.4	1 in 63	18.3
Female breast	208	19.4	13.0	1 in 76	12.4
Colon and rectum	183	15.2	8.5	1 in 165	10.9
Pancreas	131	11.2	6.5	1 in 163	7.8
Other and unspecified sites	106	8.7	4.7	1 in 277	6.3
Ovary	65	5.7	3.4	1 in 322	3.9
Non-Hodgkin lymphoma	64	5.4	3.1	1 in 403	3.8
All leukaemias	54	4.6	2.7	1 in 519	3.2
Body of the uterus	50	4.3	2.5	1 in 479	3.0
Brain	48	4.4	3.0	1 in 320	2.9
Stomach	40	3.3	1.7	1 in 797	2.4
Gallbladder and bile ducts	40	3.3	1.8	1 in 661	2.4
Liver and intrahepatic bile ducts	36	3.2	1.9	1 in 485	2.1
Multiple myeloma/Plasma cell tumours	36	3.0	1.8	1 in 644	2.1
Bladder	32	2.6	1.4	1 in 827	1.9
Cervix uteri	26	2.6	1.9	1 in 530	1.6
Kidney	26	2.1	1.2	1 in 1263	1.6
Oesophagus	24	2.0	1.1	1 in 1609	1.4
Myelodysplastic syndromes	24	1.9	0.9	1 in 2846	1.4
Connective and other soft tissue	21	1.9	1.2	1 in 1833	1.3
Retroperitoneum and peritoneum	20	1.7	1.0	1 in 1329	1.2
Renal pelvis, other and unspecified urinary organs	17	1.4	0.7	1 in 2441	1.0
Other and unspecified female genitalia	14	1.2	0.7	1 in 1412	0.8
Melanoma of skin	13	1.1	0.6	1 in 2594	0.8
Small intestine	10	0.9	0.5	1 in 2078	0.6
Thyroid gland	10	0.8	0.5	1 in 2138	0.6
Heart, mediastinum and pleura	9	0.8	0.5	1 in 2500	0.5
Tongue	7	0.6	0.4	1 in 3285	0.4
Anus, anal canal, anorectum	7	0.7	0.4	1 in 2049	0.4
Vulva	7	0.5	0.2	1 in 9737	0.4
Other chronic myeloproliferative and haematological disorders	7	0.6	0.4	1 in 4869	0.4
Mouth	4	0.3	0.1	N/A	0.2
Eye	4	0.3	0.2	1 in 4021	0.2
Other lymphomas	4	0.3	0.1	N/A	0.2
Cranial nerves, spinal cord, meninges etc.	3	0.3	0.2	1 in 5476	0.2
Oropharynx	2	0.2	0.1	1 in 8041	0.1
Nose, nasal cavities, middle ear and accessory sinuses	2	0.2	0.1	1 in 9737	0.1
Larynx	2	0.2	0.2	1 in 5247	0.1
Thymus	2	0.2	0.1	1 in 11561	0.1
Bone, joints and articular cartilage	2	0.2	0.2	1 in 10107	0.1
Skin of lip	2	0.2	0.1	1 in 10560	0.1
Skin of anus (including perineum, perianal skin)	2	0.1	0.1	N/A	0.1
Vagina	2	0.2	0.1	N/A	0.1
Unspecified sites - lip, oral cavity and pharynx	1	0.1	0.0	N/A	0.1
Other endocrine glands	1	0.1	0.0	N/A	0.1
Hodgkin lymphoma	1	0.1	0.1	1 in 8041	0.1
All cancers	1675	143.6	85.2	1 in 14	100.0

Notes: See Appendix 2 for ICD-O-3 coding ranges

Other coding groups of interest (eg Mesothelioma, Leukaemias, Melanomas etc) can be found in Tables A2.62-A2.82


Age-standardised rates are expressed per 100,000 and standardised to the Australian 2011 population ASR (A)

Age-standardised rates are expressed per 100,000 and standardised to the new World standard population 2011 ASR (W)

Lifetime risk is calculated to age 75. Where risk marked N/A not calculated due to unreliable calculation.


Figure 2.6 Most common cancer deaths in South Australia 2017, by age group

Ages 15 - 44 years (n=62)




- Colon and rectum - 18%
- Female breast - 11%
- Brain - 11%
- Cervical Cancer - 10%
- Other and unspecified site - 8%
- Other cancers - 42%

Ages 45 - 64 years (n=716)



- Trachea, bronchus and lung - 20%
- Colon and rectum - 11%
- Female breast - 11%
- Liver and intrahepatic bile ducts - 7%
- Pancreas - 6%
- Other cancers - 45%

Ages 65 years + (n=2,931)




- Trachea, bronchus and lung - 20%
- Colon and rectum - 11%
- Prostate - 8%
- Pancreas - 7%
- Other and unspecified site - 6%
- Other cancers - 49%

3. Trends in Cancer Incidence and Mortality

3.1 Incidence

When accounting for a generally ageing population, age-standardisation or adjustment is often used to enhance the comparability of rates to account for differences in age structure. The age-adjusted (Australian population) incidence rate for South Australia in 2017 was 594.0 new cases per 100,000 for males and 452.3 for females (Table A2.61). Figure 3.1 shows the trends in both numbers and rate of cancers in South Australia since 1977.

Figure 3.1 Trends in cancer incidence - numbers and rates, South Australia, 1977-2017




Male incidence rates decreased by 2.0% per annum between 2013 and 2017, while female rates remained relatively stable over this period with a 0.2% decrease (see Table A2.61, change in incidence and mortality calculated using a Poisson regression model).

3.2 Mortality

The age-adjusted mortality rate for South Australia in 2017 was 211.8 deaths per 100,000 for males and 143.6 for females. Figure 3.2 shows the trends in both numbers and rate of cancers in South Australia since 1977.

Male mortality rates have decreased by 1.8% per annum between 2013 and 2017, while female mortality rates have decreased 1.2% over the same period (see Table A2.61, change in incidence and mortality calculated using a Poisson regression model).

Figure 3.2 Trends in cancer mortality - numbers and rates, South Australia, 1977-2017



3.3 Projections

Numbers of cases, deaths and rates have been projected from 2018 to 2020 for all cancers and for each of the most common cancers (Tables 3.1 and 3.2) based on the previous 10 years of data held in the SACR. The exception being prostate cancer incidence, which has been projected based on the previous 5 years of data, due to non-linear trends.

These projections account for the current age/sex patterns of cancer and changing populations over the projected years. The overall cancer projections show projected decreasing male incidence and mortality rates in males from 2018. The projections for females show an increasing incidence rate from 2018 through to 2020 and a decreasing mortality rate projection from 2018 (Tables 3.1 and 3.2).

Table 3.1 Male cancer incidence, mortality rates (2017) and projections (2018-2020), South Australia

Males Site/Year	Incidence (new cases)				Mortality (deaths)			
	2017	2018	2019	2020	2017	2018	2019	2020
Prostate*	163.8 (1635)	147.9 (1516)	152.3 (1600)	153.3 (1640)	25.3 (244)	24.4 (238)	22.9 (230)	22.0 (225)
Colorectal	63.2 (605)	66.0 (645)	64.0 (639)	61.4 (622)	23.6 (224)	23.2 (224)	22.2 (217)	21.1 (207)
Lung	53.5 (524)	50.4 (504)	48.9 (503)	47.8 (501)	44.0 (430)	39.7 (396)	38.1 (390)	36.6 (382)
Melanoma	47.6 (450)	49.0 (475)	49.9 (494)	49.9 (502)	4.3 (43)	4.1 (41)	3.8 (39)	3.3 (34)
NHL	30.1 (289)	29.5 (289)	28.7 (288)	28.9 (295)	7.7 (74)	7.3 (72)	7.1 (72)	6.7 (69)
All cancers	594.0 (5,733)	566.7 (5,583)	555.5 (5,594)	546.2 (5,589)	211.8 (2,038)	203.9 (2,002)	200.4 (2,016)	196.6 (2,008)

Notes: Rates are expressed per 100,000 and standardised to the Australian 2011 population. Number of new cases and deaths are presented in brackets. *Prostate incidence based on previous 5 years

Table 3.2 Female cancer incidence, mortality rates (2017) and projections (2018-2020), South Australia

Females Site/Year	Incidence (new cases)				Mortality (deaths)			
	2017	2018	2019	2020	2017	2018	2019	2020
Breast	138.4 (1396)	142.1 (1459)	144.9 (1510)	146.4 (1543)	19.4 (208)	19.8 (224)	18.9 (217)	18.7 (216)
Colorectal	52.5 (576)	48.5 (546)	48.4 (554)	47.7 (554)	15.2 (183)	14.5 (178)	14.2 (177)	13.6 (171)
Melanoma	31.4 (325)	30.0 (316)	30.4 (325)	30.0 (326)	1.1 (13)	1.7 (20)	1.6 (20)	1.6 (19)
Lung	41.8 (470)	39.7 (455)	41.1 (484)	42.9 (515)	25.9 (306)	25.8 (309)	25.7 (316)	25.6 (322)
NHL	16.5 (179)	18.6 (205)	17.7 (200)	17.2 (198)	5.4 (64)	4.1 (50)	3.9 (49)	4.0 (50)
All cancers	452.3 (4781)	454.9 (4902)	460.0 (5043)	461.9 (5134)	143.6 (1675)	136.6 (1631)	135.6 (1653)	133.5 (1651)

Notes: Rates are expressed per 100,000 and standardised to the Australian 2011 population. Number of new cases and deaths are presented in brackets

3.4 Most Common Cancers

Figure 3.3 shows the trends in female breast cancer incidence and mortality in South Australia from 1977. Female breast cancer incidence rates in South Australia have decreased slightly by 0.7% per annum between 2013 and 2017, and mortality rates have decreased by 1.7% per annum over the same period (Table A2.28). Female breast cancer incidence rates are projected to increase between 2018 and 2020, while mortality rates are projected to decrease (Table 3.2, Figure 3.3).

Figure 3.3 Breast cancer incidence and mortality, South Australia, 1977-2017 with projections to 2020




Figure 3.4 shows the trends in prostate cancer incidence and mortality in South Australia from 1977. Prostate cancer incidence rates in South Australia have decreased by 1.7% per annum between 2013 and 2017, and mortality rates have decreased by 3.6% per annum over the same period (Table A2.38). Prostate cancer incidence and mortality rates are projected to further decrease between 2017 and 2019 (Table 3.1, Figure 3.4).

Figure 3.4 Prostate cancer incidence and mortality, South Australia, 1977-2017 with projections to 2020




Figure 3.5 shows the trends in lung cancer incidence and mortality in South Australia from 1977. Lung cancer incidence rates in males have decreased by 3.3% per annum between 2013 and 2017, and mortality rates have decreased by 2.6% per annum over the same period (Table A2.19). Lung cancer incidence rates in females have increased by 7.0% per annum between 2013 and 2017, and mortality rates have increased by 0.9% per annum over the same period (Table A2.19). Lung cancer incidence rates and mortality rates for males are projected to decrease between 2018 and 2020 (Table 3.1, Figure 3.5). Whereas lung cancer incidence rates are projected to increase for females, and mortality rates are projected to plateau over the same period (Table 3.2, Figure 3.5).

Figure 3.5 Lung cancer incidence and mortality, South Australia, 1977-2017 with projections to 2020




Figure 3.6 shows the trends in colorectal cancer incidence and mortality in South Australia from 1977. Colorectal cancer incidence rates in males have decreased by 4.9% per annum between 2013 and 2017, and mortality rates have decreased by 1.6% per annum over the same period (Table A2.12). Colorectal cancer incidence rates in females have decreased by 2.5% per annum between 2013 and 2017, and mortality rates have decreased by 4.6% per annum over the same period (Table A2.12).

Colorectal cancer incidence rates for males are projected to increase in 2018 before decreasing again through to 2020, while male mortality rates are projected to decrease between 2018 and 2020 (Table 3.1, Figure 3.6). Colorectal cancer incidence and mortality for females are both projected to decrease from 2018 (Table 3.2, Figure 3.6).

Figure 3.6 Colorectal cancer incidence and mortality, South Australia, 1977-2017 with projections to 2020





Figure 3.7 shows the trends in melanoma incidence and mortality in South Australia from 1977. Melanoma incidence rates in males have decreased by 1.6% per annum between 2013 and 2017, while mortality rates have decreased by 9.5% per annum over the same period (Table A2.23). Melanoma incidence rates in females have increased by 0.9% per annum between 2013 and 2017, while mortality rates have decreased by 13.7% per annum over the same period (Table A2.23).

Melanoma incidence rates for males are projected to increase between 2018 and 2020, while male mortality rates are projected to decrease slightly over the same period (Table 3.1, Figure 3.7). Melanoma incidence for females is also projected to decrease between 2018 and 2020, while female melanoma mortality rates are projected to plateau (Table 3.2, Figure 3.7).

Figure 3.7 Melanoma incidence and mortality, South Australia, 1977-2017 with projections to 2020



Appendix 1 Methods and Terminology

A number of terms are used to define concepts in cancer registry work. Some of the most common ones are discussed below, as well as the methodology used in creating this report.

Inclusion criteria

All cancer cases that were resident in South Australia at diagnosis and with a diagnosis date from 01/01/1977 through to the reporting year were included as incident cancers. The mortality data include the deaths in the reporting year for all those cancer cases that met the incidence inclusion criteria. As a result, a small number of mortality cases may have died in a jurisdiction outside South Australia.

Projections of cancer rates for selected sites

Key sites were selected as the base for projections. Projections of cancer rates for selected sites were done separately for males and females. Ten years of prior data, which best reflected recent trends in incidence for these sites, were used to model the projections for three subsequent years. The expected incidence and mortality for the projected years were computed using the “FORECAST” function in Excel for all the age groups separately. If any of the expected counts for the projected years was negative, it was set to zero before modelling the projections. The 2011 census population data from ABS were used to calculate the projected rates.

Age-specific rate

Age-specific incidence or mortality rates were calculated by dividing the number of new cases or deaths in each age group by the at risk population for that age group and multiplying by 100,000. These rates are usually presented in five-year age groups and by sex.

Cancer incidence

Cancer incidence is defined as the number of new cases of cancer notified for a specified period and for a specified population. It is usually presented as either the number of new cases or as a rate per 100,000 population.

Cancer mortality

Cancer mortality is defined as the number of deaths where cancer is specified as the underlying cause of death. The underlying cause of death is derived from the death certificate issued by a certified medical practitioner and is based on the World Health Organisation’s rules for attribution of cause of death. The main source of death information comes from linking the SACR records to the Registry of Births, Deaths and Marriages. Information about death and its cause may also be notified for cancer cases that die in hospital. Non-cancer deaths are also recorded on the Registry; however these are not coded specifically to their cause of death, only to a generic non-cancer death code.

Crude rate

A crude incidence or mortality rate is defined as the number of new cancer cases or deaths divided by the population at risk in a specified time period. Crude incidence and mortality rates in this report were calculated using the estimated resident South Australian population for 2014 (mid-year estimates) and are expressed as cases or deaths per 100,000 population per annum.

Age-standardised rate

A crude rate can be a misleading way to characterise a population that includes people of different ages. This problem is even more challenging when summary rates of two populations are being compared. An age-standardised rate is a summary rate that has been constructed to reflect what would be the case if the population of interest had the age distribution of some other, known population, e.g. a standard or reference population. Age-standardisation facilitates more logical comparison between populations.

Standard populations

There are two standard populations used in this report – the New World Population and the Australian Standard Population 2011. The New World Population is an estimate of the proportional age distribution of the whole world and the Australian Standard Population is the actual Australian population from the 2011 Census.

Risk

Cumulative risk is the risk an individual would have of developing or dying from a particular cancer, over a defined life span, if that person were not to die beforehand from another cause. Cumulative risk is usually calculated using the following formula:

$$\text{Cumulative risk} = (1 - e^{-\text{cumulative rate}/100})$$

The cumulative rate is the sum of the age-specific incidence or mortality rates over a certain specified age range (life expectancy or other specified range). It is calculated by using the formula:

$$\text{Cumulative rate} = \frac{5 \times (\text{sum of age-specific rates}) \times 100}{100,000}$$

This formula assumes that age groups are arranged in five-yearly blocks. Typically this rate ranges from less than 1 per cent for rare cancers to around nine per cent for common cancers. It is a good approximation to the cumulative risk and expressed as a percent.

Lifetime risk is another common way of expressing risk, where the risk is expressed as a 1 in x chance of being diagnosed with or dying of a cancer. It is calculated by the following formula:

$$\text{Lifetime risk} = 1 / \text{cumulative risk}$$

For example a cumulative rate of, say, 4.4 percent for lung cancer in males would mean that one out of every 23 males would be expected to be diagnosed with lung cancer by age 75 years if he were not to die before that age from another disease.

Person-Years of Life Lost (PYLL)

Years of potential life lost is a measure of the number of years of life lost per annum due to premature death from a particular cause, given a specified life expectancy. While life expectancy has changed, as discussed above, this report adopted the international approach of reporting this measure to age 74. There are a number of methods used to estimate cancer impact. This report used the simple approximation of:

$$\text{PYLL} = 75 - \text{age at death} \times \text{number of deaths at each age}$$

The calculation in this report was performed on five-year age groups from 0-4 through to 70-74.

Appendix 2 List of Site-Specific Tables

All incidence and mortality rates in this appendix are per 100,000 people, adjusted to the Australian 2011 population.

Site-specific tables of incidence and mortality by age and sex

Table	ICDO-3 codes
A2.1 Lip	C00
A2.2 Tongue	C01 C02
A2.3 Salivary gland	C07 C08
A2.4 Mouth	C03-C06
A2.5 Oropharynx	C09 C10
A2.6 Nasopharynx	C11
A2.7 Hypopharynx	C12 C13
A2.8 Unspecified sites - lip, oral cavity and pharynx	C14
A2.9 Oesophagus	C15
A2.10 Stomach	C16
A2.11 Small intestine	C17
A2.12 Colon and rectum	C18-C20
A2.13 Anus, anal canal, anorectum	C21
A2.14 Liver and intrahepatic bile ducts	C22
A2.15 Gallbladder and bile ducts	C23 C24
A2.16 Pancreas	C25
A2.17 Nose, nasal cavities, middle ear and accessory sinuses	C30 C31
A2.18 Larynx	C32
A2.19 Trachea, bronchus and lung	C33 C34
A2.20 Heart, mediastinum and pleura	C38
A2.21 Thymus	C37.9
A2.22 Bone, joints and articular cartilage	C40-C41
A2.23 Melanoma of skin	C44._ + M872-879
A2.24 Skin of lip	C44.0 (M800-811)
A2.25 Skin of anus (including perineum, perianal skin)	C44.5 (M800-811 8542)
A2.26 Connective and other soft tissue	C44._ + M800-958 (excl tables A2.23 A2.24 A2.25) C47 C49
A2.27 Retroperitoneum and peritoneum	C48
A2.28 Female breast	C50f
A2.29 Male breast	C50m
A2.30 Vulva	C51
A2.31 Vagina	C52.9
A2.32 Cervix uteri	C53
A2.33 Body of the uterus	C54 C55
A2.34 Ovary	C56.9
A2.35 Other and unspecified female genitalia	C57
A2.36 Placenta	C58.9
A2.37 Penis	C60
A2.38 Prostate	C61.9
A2.39 Testis	C62

Table	ICDO-3 codes
A2.40 Other male genital organs	C63
A2.41 Kidney	C64
A2.42 Renal pelvis, other and unspecified urinary organs	C65 C66 C68
A2.43 Bladder	C67
A2.44 Eye	C69
A2.45 Brain	C71
A2.46 Cranial nerves, spinal cord, meninges etc.	C70 C72
A2.47 Thyroid gland	C73
A2.48 Other endocrine glands	C74 C75
A2.49 Other and unspecified sites	C26 C39 C42 C76 C77 C80
A2.50 Non-Hodgkin lymphoma	M9591 9597 967-972 9735 9737 9738
A2.51 Hodgkin lymphoma	M965-966
A2.52 Other lymphomas	M9590, 9596
A2.53 Mast cell tumours	M974
A2.54 Malignancy of histiocytes and accessory lymphoid cells	M975
A2.55 Multiple myeloma/Plasma cell tumours	M9731-9734
A2.56 Immunoproliferative neoplasms	M976
A2.57 All leukaemias	M980-994
A2.58 Polycythaemia vera	M9950
A2.59 Myelodysplastic syndromes	M998 999
A2.60 Other chronic myeloproliferative and haematological disorders	M996 9971 9975
A2.61 All cancers	
A2.62 Mesothelioma	M905
A2.63 Kaposi sarcoma	M9140
A2.64 Acute lymphocytic leukaemia	M9826 9835-9837
A2.65 Chronic lymphocytic leukaemia	M9823
A2.66 Other and unspecified lymphoid leukaemia	M9820 9826-9837
A2.67 Acute myeloid leukaemia	M9840 9861 9865-9874 9891-9920 9930-9931
A2.68 Chronic myeloid leukaemia	M9863 9875-9876
A2.69 Other and unspecified myeloid leukaemia	M9860
A2.70 Other specified leukaemias	M994
A2.71 Leukaemias NOS	M9800-9805
A2.72 Lip, and skin of lip (non-melanoma)	C00, C44.0 (M800-811)
A2.73 Melanoma of lip	C44.0 + M872-879
A2.74 Melanoma of eyelid, including canthus	C44.1 + M872-879
A2.75 Melanoma of ear	C44.2 + M872-879
A2.76 Melanoma of other and unspecified parts of face	C44.3 + M872-879
A2.77 Melanoma of scalp and neck	C44.4 + M872-879
A2.78 Melanoma of trunk	C44.5 + M872-879
A2.79 Melanoma of upper limb, including shoulder	C44.6 + M872-879
A2.80 Melanoma of lower limb, including hip	C44.7 + M872-879
A2.81 Melanoma of other site	C44.8 + M872-879
A2.82 Melanoma, site unspecified	C44.9 + M872-879

Table A2.1 – Cancer of the Lip												
South Australia												
Year – 2017												
	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	2	0	2	3.5	0.0	1.7	0	0	0	0.0	0.0	0.0
35–39	4	0	4	7.6	0.0	3.8	0	0	0	0.0	0.0	0.0
40–44	3	0	3	5.7	0.0	2.8	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	6	2	8	10.8	3.5	7.1	0	0	0	0.0	0.0	0.0
55–59	7	1	8	12.6	1.7	7.1	0	0	0	0.0	0.0	0.0
60–64	1	0	1	2.0	0.0	1.0	0	0	0	0.0	0.0	0.0
65–69	3	2	5	6.5	4.1	5.3	0	0	0	0.0	0.0	0.0
70–74	6	1	7	16.0	2.5	9.0	0	0	0	0.0	0.0	0.0
75–79	1	1	2	3.9	3.4	3.6	0	0	0	0.0	0.0	0.0
80–84	3	3	6	17.0	13.7	15.2	0	0	0	0.0	0.0	0.0
85+	3	2	5	18.2	7.2	11.3	0	0	0	0.0	0.0	0.0
Total/Crude rate	39	12	51	4.6	1.4	3.0	0	0	0	0.0	0.0	0.0
AS Rate (Aust)				4.3	1.1	2.6				0.0	0.0	0.0
Confidence Interval (95%)				3.0 – 5.7	0.5 – 1.7	1.9 – 3.4				0.0 – 0.0	0.0 – 0.0	0.0 – 0.0
AS Rate (World)				3.3	0.7	1.9				0.0	0.0	0.0
Confidence Interval (95%)				2.3 – 4.2	0.3 – 1.0	1.4 – 2.5				0.0 – 0.0	0.0 – 0.0	0.0 – 0.0
Lifetime Risk				1 in 310	1 in 1689	1 in 530				N/A	N/A	N/A
PYLL										0	0	0
% of all cancers				0.7	0.3	0.5				0.0	0.0	0.0
Trend 2013–2017 (per annum)				-9.6%	-2.0%	-7.8%				0.0%	-25.0%	1.1%

Table A2.2 – Cancer of the Tongue												
South Australia												
Year – 2017												
	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	1	1	0.0	1.9	0.9	0	0	0	0.0	0.0	0.0
45–49	1	1	2	1.8	1.7	1.7	1	1	2	1.8	1.7	1.7
50–54	2	4	6	3.6	7.0	5.3	0	0	0	0.0	0.0	0.0
55–59	10	1	11	18.0	1.7	9.7	0	0	0	0.0	0.0	0.0
60–64	7	7	14	14.0	13.3	13.6	0	1	1	0.0	1.9	1.0
65–69	8	7	15	17.4	14.4	15.8	3	0	3	6.5	0.0	3.2
70–74	11	3	14	29.4	7.5	18.0	4	1	5	10.7	2.5	6.4
75–79	4	2	6	15.6	6.8	10.9	0	1	1	0.0	3.4	1.8
80–84	1	2	3	5.7	9.1	7.6	0	2	2	0.0	9.1	5.1
85+	2	3	5	12.2	10.7	11.3	0	1	1	0.0	3.6	2.3
Total/Crude rate	46	31	77	5.4	3.6	4.5	8	7	15	0.9	0.8	0.9
AS Rate (Aust)				4.6	3.0	3.8				0.7	0.6	0.7
Confidence Interval (95%)				3.3 – 6.0	1.9 – 4.0	2.9 – 4.6				0.2 – 1.3	0.2 – 1.1	0.3 – 1.1
AS Rate (World)				3.2	2.0	2.6				0.5	0.4	0.5
Confidence Interval (95%)				2.3 – 4.0	1.3 – 2.7	2.0 – 3.1				0.2 – 0.9	0.1 – 0.7	0.2 – 0.7
Lifetime Risk				1 in 238	1 in 422	1 in 307				1 in 1,056	1 in 3,285	1 in 1,625
PYLL										60	43	103
% of all cancers				0.8	0.6	0.7				0.4	0.4	0.4
Trend 2013–2017 (per annum)				-6.3%	4.9%	-3.2%				2.5%	-12.3%	-4.6%

Table A2.3 – Cancer of the Salivary gland												
South Australia												
Year – 2017												
	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	1	1	0.0	1.7	0.9	0	0	0	0.0	0.0	0.0
35–39	1	1	2	1.9	1.9	1.9	0	0	0	0.0	0.0	0.0
40–44	1	1	2	1.9	1.9	1.9	0	0	0	0.0	0.0	0.0
45–49	2	0	2	3.5	0.0	1.7	0	0	0	0.0	0.0	0.0
50–54	3	0	3	5.4	0.0	2.7	1	0	1	1.8	0.0	0.9
55–59	1	0	1	1.8	0.0	0.9	0	0	0	0.0	0.0	0.0
60–64	2	0	2	4.0	0.0	1.9	0	0	0	0.0	0.0	0.0
65–69	2	1	3	4.3	2.1	3.2	1	0	1	2.2	0.0	1.1
70–74	1	2	3	2.7	5.0	3.9	0	0	0	0.0	0.0	0.0
75–79	5	2	7	19.5	6.8	12.7	1	0	1	3.9	0.0	1.8
80–84	2	0	2	11.4	0.0	5.1	0	0	0	0.0	0.0	0.0
85+	2	2	4	12.2	7.2	9.0	0	0	0	0.0	0.0	0.0
Total/Crude rate	22	10	32	2.6	1.1	1.9	3	0	3	0.4	0.0	0.2
AS Rate (Aust)				2.4	0.9	1.6				0.3	0.0	0.2
Confidence Interval (95%)				1.4 – 3.4	0.3 – 1.5	1.1 – 2.2				0.0 – 0.7	0.0 – 0.0	0.0 – 0.3
AS Rate (World)				1.7	0.7	1.2				0.2	0.0	0.1
Confidence Interval (95%)				1.0 – 2.3	0.3 – 1.1	0.8 – 1.5				0.0 – 0.5	0.0 – 0.0	0.0 – 0.2
Lifetime Risk				1 in 785	1 in 1600	1 in 1059				1 in 5,033	N/A	1 in 10,279
PYLL										30	0	30
% of all cancers				0.4	0.2	0.3				0.1	0.0	0.1
Trend 2013–2017 (per annum)				-6.0%	-8.4%	-6.8%				-3.6%	-1.4%	-2.1%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.4 – Cancer of the Mouth												
South Australia												
Year – 2017												
	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	1	1	0.0	1.7	0.9	0	0	0	0.0	0.0	0.0
30–34	1	0	1	1.7	0.0	0.9	0	0	0	0.0	0.0	0.0
35–39	1	0	1	1.9	0.0	0.9	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	4	1	5	7.2	1.8	4.5	0	0	0	0.0	0.0	0.0
55–59	0	3	3	0.0	5.2	2.6	1	0	1	1.8	0.0	0.9
60–64	4	0	4	8.0	0.0	3.9	0	0	0	0.0	0.0	0.0
65–69	6	3	9	13.0	6.2	9.5	2	0	2	4.3	0.0	2.1
70–74	7	2	9	18.7	5.0	11.6	4	0	4	10.7	0.0	5.2
75–79	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
80–84	1	2	3	5.7	9.1	7.6	0	1	1	0.0	4.6	2.5
85+	0	5	5	0.0	17.9	11.3	0	3	3	0.0	10.7	6.8
Total/Crude rate	24	17	41	2.8	1.9	2.4	7	4	11	0.8	0.5	0.6
AS Rate (Aust)				2.5	1.5	2.0				0.6	0.3	0.5
Confidence Interval (95%)				1.5 – 3.4	0.8 – 2.2	1.4 – 2.6				0.2 – 1.1	0.0 – 0.6	0.2 – 0.8
AS Rate (World)				1.8	1.0	1.4				0.4	0.1	0.3
Confidence Interval (95%)				1.1 – 2.5	0.5 – 1.4	1.0 – 1.8				0.1 – 0.8	0.0 – 0.2	0.1 – 0.4
Lifetime Risk				1 in 396	1 in 1009	1 in 576				1 in 1,189	N/A	1 in 2,456
PYLL										43	0	43
% of all cancers				0.4	0.4	0.4				0.3	0.2	0.3
Trend 2013–2017 (per annum)				-4.9%	-5.5%	-5.0%				10.4%	-9.1%	4.0%

Table A2.5 – Cancer of the Oropharynx												
South Australia												
Year – 2017												
	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	1	0	1	1.9	0.0	0.9	0	0	0	0.0	0.0	0.0
40–44	1	1	2	1.9	1.9	1.9	0	0	0	0.0	0.0	0.0
45–49	7	1	8	12.3	1.7	6.9	1	0	1	1.8	0.0	0.9
50–54	6	0	6	10.8	0.0	5.3	1	0	1	1.8	0.0	0.9
55–59	13	2	15	23.4	3.5	13.2	1	0	1	1.8	0.0	0.9
60–64	5	0	5	10.0	0.0	4.9	0	0	0	0.0	0.0	0.0
65–69	2	1	3	4.3	2.1	3.2	1	0	1	2.2	0.0	1.1
70–74	8	1	9	21.4	2.5	11.6	1	1	2	2.7	2.5	2.6
75–79	5	2	7	19.5	6.8	12.7	4	1	5	15.6	3.4	9.1
80–84	3	1	4	17.0	4.6	10.1	2	0	2	11.4	0.0	5.1
85+	1	0	1	6.1	0.0	2.3	1	0	1	6.1	0.0	2.3
Total/Crude rate	52	9	61	6.1	1.0	3.5	12	2	14	1.4	0.2	0.8
AS Rate (Aust)				5.6	0.9	3.2				1.3	0.2	0.7
Confidence Interval (95%)				4.1 – 7.1	0.3 – 1.5	2.4 – 4.0				0.5 – 2.0	0.0 – 0.4	0.3 – 1.0
AS Rate (World)				4.1	0.6	2.3				0.8	0.1	0.4
Confidence Interval (95%)				3.0 – 5.2	0.2 – 1.0	1.8 – 2.9				0.4 – 1.2	0.0 – 0.2	0.2 – 0.6
Lifetime Risk				1 in 233	1 in 1724	1 in 418				1 in 1,962	1 in 8,041	1 in 3,191
PYLL										78	3	80
% of all cancers				0.9	0.2	0.6				0.6	0.1	0.4
Trend 2013–2017 (per annum)				10.2%	-9.7%	5.8%				3.4%	-11.7%	-1.1%

Table A2.6 – Cancer of the Nasopharynx												
South Australia												
Year – 2017												
	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	1	0	1	1.9	0.0	0.9	0	0	0	0.0	0.0	0.0
45–49	1	1	2	1.8	1.7	1.7	0	0	0	0.0	0.0	0.0
50–54	0	0	0	0.0	0.0	0.0	1	0	1	1.8	0.0	0.9
55–59	2	1	3	3.6	1.7	2.6	0	0	0	0.0	0.0	0.0
60–64	0	0	0	0.0	0.0	0.0	1	0	1	2.0	0.0	1.0
65–69	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
70–74	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
75–79	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
80–84	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
85+	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
Total/Crude rate	4	2	6	0.5	0.2	0.3	2	0	2	0.2	0.0	0.1
AS Rate (Aust)				0.5	0.2	0.3				0.2	0.0	0.1
Confidence Interval (95%)				0.0 – 0.9	0.0 – 0.5	0.1 – 0.6				0.0 – 0.6	0.0 – 0.0	0.0 – 0.3
AS Rate (World)				0.4	0.2	0.3				0.2	0.0	0.1
Confidence Interval (95%)				0.0 – 0.8	0.0 – 0.4	0.1 – 0.5				0.0 – 0.4	0.0 – 0.0	0.0 – 0.2
Lifetime Risk				1 in 2767	1 in 5817	1 in 3762				1 in 5,252	N/A	1 in 10,729
PYLL										35	0	35
% of all cancers				0.1	0.0	0.1				0.1	0.0	0.1
Trend 2013–2017 (per annum)				4.8%	undefined	16.8%				0.6%	-26.1%	-6.2%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.7 – Cancer of the Hypopharynx

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	1	0	1	1.8	0.0	0.9	0	0	0	0.0	0.0	0.0
55–59	1	0	1	1.8	0.0	0.9	1	0	1	1.8	0.0	0.9
60–64	1	0	1	2.0	0.0	1.0	1	0	1	2.0	0.0	1.0
65–69	1	0	1	2.2	0.0	1.1	0	0	0	0.0	0.0	0.0
70–74	2	0	2	5.3	0.0	2.6	2	0	2	5.3	0.0	2.6
75–79	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
80–84	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
85+	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
Total/Crude rate	6	0	6	0.7	0.0	0.3	4	0	4	0.5	0.0	0.2
AS Rate (Aust)				0.6	0.0	0.3				0.4	0.0	0.2
Confidence Interval (95%)				0.1 – 1.1	0.0 – 0.0	0.1 – 0.5				0.0 – 0.8	0.0 – 0.0	0.0 – 0.4
AS Rate (World)				0.4	0.0	0.2				0.3	0.0	0.1
Confidence Interval (95%)				0.1 – 0.8	0.0 – 0.0	0.0 – 0.4				0.0 – 0.5	0.0 – 0.0	0.0 – 0.3
Lifetime Risk				1 in 1525	N/A	1 in 3136				1 in 2,187	N/A	1 in 4,513
PYLL										35	0	35
% of all cancers				0.1	0.0	0.1				0.2	0.0	0.1
Trend 2013–2017 (per annum)				-13.6%	-21.9%	-15.3%				-3.7%	-19.1%	-6.3%

Table A2.8 – Cancer of Unspecified sites - lip, oral cavity and pharynx

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
55–59	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
60–64	1	0	1	2.0	0.0	1.0	1	0	1	2.0	0.0	1.0
65–69	1	0	1	2.2	0.0	1.1	1	0	1	2.2	0.0	1.1
70–74	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
75–79	1	1	2	3.9	3.4	3.6	1	0	1	3.9	0.0	1.8
80–84	1	0	1	5.7	0.0	2.5	1	0	1	5.7	0.0	2.5
85+	0	0	0	0.0	0.0	0.0	0	1	1	0.0	3.6	2.3
Total/Crude rate	4	1	5	0.5	0.1	0.3	4	1	5	0.5	0.1	0.3
AS Rate (Aust)				0.4	0.1	0.2				0.4	0.1	0.2
Confidence Interval (95%)				0.0 – 0.8	0.0 – 0.3	0.0 – 0.5				0.0 – 0.8	0.0 – 0.2	0.0 – 0.4
AS Rate (World)				0.2	0.1	0.1				0.2	0.0	0.1
Confidence Interval (95%)				0.0 – 0.5	0.0 – 0.1	0.0 – 0.3				0.0 – 0.5	0.0 – 0.1	0.0 – 0.2
Lifetime Risk				1 in 4793	N/A	1 in 9859				1 in 4,793	N/A	1 in 9,859
PYLL										20	0	20
% of all cancers				0.1	0.0	0.0				0.2	0.1	0.1
Trend 2013–2017 (per annum)				9.4%	56.1%	18.7%				56.5%	-6.9%	26.3%

Table A2.9 – Cancer of the Oesophagus

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	1	0	1	1.7	0.0	0.9
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	1	1	2	1.9	1.9	1.9	0	0	0	0.0	0.0	0.0
45–49	2	0	2	3.5	0.0	1.7	2	0	2	3.5	0.0	1.7
50–54	3	1	4	5.4	1.8	3.6	2	0	2	3.6	0.0	1.8
55–59	8	1	9	14.4	1.7	7.9	4	1	5	7.2	1.7	4.4
60–64	14	4	18	28.0	7.6	17.5	6	0	6	12.0	0.0	5.8
65–69	23	7	30	49.9	14.4	31.7	11	4	15	23.9	8.2	15.8
70–74	14	4	18	37.4	9.9	23.2	5	1	6	13.4	2.5	7.7
75–79	15	5	20	58.6	17.0	36.3	11	4	15	43.0	13.6	27.3
80–84	9	3	12	51.1	13.7	30.4	5	9	14	28.4	41.2	35.5
85+	10	6	16	60.8	21.5	36.1	8	5	13	48.6	17.9	29.3
Total/Crude rate	99	32	131	11.6	3.7	7.6	55	24	79	6.5	2.8	4.6
AS Rate (Aust)				10.1	2.8	6.2				5.7	2.0	3.7
Confidence Interval (95%)				8.1 – 12.1	1.8 – 3.8	5.1 – 7.3				4.2 – 7.2	1.2 – 2.8	2.9 – 4.6
AS Rate (World)				6.3	1.7	3.9				3.5	1.1	2.2
Confidence Interval (95%)				5.2 – 7.5	1.1 – 2.3	3.3 – 4.6				2.6 – 4.4	0.7 – 1.4	1.8 – 2.7
Lifetime Risk				1 in 143	1 in 537	1 in 229				1 in 307	1 in 1,609	1 in 524
PYLL										383	50	433
% of all cancers				1.7	0.7	1.2				2.7	1.4	2.1
Trend 2013–2017 (per annum)				0.3%	4.4%	1.4%				-1.5%	0.6%	-0.7%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.10 – Cancer of the Stomach

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	1	1	0.0	1.8	0.9	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	1	0	1	1.7	0.0	0.9
35–39	3	0	3	5.7	0.0	2.8	0	0	0	0.0	0.0	0.0
40–44	2	1	3	3.8	1.9	2.8	0	0	0	0.0	0.0	0.0
45–49	5	6	11	8.8	10.3	9.5	2	0	2	3.5	0.0	1.7
50–54	9	4	13	16.2	7.0	11.6	3	0	3	5.4	0.0	2.7
55–59	12	4	16	21.6	6.9	14.1	7	2	9	12.6	3.5	7.9
60–64	9	3	12	18.0	5.7	11.7	5	4	9	10.0	7.6	8.8
65–69	17	4	21	36.9	8.2	22.2	10	2	12	21.7	4.1	12.7
70–74	19	7	26	50.8	17.4	33.5	9	4	13	24.1	9.9	16.8
75–79	20	7	27	78.1	23.8	49.1	12	5	17	46.9	17.0	30.9
80–84	18	10	28	102.2	45.7	70.9	10	9	19	56.8	41.2	48.1
85+	14	9	23	85.1	32.2	51.8	11	14	25	66.9	50.2	56.3
Total/Crude rate	128	56	184	15.0	6.4	10.7	70	40	110	8.2	4.6	6.4
AS Rate (Aust)				13.4	5.2	9.0				7.2	3.3	5.1
Confidence Interval (95%)				11.0 – 15.7	3.8 – 6.6	7.7 – 10.3				5.5 – 8.9	2.2 – 4.3	4.2 – 6.1
AS Rate (World)				8.5	3.4	5.8				4.4	1.7	3.0
Confidence Interval (95%)				7.2 – 9.9	2.5 – 4.3	5.0 – 6.6				3.4 – 5.3	1.2 – 2.2	2.5 – 3.5
Lifetime Risk				1 in 124	1 in 338	1 in 184				1 in 254	1 in 797	1 in 390
PYLL										448	110	558
% of all cancers				2.2	1.2	1.8				3.4	2.4	3.0
Trend 2013–2017 (per annum)				3.9%	-1.7%	1.6%				-4.1%	-1.5%	-3.5%

Table A2.11 – Cancer of the Small intestine

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	1	1	0.0	1.9	0.9	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	2	2	4	3.5	3.4	3.5	0	0	0	0.0	0.0	0.0
50–54	2	2	4	3.6	3.5	3.6	0	0	0	0.0	0.0	0.0
55–59	2	4	6	3.6	6.9	5.3	0	1	1	0.0	1.7	0.9
60–64	2	5	7	4.0	9.5	6.8	2	2	4	4.0	3.8	3.9
65–69	5	3	8	10.8	6.2	8.4	0	2	2	0.0	4.1	2.1
70–74	3	5	8	8.0	12.4	10.3	2	0	2	5.3	0.0	2.6
75–79	8	6	14	31.2	20.4	25.4	1	1	2	3.9	3.4	3.6
80–84	3	3	6	17.0	13.7	15.2	1	1	2	5.7	4.6	5.1
85+	4	1	5	24.3	3.6	11.3	2	3	5	12.2	10.7	11.3
Total/Crude rate	31	32	63	3.6	3.7	3.7	8	10	18	0.9	1.1	1.0
AS Rate (Aust)				3.2	3.1	3.1				0.8	0.9	0.8
Confidence Interval (95%)				2.1 – 4.3	2.0 – 4.1	2.3 – 3.8				0.3 – 1.4	0.3 – 1.4	0.4 – 1.2
AS Rate (World)				2.0	2.1	2.0				0.4	0.5	0.5
Confidence Interval (95%)				1.3 – 2.6	1.4 – 2.8	1.6 – 2.5				0.2 – 0.7	0.2 – 0.8	0.3 – 0.7
Lifetime Risk				1 in 596	1 in 457	1 in 516				1 in 2,138	1 in 2,078	1 in 2,114
PYLL										30	58	88
% of all cancers				0.5	0.7	0.6				0.4	0.6	0.5
Trend 2013–2017 (per annum)				10.9%	8.9%	9.4%				13.8%	14.2%	13.3%

Table A2.12 – Cancer of the Colon and rectum

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	5	5	0.0	9.9	4.8	0	0	0	0.0	0.0	0.0
20–24	1	2	3	1.7	3.6	2.6	0	0	0	0.0	0.0	0.0
25–29	3	6	9	5.2	10.4	7.8	1	0	1	1.7	0.0	0.9
30–34	6	9	15	10.4	15.4	12.9	0	0	0	0.0	0.0	0.0
35–39	7	10	17	13.2	18.7	16.0	2	2	4	3.8	3.7	3.8
40–44	6	6	12	11.3	11.3	11.3	4	2	6	7.5	3.8	5.7
45–49	17	25	42	29.8	42.7	36.3	5	4	9	8.8	6.8	7.8
50–54	36	28	64	65.0	49.2	57.0	15	6	21	27.1	10.5	18.7
55–59	50	44	94	89.8	76.1	82.9	9	8	17	16.2	13.8	15.0
60–64	82	47	129	164.3	89.0	125.6	18	14	32	36.1	26.5	31.2
65–69	83	75	158	180.1	154.1	166.7	33	13	46	71.6	26.7	48.5
70–74	91	86	177	243.3	213.9	228.1	25	12	37	66.8	29.8	47.7
75–79	75	80	155	292.9	272.0	281.7	25	25	50	97.6	85.0	90.9
80–84	86	64	150	488.1	292.8	380.0	39	27	66	221.4	123.5	167.2
85+	62	89	151	376.9	318.8	340.3	48	70	118	291.8	250.8	266.0
Total/Crude rate	605	576	1,181	71.0	66.0	68.5	224	183	407	26.3	21.0	23.6
AS Rate (Aust)				63.2	52.5	57.4				23.6	15.2	19.2
Confidence Interval (95%)				58.1 – 68.3	48.1 – 56.8	54.1 – 60.7				20.5 – 26.8	13.0 – 17.5	17.3 – 21.0
AS Rate (World)				40.3	35.2	37.5				13.8	8.5	11.0
Confidence Interval (95%)				37.3 – 43.4	32.3 – 38.1	35.4 – 39.6				12.1 – 15.5	7.2 – 9.7	10.0 – 12.0
Lifetime Risk				1 in 25	1 in 29	1 in 27				1 in 84	1 in 165	1 in 112
PYLL										1,420	828	2,248
% of all cancers				10.6	12.0	11.2				11.0	10.9	11.0
Trend 2013–2017 (per annum)				-4.9%	-2.5%	-3.9%				-1.6%	-4.6%	-2.8%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.13 – Cancer of the Anus, anal canal, anorectum

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	1	1	0.0	1.9	0.9	0	0	0	0.0	0.0	0.0
45–49	1	4	5	1.8	6.8	4.3	0	0	0	0.0	0.0	0.0
50–54	0	0	0	0.0	0.0	0.0	0	1	1	0.0	1.8	0.9
55–59	2	6	8	3.6	10.4	7.1	0	1	1	0.0	1.7	0.9
60–64	2	4	6	4.0	7.6	5.8	1	2	3	2.0	3.8	2.9
65–69	2	4	6	4.3	8.2	6.3	0	0	0	0.0	0.0	0.0
70–74	2	3	5	5.3	7.5	6.4	0	1	1	0.0	2.5	1.3
75–79	0	3	3	0.0	10.2	5.5	0	1	1	0.0	3.4	1.8
80–84	1	0	1	5.7	0.0	2.5	0	0	0	0.0	0.0	0.0
85+	1	2	3	6.1	7.2	6.8	1	1	2	6.1	3.6	4.5
Total/Crude rate	11	27	38	1.3	3.1	2.2	2	7	9	0.2	0.8	0.5
AS Rate (Aust)				1.1	2.6	1.9				0.2	0.7	0.4
Confidence Interval (95%)				0.5 – 1.8	1.6 – 3.6	1.3 – 2.5				0.0 – 0.5	0.2 – 1.2	0.2 – 0.7
AS Rate (World)				0.8	1.9	1.3				0.1	0.4	0.3
Confidence Interval (95%)				0.3 – 1.2	1.2 – 2.6	0.9 – 1.8				0.0 – 0.3	0.1 – 0.8	0.1 – 0.5
Lifetime Risk				1 in 1051	1 in 473	1 in 647				1 in 9,983	1 in 2,049	1 in 3,344
PYLL										13	68	80
% of all cancers				0.2	0.6	0.4				0.1	0.4	0.2
Trend 2013–2017 (per annum)				-0.7%	7.3%	4.1%				-17.6%	83.3%	-0.8%

Table A2.14 – Cancer of the Liver and intrahepatic bile ducts

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	1	0	1	1.9	0.0	1.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	1	0	1	2.0	0.0	1.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	1	0	1	1.7	0.0	0.9	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	1	0	1	1.9	0.0	0.9	0	0	0	0.0	0.0	0.0
40–44	1	1	2	1.9	1.9	1.9	0	0	0	0.0	0.0	0.0
45–49	2	1	3	3.5	1.7	2.6	0	0	0	0.0	0.0	0.0
50–54	8	4	12	14.4	7.0	10.7	6	1	7	10.8	1.8	6.2
55–59	19	7	26	34.1	12.1	22.9	14	4	18	25.2	6.9	15.9
60–64	24	5	29	48.1	9.5	28.2	19	5	24	38.1	9.5	23.4
65–69	14	4	18	30.4	8.2	19.0	11	4	15	23.9	8.2	15.8
70–74	18	8	26	48.1	19.9	33.5	11	6	17	29.4	14.9	21.9
75–79	16	5	21	62.5	17.0	38.2	10	4	14	39.0	13.6	25.4
80–84	11	5	16	62.4	22.9	40.5	5	7	12	28.4	32.0	30.4
85+	6	8	14	36.5	28.7	31.6	9	5	14	54.7	17.9	31.6
Total/Crude rate	122	48	170	14.3	5.5	9.9	86	36	122	10.1	4.1	7.1
AS Rate (Aust)				12.7	4.4	8.4				9.0	3.2	5.9
Confidence Interval (95%)				10.5 – 15.0	3.1 – 5.6	7.1 – 9.7				7.1 – 10.9	2.1 – 4.2	4.9 – 7.0
AS Rate (World)				8.6	2.8	5.6				5.9	1.9	3.8
Confidence Interval (95%)				7.1 – 10.1	2.0 – 3.6	4.8 – 6.4				4.6 – 7.1	1.3 – 2.5	3.2 – 4.5
Lifetime Risk				1 in 108	1 in 332	1 in 165				1 in 155	1 in 485	1 in 238
PYLL										790	200	990
% of all cancers				2.1	1.0	1.6				4.2	2.1	3.3
Trend 2013–2017 (per annum)				-0.3%	6.9%	1.3%				1.2%	4.3%	2.3%

Table A2.15 – Cancer of the Gallbladder and bile ducts

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	1	1	2	1.8	1.7	1.7	0	0	0	0.0	0.0	0.0
50–54	1	2	3	1.8	3.5	2.7	2	2	4	3.6	3.5	3.6
55–59	6	1	7	10.8	1.7	6.2	0	0	0	0.0	0.0	0.0
60–64	1	7	8	2.0	13.3	7.8	3	3	6	6.0	5.7	5.8
65–69	6	8	14	13.0	16.4	14.8	3	3	6	6.5	6.2	6.3
70–74	2	2	4	5.3	5.0	5.2	4	6	10	10.7	14.9	12.9
75–79	6	7	13	23.4	23.8	23.6	4	8	12	15.6	27.2	21.8
80–84	5	10	15	28.4	45.7	38.0	5	7	12	28.4	32.0	30.4
85+	5	12	17	30.4	43.0	38.3	6	11	17	36.5	39.4	38.3
Total/Crude rate	33	50	83	3.9	5.7	4.8	27	40	67	3.2	4.6	3.9
AS Rate (Aust)				3.4	4.3	3.9				2.8	3.3	3.1
Confidence Interval (95%)				2.3 – 4.6	3.1 – 5.6	3.1 – 4.8				1.7 – 3.9	2.3 – 4.4	2.3 – 3.8
AS Rate (World)				2.1	2.5	2.3				1.6	1.8	1.7
Confidence Interval (95%)				1.4 – 2.7	1.8 – 3.2	1.8 – 2.8				1.0 – 2.1	1.3 – 2.4	1.3 – 2.1
Lifetime Risk				1 in 577	1 in 481	1 in 523				1 in 746	1 in 661	1 in 699
PYLL										115	120	235
% of all cancers				0.6	1.0	0.8				1.3	2.4	1.8
Trend 2013–2017 (per annum)				-1.1%	8.7%	4.4%				6.3%	2.4%	4.7%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.16 – Cancer of the Pancreas

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	4	4	0.0	7.5	3.8	0	0	0	0.0	0.0	0.0
40–44	1	2	3	1.9	3.8	2.8	0	0	0	0.0	0.0	0.0
45–49	8	6	14	14.0	10.3	12.1	7	3	10	12.3	5.1	8.6
50–54	8	4	12	14.4	7.0	10.7	8	3	11	14.4	5.3	9.8
55–59	5	9	14	9.0	15.6	12.3	2	3	5	3.6	5.2	4.4
60–64	10	12	22	20.0	22.7	21.4	7	11	18	14.0	20.8	17.5
65–69	20	16	36	43.4	32.9	38.0	9	19	28	19.5	39.0	29.5
70–74	20	19	39	53.5	47.3	50.3	17	19	36	45.5	47.3	46.4
75–79	26	24	50	101.5	81.6	90.9	18	23	41	70.3	78.2	74.5
80–84	16	23	39	90.8	105.2	98.8	21	23	44	119.2	105.2	111.5
85+	18	25	43	109.4	89.6	96.9	19	27	46	115.5	96.7	103.7
Total/Crude rate	132	144	276	15.5	16.5	16.0	108	131	239	12.7	15.0	13.9
AS Rate (Aust)				13.6	12.8	13.2				11.3	11.2	11.2
Confidence Interval (95%)				11.3 – 16.0	10.7 – 15.0	11.6 – 14.7				9.2 – 13.5	9.2 – 13.1	9.8 – 12.6
AS Rate (World)				8.4	8.1	8.2				6.6	6.5	6.5
Confidence Interval (95%)				7.0 – 9.7	6.8 – 9.4	7.3 – 9.1				5.5 – 7.8	5.4 – 7.6	5.8 – 7.3
Lifetime Risk				1 in 129	1 in 137	1 in 133				1 in 183	1 in 163	1 in 172
PYLL				2.3	3.0	2.6				605	530	1,135
% of all cancers				2.3	3.0	2.6				5.3	7.8	6.4
Trend 2013–2017 (per annum)				-2.3%	-1.2%	-1.9%				2.8%	-3.0%	-0.2%

Table A2.17 – Cancer of the Nose, nasal cavities, middle ear and accessory sinuses

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	1	0	1	1.9	0.0	0.9	0	0	0	0.0	0.0	0.0
45–49	0	1	1	0.0	1.7	0.9	0	0	0	0.0	0.0	0.0
50–54	1	2	3	1.8	3.5	2.7	1	0	1	1.8	0.0	0.9
55–59	1	0	1	1.8	0.0	0.9	0	0	0	0.0	0.0	0.0
60–64	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
65–69	0	1	1	0.0	2.1	1.1	2	1	3	4.3	2.1	3.2
70–74	0	1	1	0.0	2.5	1.3	1	0	1	2.7	0.0	1.3
75–79	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
80–84	1	1	2	5.7	4.6	5.1	0	0	0	0.0	0.0	0.0
85+	1	0	1	6.1	0.0	2.3	3	1	4	18.2	3.6	9.0
Total/Crude rate	5	6	11	0.6	0.7	0.6	7	2	9	0.8	0.2	0.5
AS Rate (Aust)				0.6	0.6	0.6				0.7	0.2	0.4
Confidence Interval (95%)				0.1 – 1.1	0.1 – 1.1	0.2 – 0.9				0.2 – 1.3	0.0 – 0.4	0.1 – 0.7
AS Rate (World)				0.4	0.4	0.4				0.4	0.1	0.2
Confidence Interval (95%)				0.1 – 0.7	0.1 – 0.8	0.2 – 0.7				0.1 – 0.7	0.0 – 0.2	0.1 – 0.4
Lifetime Risk				1 in 3646	1 in 2048	1 in 2596				1 in 2,269	1 in 9,737	1 in 3,743
PYLL				0.1	0.1	0.1				40	8	48
% of all cancers				0.1	0.1	0.1				0.3	0.1	0.2
Trend 2013–2017 (per annum)				-7.5%	10.2%	-1.8%				5.9%	-11.6%	-3.4%

Table A2.18 – Cancer of the Larynx

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	1	0	1	1.8	0.0	0.9	1	0	1	1.8	0.0	0.9
50–54	3	1	4	5.4	1.8	3.6	2	1	3	3.6	1.8	2.7
55–59	7	0	7	12.6	0.0	6.2	0	0	0	0.0	0.0	0.0
60–64	3	0	3	6.0	0.0	2.9	1	0	1	2.0	0.0	1.0
65–69	9	2	11	19.5	4.1	11.6	2	1	3	4.3	2.1	3.2
70–74	8	1	9	21.4	2.5	11.6	0	0	0	0.0	0.0	0.0
75–79	3	0	3	11.7	0.0	5.5	2	0	2	7.8	0.0	3.6
80–84	12	0	12	68.1	0.0	30.4	1	0	1	5.7	0.0	2.5
85+	2	2	4	12.2	7.2	9.0	1	0	1	6.1	0.0	2.3
Total/Crude rate	48	6	54	5.6	0.7	3.1	10	2	12	1.2	0.2	0.7
AS Rate (Aust)				5.0	0.5	2.6				1.1	0.2	0.6
Confidence Interval (95%)				3.5 – 6.4	0.1 – 0.9	1.9 – 3.3				0.4 – 1.7	0.0 – 0.5	0.3 – 1.0
AS Rate (World)				3.1	0.3	1.6				0.7	0.2	0.4
Confidence Interval (95%)				2.3 – 3.9	0.0 – 0.6	1.2 – 2.1				0.3 – 1.1	0.0 – 0.4	0.2 – 0.7
Lifetime Risk				1 in 300	1 in 2395	1 in 545				1 in 1,709	1 in 5,247	1 in 2,606
PYLL				0.8	0.1	0.5				100	30	130
% of all cancers				0.8	0.1	0.5				0.5	0.1	0.3
Trend 2013–2017 (per annum)				1.5%	14.5%	3.2%				-10.0%	32.0%	-4.4%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.19 – Cancer of the Trachea, bronchus and lung

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	1	1	0.0	1.7	0.9	0	0	0	0.0	0.0	0.0
30–34	0	2	2	0.0	3.4	1.7	0	0	0	0.0	0.0	0.0
35–39	1	2	3	1.9	3.7	2.8	0	0	0	0.0	0.0	0.0
40–44	2	3	5	3.8	5.7	4.7	1	0	1	1.9	0.0	0.9
45–49	7	5	12	12.3	8.5	10.4	3	2	5	5.3	3.4	4.3
50–54	17	22	39	30.7	38.7	34.7	11	6	17	19.9	10.5	15.1
55–59	38	34	72	68.3	58.8	63.5	23	17	40	41.3	29.4	35.3
60–64	70	62	132	140.2	117.4	128.5	43	38	81	86.2	72.0	78.9
65–69	75	55	130	162.7	113.0	137.2	55	36	91	119.3	73.9	96.0
70–74	98	95	193	262.0	236.3	248.7	75	53	128	200.5	131.8	164.9
75–79	78	72	150	304.6	244.8	272.6	69	51	120	269.4	173.4	218.1
80–84	67	55	122	380.3	251.6	309.0	59	32	91	334.9	146.4	230.5
85+	71	62	133	431.6	222.1	299.8	91	71	162	553.1	254.3	365.1
Total/Crude rate	524	470	994	61.5	53.9	57.7	430	306	736	50.5	35.1	42.7
AS Rate (Aust)				53.5	41.8	46.9				44.0	25.9	33.9
Confidence Interval (95%)				48.9 – 58.1	38.0 – 45.6	44.0 – 49.9				39.8 – 48.2	23.0 – 28.9	31.4 – 36.4
AS Rate (World)				32.3	26.6	29.1				25.0	15.4	19.7
Confidence Interval (95%)				29.8 – 34.9	24.2 – 28.9	27.4 – 30.9				22.8 – 27.1	13.7 – 17.0	18.4 – 21.1
Lifetime Risk				1 in 30	1 in 35	1 in 32				1 in 43	1 in 63	1 in 51
PYLL										1,903	1,365	3,268
% of all cancers				9.1	9.8	9.5				21.1	18.3	19.8
Trend 2013–2017 (per annum)				-3.3%	7.0%	0.8%				-2.6%	0.9%	-1.3%

Table A2.20 – Cancer of the Heart, mediastinum and pleura

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	1	1	0.0	2.1	1.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
55–59	4	1	5	7.2	1.7	4.4	2	2	4	3.6	3.5	3.5
60–64	7	1	8	14.0	1.9	7.8	4	0	4	8.0	0.0	3.9
65–69	2	2	4	4.3	4.1	4.2	3	1	4	6.5	2.1	4.2
70–74	8	1	9	21.4	2.5	11.6	4	1	5	10.7	2.5	6.4
75–79	6	3	9	23.4	10.2	16.4	9	1	10	35.1	3.4	18.2
80–84	11	1	12	62.4	4.6	30.4	9	2	11	51.1	9.1	27.9
85+	10	1	11	60.8	3.6	24.8	14	2	16	85.1	7.2	36.1
Total/Crude rate	48	11	59	5.6	1.3	3.4	45	9	54	5.3	1.0	3.1
AS Rate (Aust)				5.0	1.0	2.8				4.7	0.8	2.5
Confidence Interval (95%)				3.6 – 6.4	0.4 – 1.6	2.1 – 3.5				3.3 – 6.1	0.3 – 1.3	1.8 – 3.1
AS Rate (World)				2.7	0.7	1.6				2.4	0.5	1.3
Confidence Interval (95%)				2.0 – 3.4	0.2 – 1.2	1.2 – 2.0				1.8 – 3.0	0.2 – 0.7	1.0 – 1.6
Lifetime Risk				1 in 427	1 in 1629	1 in 690				1 in 695	1 in 2,500	1 in 1,106
PYLL										118	45	163
% of all cancers				0.8	0.2	0.6				2.2	0.5	1.5
Trend 2013–2017 (per annum)				-11.0%	-3.1%	-9.7%				-7.8%	4.5%	-6.2%

Table A2.21 – Cancer of the Thymus

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	1	0	1	1.7	0.0	0.9	0	0	0	0.0	0.0	0.0
30–34	0	1	1	0.0	1.7	0.9	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	1	1	0.0	1.7	0.9	0	0	0	0.0	0.0	0.0
50–54	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
55–59	0	0	0	0.0	0.0	0.0	0	1	1	0.0	1.7	0.9
60–64	2	2	4	4.0	3.8	3.9	0	0	0	0.0	0.0	0.0
65–69	0	2	2	0.0	4.1	2.1	0	0	0	0.0	0.0	0.0
70–74	2	1	3	5.3	2.5	3.9	1	0	1	2.7	0.0	1.3
75–79	1	0	1	3.9	0.0	1.8	1	0	1	3.9	0.0	1.8
80–84	0	1	1	0.0	4.6	2.5	0	0	0	0.0	0.0	0.0
85+	0	0	0	0.0	0.0	0.0	0	1	1	0.0	3.6	2.3
Total/Crude rate	6	8	14	0.7	0.9	0.8	2	2	4	0.2	0.2	0.2
AS Rate (Aust)				0.6	0.8	0.7				0.2	0.2	0.2
Confidence Interval (95%)				0.1 – 1.1	0.2 – 1.3	0.3 – 1.1				0.0 – 0.4	0.0 – 0.4	0.0 – 0.4
AS Rate (World)				0.5	0.6	0.5				0.1	0.1	0.1
Confidence Interval (95%)				0.1 – 0.8	0.2 – 1.0	0.2 – 0.8				0.0 – 0.2	0.0 – 0.2	0.0 – 0.2
Lifetime Risk				1 in 1805	1 in 1449	1 in 1605				1 in 7,480	1 in 11,561	1 in 9,217
PYLL										3	18	20
% of all cancers				0.1	0.2	0.1				0.1	0.1	0.1
Trend 2013–2017 (per annum)				7.9%	228.6%	44.5%				144.1%	undefined	undefined

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.22 – Cancer of the Bone, joints and articular cartilage

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	1	1	0.0	2.0	1.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	1	1	2	1.9	2.0	1.9	0	1	1	0.0	2.0	1.0
20–24	0	1	1	0.0	1.8	0.9	1	0	1	1.7	0.0	0.9
25–29	0	1	1	0.0	1.7	0.9	0	0	0	0.0	0.0	0.0
30–34	0	1	1	0.0	1.7	0.9	1	0	1	1.7	0.0	0.9
35–39	1	1	2	1.9	1.9	1.9	0	0	0	0.0	0.0	0.0
40–44	1	0	1	1.9	0.0	0.9	0	0	0	0.0	0.0	0.0
45–49	1	0	1	1.8	0.0	0.9	0	0	0	0.0	0.0	0.0
50–54	1	1	2	1.8	1.8	1.8	0	0	0	0.0	0.0	0.0
55–59	1	1	2	1.8	1.7	1.8	0	0	0	0.0	0.0	0.0
60–64	1	0	1	2.0	0.0	1.0	0	0	0	0.0	0.0	0.0
65–69	1	1	2	2.2	2.1	2.1	0	0	0	0.0	0.0	0.0
70–74	1	1	2	2.7	2.5	2.6	0	0	0	0.0	0.0	0.0
75–79	1	1	2	3.9	3.4	3.6	0	0	0	0.0	0.0	0.0
80–84	0	0	0	0.0	0.0	0.0	1	0	1	5.7	0.0	2.5
85+	0	0	0	0.0	0.0	0.0	2	1	3	12.2	3.6	6.8
Total/Crude rate	10	11	21	1.2	1.3	1.2	5	2	7	0.6	0.2	0.4
AS Rate (Aust)				1.1	1.2	1.2				0.6	0.2	0.4
Confidence Interval (95%)				0.4 – 1.8	0.5 – 2.0	0.7 – 1.7				0.1 – 1.1	0.0 – 0.5	0.1 – 0.6
AS Rate (World)				1.0	1.2	1.1				0.4	0.2	0.3
Confidence Interval (95%)				0.4 – 1.6	0.5 – 2.0	0.6 – 1.6				0.0 – 0.7	0.0 – 0.5	0.0 – 0.5
Lifetime Risk				1 in 1120	1 in 1049	1 in 1089				1 in 5,846	1 in 10,107	1 in 7,424
PYLL										95	58	153
% of all cancers				0.2	0.2	0.2				0.2	0.1	0.2
Trend 2013–2017 (per annum)				20.4%	35.9%	27.0%				2.9%	18.7%	5.2%

Table A2.23 – Melanoma of skin

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	1	1	2	1.7	1.8	1.7	0	0	0	0.0	0.0	0.0
25–29	4	2	6	6.9	3.5	5.2	0	0	0	0.0	0.0	0.0
30–34	10	6	16	17.3	10.3	13.8	0	0	0	0.0	0.0	0.0
35–39	12	11	23	22.7	20.6	21.6	0	0	0	0.0	0.0	0.0
40–44	13	15	28	24.5	28.4	26.4	1	0	1	1.9	0.0	0.9
45–49	25	24	49	43.8	41.0	42.4	1	1	2	1.8	1.7	1.7
50–54	30	26	56	54.1	45.7	49.9	0	0	0	0.0	0.0	0.0
55–59	43	22	65	77.3	38.1	57.3	0	0	0	0.0	0.0	0.0
60–64	44	41	85	88.2	77.7	82.8	3	1	4	6.0	1.9	3.9
65–69	72	38	110	156.2	78.1	116.1	8	2	10	17.4	4.1	10.6
70–74	64	45	109	171.1	111.9	140.5	10	0	10	26.7	0.0	12.9
75–79	46	37	83	179.6	125.8	150.9	5	1	6	19.5	3.4	10.9
80–84	47	22	69	266.8	100.6	174.8	7	2	9	39.7	9.1	22.8
85+	39	35	74	237.1	125.4	166.8	8	6	14	48.6	21.5	31.6
Total/Crude rate	450	325	775	52.8	37.3	45.0	43	13	56	5.0	1.5	3.2
AS Rate (Aust)				47.6	31.4	38.9				4.3	1.1	2.6
Confidence Interval (95%)				43.2 – 52.0	27.9 – 34.9	36.1 – 41.7				3.0 – 5.7	0.5 – 1.6	1.9 – 3.2
AS Rate (World)				32.6	22.5	27.2				2.5	0.6	1.5
Confidence Interval (95%)				29.7 – 35.5	20.0 – 24.9	25.4 – 29.1				1.8 – 3.2	0.2 – 0.9	1.1 – 1.8
Lifetime Risk				1 in 31	1 in 44	1 in 36				1 in 373	1 in 2,594	1 in 667
PYLL										183	55	238
% of all cancers				7.8	6.8	7.4				2.1	0.8	1.5
Trend 2013–2017 (per annum)				-1.6%	0.9%	-0.4%				-9.5%	-13.7%	-11.0%

Table A2.24 – Cancer of the Skin of lip

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	1	0	1	1.7	0.0	0.9	0	0	0	0.0	0.0	0.0
35–39	1	0	1	1.9	0.0	0.9	0	0	0	0.0	0.0	0.0
40–44	3	0	3	5.7	0.0	2.8	0	0	0	0.0	0.0	0.0
45–49	1	0	1	1.8	0.0	0.9	0	0	0	0.0	0.0	0.0
50–54	1	0	1	1.8	0.0	0.9	0	0	0	0.0	0.0	0.0
55–59	3	0	3	5.4	0.0	2.6	0	0	0	0.0	0.0	0.0
60–64	3	2	5	6.0	3.8	4.9	0	1	1	0.0	1.9	1.0
65–69	5	2	7	10.8	4.1	7.4	1	0	1	2.2	0.0	1.1
70–74	3	3	6	8.0	7.5	7.7	0	0	0	0.0	0.0	0.0
75–79	5	3	8	19.5	10.2	14.5	0	1	1	0.0	3.4	1.8
80–84	2	4	6	11.4	18.3	15.2	0	0	0	0.0	0.0	0.0
85+	3	3	6	18.2	10.7	13.5	0	0	0	0.0	0.0	0.0
Total/Crude rate	31	17	48	3.6	1.9	2.8	1	2	3	0.1	0.2	0.2
AS Rate (Aust)				3.3	1.4	2.3				0.1	0.2	0.1
Confidence Interval (95%)				2.1 – 4.5	0.7 – 2.1	1.7 – 3.0				0.0 – 0.3	0.0 – 0.5	0.0 – 0.3
AS Rate (World)				2.3	0.8	1.5				0.1	0.1	0.1
Confidence Interval (95%)				1.5 – 3.1	0.5 – 1.2	1.1 – 2.0				0.0 – 0.2	0.0 – 0.3	0.0 – 0.2
Lifetime Risk				1 in 465	1 in 1303	1 in 690				1 in 9,219	1 in 10,560	1 in 9,859
PYLL										8	13	20
% of all cancers				0.5	0.4	0.5				0.0	0.1	0.1
Trend 2013–2017 (per annum)				-8.0%	-18.0%	-12.4%				86.4%	367.6%	169.0%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.25 – Cancer of the Skin of anus (including perineum, perianal skin)

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
55–59	1	0	1	1.8	0.0	0.9	0	0	0	0.0	0.0	0.0
60–64	0	1	1	0.0	1.9	1.0	0	0	0	0.0	0.0	0.0
65–69	0	1	1	0.0	2.1	1.1	0	0	0	0.0	0.0	0.0
70–74	0	1	1	0.0	2.5	1.3	0	0	0	0.0	0.0	0.0
75–79	0	0	0	0.0	0.0	0.0	0	1	1	0.0	3.4	1.8
80–84	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
85+	0	1	1	0.0	3.6	2.3	0	1	1	0.0	3.6	2.3
Total/Crude rate	1	4	5	0.1	0.5	0.3	0	2	2	0.0	0.2	0.1
AS Rate (Aust)				0.1	0.3	0.2				0.0	0.1	0.1
Confidence Interval (95%)				0.0 – 0.3	0.0 – 0.7	0.0 – 0.4				0.0 – 0.0	0.0 – 0.4	0.0 – 0.2
AS Rate (World)				0.1	0.2	0.2				0.0	0.1	0.0
Confidence Interval (95%)				0.0 – 0.2	0.0 – 0.4	0.0 – 0.3				0.0 – 0.0	0.0 – 0.1	0.0 – 0.1
Lifetime Risk				1 in 11131	1 in 3108	1 in 4764				N/A	N/A	N/A
PYLL										0	0	0
% of all cancers				0.0	0.1	0.0				0.0	0.1	0.1
Trend 2013–2017 (per annum)				-24.7%	1.2%	-15.2%				-28.6%	undefined	-0.7%

Table A2.26 – Cancer of the Connective and other soft tissue

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	1	1	0.0	2.0	1.0	0	0	0	0.0	0.0	0.0
5–9	0	1	1	0.0	2.0	1.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	1	0	1	1.9	0.0	1.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	3	3	0.0	5.3	2.6
25–29	0	1	1	0.0	1.7	0.9	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	1	1	2	1.9	1.9	1.9	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	3	0	3	5.3	0.0	2.6	1	0	1	1.8	0.0	0.9
50–54	1	0	1	1.8	0.0	0.9	1	2	3	1.8	3.5	2.7
55–59	4	3	7	7.2	5.2	6.2	1	0	1	1.8	0.0	0.9
60–64	4	3	7	8.0	5.7	6.8	0	0	0	0.0	0.0	0.0
65–69	11	3	14	23.9	6.2	14.8	1	1	2	2.2	2.1	2.1
70–74	11	10	21	29.4	24.9	27.1	3	0	3	8.0	0.0	3.9
75–79	7	7	14	27.3	23.8	25.4	6	3	9	23.4	10.2	16.4
80–84	13	5	18	73.8	22.9	45.6	5	5	10	28.4	22.9	25.3
85+	10	8	18	60.8	28.7	40.6	4	7	11	24.3	25.1	24.8
Total/Crude rate	66	43	109	7.7	4.9	6.3	22	21	43	2.6	2.4	2.5
AS Rate (Aust)				6.8	3.8	5.1				2.3	1.9	2.1
Confidence Interval (95%)				5.2 – 8.5	2.6 – 4.9	4.2 – 6.1				1.3 – 3.3	1.0 – 2.7	1.4 – 2.7
AS Rate (World)				4.1	2.5	3.3				1.3	1.2	1.2
Confidence Interval (95%)				3.2 – 5.1	1.7 – 3.4	2.6 – 3.9				0.8 – 1.7	0.6 – 1.8	0.9 – 1.6
Lifetime Risk				1 in 253	1 in 405	1 in 313				1 in 1,287	1 in 1,833	1 in 1,540
PYLL										83	210	293
% of all cancers				1.2	0.9	1.0				1.1	1.3	1.2
Trend 2013–2017 (per annum)				-0.4%	-1.8%	-1.0%				-3.6%	-4.4%	-3.9%

Table A2.27 – Cancer of Retroperitoneum and peritoneum

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	1	0	1	1.7	0.0	0.9
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	1	1	0.0	1.9	0.9	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	0	1	1	0.0	1.8	0.9	0	1	1	0.0	1.8	0.9
55–59	1	3	4	1.8	5.2	3.5	0	1	1	0.0	1.7	0.9
60–64	0	3	3	0.0	5.7	2.9	1	0	1	2.0	0.0	1.0
65–69	2	2	4	4.3	4.1	4.2	1	2	3	2.2	4.1	3.2
70–74	0	3	3	0.0	7.5	3.9	0	3	3	0.0	7.5	3.9
75–79	4	2	6	15.6	6.8	10.9	0	8	8	0.0	27.2	14.5
80–84	1	2	3	5.7	9.1	7.6	0	2	2	0.0	9.1	5.1
85+	0	2	2	0.0	7.2	4.5	1	3	4	6.1	10.7	9.0
Total/Crude rate	8	19	27	0.9	2.2	1.6	4	20	24	0.5	2.3	1.4
AS Rate (Aust)				0.8	1.8	1.3				0.4	1.7	1.1
Confidence Interval (95%)				0.2 – 1.3	1.0 – 2.6	0.8 – 1.8				0.0 – 0.9	0.9 – 2.4	0.7 – 1.6
AS Rate (World)				0.5	1.2	0.9				0.3	1.0	0.7
Confidence Interval (95%)				0.2 – 0.8	0.7 – 1.7	0.6 – 1.2				0.0 – 0.7	0.6 – 1.4	0.4 – 1.0
Lifetime Risk				1 in 3260	1 in 767	1 in 1222				1 in 3,413	1 in 1,329	1 in 1,880
PYLL										73	63	135
% of all cancers				0.1	0.4	0.3				0.2	1.2	0.6
Trend 2013–2017 (per annum)				1.8%	-8.9%	-6.6%				-0.6%	2.7%	2.0%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.28 – Cancer of the Female breast

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	2	2	0.0	3.5	1.7	0	0	0	0.0	0.0	0.0
30–34	0	16	16	0.0	27.4	13.8	0	1	1	0.0	1.7	0.9
35–39	0	28	28	0.0	52.4	26.3	0	2	2	0.0	3.7	1.9
40–44	0	64	64	0.0	121.0	60.4	0	4	4	0.0	7.6	3.8
45–49	0	139	139	0.0	237.5	120.2	0	18	18	0.0	30.8	15.6
50–54	0	170	170	0.0	298.9	151.4	0	17	17	0.0	29.9	15.1
55–59	0	148	148	0.0	256.1	130.5	0	21	21	0.0	36.3	18.5
60–64	0	168	168	0.0	318.2	163.6	0	22	22	0.0	41.7	21.4
65–69	0	192	192	0.0	394.4	202.6	0	29	29	0.0	59.6	30.6
70–74	0	203	203	0.0	505.0	261.6	0	22	22	0.0	54.7	28.4
75–79	0	132	132	0.0	448.8	239.9	0	17	17	0.0	57.8	30.9
80–84	0	57	57	0.0	260.8	144.4	0	21	21	0.0	96.1	53.2
85+	0	77	77	0.0	275.8	173.5	0	34	34	0.0	121.8	76.6
Total/Crude rate	0	1,396	1,396	0.0	160.1	81.0	0	208	208	0.0	23.9	12.1
AS Rate (Aust)				0.0	138.4	71.6				0.0	19.4	10.3
Confidence Interval (95%)				0.0 – 0.0	131.0 – 145.7	67.8 – 75.5				0.0 – 0.0	16.7 – 22.1	8.9 – 11.7
AS Rate (World)				0.0	101.7	52.3				0.0	13.0	6.8
Confidence Interval (95%)				0.0 – 0.0	96.4 – 107.0	49.6 – 55.0				0.0 – 0.0	11.2 – 14.8	5.9 – 7.7
Lifetime Risk				N/A	1 in 10	1 in 18				N/A	1 in 76	1 in 147
PYLL										0	2,040	2,040
% of all cancers				0.0	29.2	13.3				0.0	12.4	5.6
Trend 2013–2017 (per annum)				0.0%	-0.7%	-0.8%				0.0%	-1.7%	-2.2%

Table A2.29 – Cancer of the Male breast

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
55–59	2	0	2	3.6	0.0	1.8	0	0	0	0.0	0.0	0.0
60–64	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
65–69	1	0	1	2.2	0.0	1.1	1	0	1	2.2	0.0	1.1
70–74	3	0	3	8.0	0.0	3.9	1	0	1	2.7	0.0	1.3
75–79	1	0	1	3.9	0.0	1.8	0	0	0	0.0	0.0	0.0
80–84	0	0	0	0.0	0.0	0.0	1	0	1	5.7	0.0	2.5
85+	2	0	2	12.2	0.0	4.5	1	0	1	6.1	0.0	2.3
Total/Crude rate	9	0	9	1.1	0.0	0.5	4	0	4	0.5	0.0	0.2
AS Rate (Aust)				0.9	0.0	0.4				0.4	0.0	0.2
Confidence Interval (95%)				0.3 – 1.5	0.0 – 0.0	0.1 – 0.7				0.0 – 0.8	0.0 – 0.0	0.0 – 0.4
AS Rate (World)				0.5	0.0	0.3				0.2	0.0	0.1
Confidence Interval (95%)				0.2 – 0.9	0.0 – 0.0	0.1 – 0.4				0.0 – 0.4	0.0 – 0.0	0.0 – 0.2
Lifetime Risk				1 in 1451	N/A	1 in 2993				1 in 4,130	N/A	1 in 8,534
PYLL										10	0	10
% of all cancers				0.2	0.0	0.1				0.2	0.0	0.1
Trend 2013–2017 (per annum)				-12.0%	0.0%	-12.1%				-13.6%	0.0%	-12.9%

Table A2.30 – Cancer of the Vulva

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	1	1	0.0	1.7	0.9	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	3	3	0.0	5.1	2.6	0	0	0	0.0	0.0	0.0
50–54	0	3	3	0.0	5.3	2.7	0	0	0	0.0	0.0	0.0
55–59	0	3	3	0.0	5.2	2.6	0	0	0	0.0	0.0	0.0
60–64	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
65–69	0	5	5	0.0	10.3	5.3	0	1	1	0.0	2.1	1.1
70–74	0	7	7	0.0	17.4	9.0	0	0	0	0.0	0.0	0.0
75–79	0	5	5	0.0	17.0	9.1	0	1	1	0.0	3.4	1.8
80–84	0	2	2	0.0	9.1	5.1	0	1	1	0.0	4.6	2.5
85+	0	8	8	0.0	28.7	18.0	0	4	4	0.0	14.3	9.0
Total/Crude rate	0	37	37	0.0	4.2	2.1	0	7	7	0.0	0.8	0.4
AS Rate (Aust)				0.0	3.3	1.8				0.0	0.5	0.3
Confidence Interval (95%)				0.0 – 0.0	2.2 – 4.3	1.2 – 2.3				0.0 – 0.0	0.1 – 0.9	0.1 – 0.5
AS Rate (World)				0.0	2.2	1.1				0.0	0.2	0.1
Confidence Interval (95%)				0.0 – 0.0	1.5 – 2.9	0.8 – 1.5				0.0 – 0.0	0.1 – 0.4	0.0 – 0.2
Lifetime Risk				N/A	1 in 445	1 in 867				N/A	1 in 9,737	1 in 18,956
PYLL										0	8	8
% of all cancers				0.0	0.8	0.4				0.0	0.4	0.2
Trend 2013–2017 (per annum)				0.0%	5.4%	5.1%				0.0%	-17.8%	-17.0%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.31 – Cancer of the Vagina												
South Australia												
Year – 2017												
	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	1	1	0.0	1.9	0.9	0	0	0	0.0	0.0	0.0
45–49	0	1	1	0.0	1.7	0.9	0	0	0	0.0	0.0	0.0
50–54	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
55–59	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
60–64	0	4	4	0.0	7.6	3.9	0	0	0	0.0	0.0	0.0
65–69	0	2	2	0.0	4.1	2.1	0	0	0	0.0	0.0	0.0
70–74	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
75–79	0	2	2	0.0	6.8	3.6	0	1	1	0.0	3.4	1.8
80–84	0	0	0	0.0	0.0	0.0	0	1	1	0.0	4.6	2.5
85+	0	1	1	0.0	3.6	2.3	0	0	0	0.0	0.0	0.0
Total/Crude rate	0	11	11	0.0	1.3	0.6	0	2	2	0.0	0.2	0.1
AS Rate (Aust)				0.0	1.1	0.6				0.0	0.2	0.1
Confidence Interval (95%)				0.0 – 0.0	0.4 – 1.7	0.2 – 0.9				0.0 – 0.0	0.0 – 0.4	0.0 – 0.2
AS Rate (World)				0.0	0.8	0.4				0.0	0.1	0.1
Confidence Interval (95%)				0.0 – 0.0	0.3 – 1.2	0.2 – 0.6				0.0 – 0.0	0.0 – 0.2	0.0 – 0.1
Lifetime Risk				N/A	1 in 1309	1 in 2560				N/A	N/A	N/A
PYLL										0	0	0
% of all cancers				0.0	0.2	0.1				0.0	0.1	0.1
Trend 2013–2017 (per annum)				0.0%	54.5%	50.7%				0.0%	-8.4%	-10.0%

Table A2.32 – Cancer of the Cervix uteri												
South Australia												
Year – 2017												
	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	6	6	0.0	10.4	5.2	0	0	0	0.0	0.0	0.0
30–34	0	5	5	0.0	8.6	4.3	0	1	1	0.0	1.7	0.9
35–39	0	12	12	0.0	22.5	11.3	0	0	0	0.0	0.0	0.0
40–44	0	9	9	0.0	17.0	8.5	0	5	5	0.0	9.5	4.7
45–49	0	4	4	0.0	6.8	3.5	0	2	2	0.0	3.4	1.7
50–54	0	4	4	0.0	7.0	3.6	0	0	0	0.0	0.0	0.0
55–59	0	4	4	0.0	6.9	3.5	0	2	2	0.0	3.5	1.8
60–64	0	7	7	0.0	13.3	6.8	0	3	3	0.0	5.7	2.9
65–69	0	2	2	0.0	4.1	2.1	0	2	2	0.0	4.1	2.1
70–74	0	1	1	0.0	2.5	1.3	0	4	4	0.0	9.9	5.2
75–79	0	3	3	0.0	10.2	5.5	0	3	3	0.0	10.2	5.5
80–84	0	2	2	0.0	9.1	5.1	0	1	1	0.0	4.6	2.5
85+	0	4	4	0.0	14.3	9.0	0	3	3	0.0	10.7	6.8
Total/Crude rate	0	63	63	0.0	7.2	3.7	0	26	26	0.0	3.0	1.5
AS Rate (Aust)				0.0	7.2	3.7				0.0	2.6	1.3
Confidence Interval (95%)				0.0 – 0.0	5.4 – 9.0	2.8 – 4.6				0.0 – 0.0	1.6 – 3.6	0.8 – 1.9
AS Rate (World)				0.0	6.3	3.2				0.0	1.9	1.0
Confidence Interval (95%)				0.0 – 0.0	4.8 – 7.8	2.4 – 4.0				0.0 – 0.0	1.2 – 2.7	0.6 – 1.4
Lifetime Risk				N/A	1 in 202	1 in 400				N/A	1 in 530	1 in 1,039
PYLL										0	358	358
% of all cancers				0.0	1.3	0.6				0.0	1.6	0.7
Trend 2013–2017 (per annum)				0.0%	-2.9%	-2.8%				0.0%	-0.9%	-0.9%

Table A2.33 – Cancer of the Body of the uterus												
South Australia												
Year – 2017												
	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	1	1	0.0	1.7	0.9	0	0	0	0.0	0.0	0.0
35–39	0	1	1	0.0	1.9	0.9	0	0	0	0.0	0.0	0.0
40–44	0	6	6	0.0	11.3	5.7	0	1	1	0.0	1.9	0.9
45–49	0	13	13	0.0	22.2	11.2	0	0	0	0.0	0.0	0.0
50–54	0	15	15	0.0	26.4	13.4	0	1	1	0.0	1.8	0.9
55–59	0	32	32	0.0	55.4	28.2	0	3	3	0.0	5.2	2.6
60–64	0	34	34	0.0	64.4	33.1	0	5	5	0.0	9.5	4.9
65–69	0	37	37	0.0	76.0	39.0	0	9	9	0.0	18.5	9.5
70–74	0	30	30	0.0	74.6	38.7	0	2	2	0.0	5.0	2.6
75–79	0	22	22	0.0	74.8	40.0	0	9	9	0.0	30.6	16.4
80–84	0	16	16	0.0	73.2	40.5	0	6	6	0.0	27.4	15.2
85+	0	22	22	0.0	78.8	49.6	0	14	14	0.0	50.2	31.6
Total/Crude rate	0	229	229	0.0	26.3	13.3	0	50	50	0.0	5.7	2.9
AS Rate (Aust)				0.0	21.6	11.3				0.0	4.3	2.3
Confidence Interval (95%)				0.0 – 0.0	18.8 – 24.5	9.9 – 12.8				0.0 – 0.0	3.1 – 5.5	1.7 – 3.0
AS Rate (World)				0.0	14.9	7.7				0.0	2.5	1.3
Confidence Interval (95%)				0.0 – 0.0	13.0 – 16.8	6.7 – 8.7				0.0 – 0.0	1.8 – 3.2	1.0 – 1.7
Lifetime Risk				N/A	1 in 60	1 in 117				N/A	1 in 479	1 in 934
PYLL										0	243	243
% of all cancers				0.0	4.8	2.2				0.0	3.0	1.3
Trend 2013–2017 (per annum)				0.0%	2.4%	2.4%				0.0%	6.1%	6.3%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.34 – Cancer of the Ovary

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	2	2	0.0	4.1	2.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	1	1	0.0	1.7	0.9	0	0	0	0.0	0.0	0.0
35–39	0	3	3	0.0	5.6	2.8	0	0	0	0.0	0.0	0.0
40–44	0	1	1	0.0	1.9	0.9	0	1	1	0.0	1.9	0.9
45–49	0	6	6	0.0	10.3	5.2	0	1	1	0.0	1.7	0.9
50–54	0	5	5	0.0	8.8	4.5	0	2	2	0.0	3.5	1.8
55–59	0	9	9	0.0	15.6	7.9	0	3	3	0.0	5.2	2.6
60–64	0	9	9	0.0	17.0	8.8	0	5	5	0.0	9.5	4.9
65–69	0	16	16	0.0	32.9	16.9	0	10	10	0.0	20.5	10.6
70–74	0	15	15	0.0	37.3	19.3	0	8	8	0.0	19.9	10.3
75–79	0	4	4	0.0	13.6	7.3	0	13	13	0.0	44.2	23.6
80–84	0	11	11	0.0	50.3	27.9	0	11	11	0.0	50.3	27.9
85+	0	14	14	0.0	50.2	31.6	0	11	11	0.0	39.4	24.8
Total/Crude rate	0	96	96	0.0	11.0	5.6	0	65	65	0.0	7.5	3.8
AS Rate (Aust)				0.0	8.9	4.7				0.0	5.7	3.0
Confidence Interval (95%)				0.0 – 0.0	7.1 – 10.8	3.8 – 5.7				0.0 – 0.0	4.3 – 7.1	2.3 – 3.8
AS Rate (World)				0.0	6.2	3.2				0.0	3.4	1.8
Confidence Interval (95%)				0.0 – 0.0	4.9 – 7.5	2.6 – 3.9				0.0 – 0.0	2.6 – 4.2	1.4 – 2.2
Lifetime Risk				N/A	1 in 148	1 in 290				N/A	1 in 322	1 in 626
PYLL										0	315	315
% of all cancers				0.0	2.0	0.9				0.0	3.9	1.8
Trend 2013–2017 (per annum)				0.0%	-4.8%	-4.7%				0.0%	-4.3%	-3.9%

Table A2.35 – Cancer of Other and unspecified female genitalia

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	3	3	0.0	5.1	2.6	0	0	0	0.0	0.0	0.0
50–54	0	3	3	0.0	5.3	2.7	0	0	0	0.0	0.0	0.0
55–59	0	5	5	0.0	8.7	4.4	0	0	0	0.0	0.0	0.0
60–64	0	5	5	0.0	9.5	4.9	0	4	4	0.0	7.6	3.9
65–69	0	4	4	0.0	8.2	4.2	0	2	2	0.0	4.1	2.1
70–74	0	2	2	0.0	5.0	2.6	0	1	1	0.0	2.5	1.3
75–79	0	5	5	0.0	17.0	9.1	0	3	3	0.0	10.2	5.5
80–84	0	1	1	0.0	4.6	2.5	0	1	1	0.0	4.6	2.5
85+	0	2	2	0.0	7.2	4.5	0	3	3	0.0	10.7	6.8
Total/Crude rate	0	30	30	0.0	3.4	1.7	0	14	14	0.0	1.6	0.8
AS Rate (Aust)				0.0	2.9	1.5				0.0	1.2	0.7
Confidence Interval (95%)				0.0 – 0.0	1.9 – 4.0	1.0 – 2.1				0.0 – 0.0	0.6 – 1.9	0.3 – 1.0
AS Rate (World)				0.0	2.0	1.1				0.0	0.7	0.4
Confidence Interval (95%)				0.0 – 0.0	1.3 – 2.8	0.7 – 1.4				0.0 – 0.0	0.3 – 1.1	0.2 – 0.6
Lifetime Risk				N/A	1 in 480	1 in 938				N/A	1 in 1,412	1 in 2,743
PYLL										0	68	68
% of all cancers				0.0	0.6	0.3				0.0	0.8	0.4
Trend 2013–2017 (per annum)				0.0%	54.3%	55.0%				0.0%	24.9%	26.6%

Table A2.36 – Cancer of the Placenta

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	1	1	0.0	1.7	0.9	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
55–59	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
60–64	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
65–69	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
70–74	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
75–79	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
80–84	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
85+	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
Total/Crude rate	0	1	1	0.0	0.1	0.1	0	0	0	0.0	0.0	0.0
AS Rate (Aust)				0.0	0.1	0.1				0.0	0.0	0.0
Confidence Interval (95%)				0.0 – 0.0	0.0 – 0.3	0.0 – 0.2				0.0 – 0.0	0.0 – 0.0	0.0 – 0.0
AS Rate (World)				0.0	0.1	0.1				0.0	0.0	0.0
Confidence Interval (95%)				0.0 – 0.0	0.0 – 0.3	0.0 – 0.2				0.0 – 0.0	0.0 – 0.0	0.0 – 0.0
Lifetime Risk				N/A	1 in 11676	1 in 23213				N/A	N/A	N/A
PYLL										0	0	0
% of all cancers				0.0	0.0	0.0				0.0	0.0	0.0
Trend 2013–2017 (per annum)				0.0%	42.4%	43.6%				0.0%	0.0%	undefined

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.37 – Cancer of the Penis

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	2	0	2	3.8	0.0	1.9	0	0	0	0.0	0.0	0.0
40–44	1	0	1	1.9	0.0	0.9	0	0	0	0.0	0.0	0.0
45–49	1	0	1	1.8	0.0	0.9	0	0	0	0.0	0.0	0.0
50–54	1	0	1	1.8	0.0	0.9	0	0	0	0.0	0.0	0.0
55–59	1	0	1	1.8	0.0	0.9	0	0	0	0.0	0.0	0.0
60–64	2	0	2	4.0	0.0	1.9	0	0	0	0.0	0.0	0.0
65–69	1	0	1	2.2	0.0	1.1	0	0	0	0.0	0.0	0.0
70–74	1	0	1	2.7	0.0	1.3	0	0	0	0.0	0.0	0.0
75–79	4	0	4	15.6	0.0	7.3	0	0	0	0.0	0.0	0.0
80–84	2	0	2	11.4	0.0	5.1	2	0	2	11.4	0.0	5.1
85+	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
Total/Crude rate	16	0	16	1.9	0.0	0.9	2	0	2	0.2	0.0	0.1
AS Rate (Aust)				1.8	0.0	0.8				0.2	0.0	0.1
Confidence Interval (95%)				0.9 – 2.6	0.0 – 0.0	0.4 – 1.3				0.0 – 0.5	0.0 – 0.0	0.0 – 0.2
AS Rate (World)				1.3	0.0	0.6				0.1	0.0	0.0
Confidence Interval (95%)				0.7 – 1.9	0.0 – 0.0	0.3 – 0.9				0.0 – 0.2	0.0 – 0.0	0.0 – 0.1
Lifetime Risk				1 in 1007	N/A	1 in 2051				N/A	N/A	N/A
PYLL										0	0	0
% of all cancers				0.3	0.0	0.2				0.1	0.0	0.1
Trend 2013–2017 (per annum)				19.3%	0.0%	22.4%				6.6%	0.0%	8.1%

Table A2.38 – Cancer of the Prostate

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	3	0	3	5.7	0.0	2.8	0	0	0	0.0	0.0	0.0
45–49	21	0	21	36.8	0.0	18.2	0	0	0	0.0	0.0	0.0
50–54	58	0	58	104.7	0.0	51.7	2	0	2	3.6	0.0	1.8
55–59	148	0	148	265.9	0.0	130.5	5	0	5	9.0	0.0	4.4
60–64	251	0	251	502.9	0.0	244.4	5	0	5	10.0	0.0	4.9
65–69	361	0	361	783.2	0.0	380.9	19	0	19	41.2	0.0	20.0
70–74	344	0	344	919.8	0.0	443.3	36	0	36	96.3	0.0	46.4
75–79	222	0	222	866.9	0.0	403.5	36	0	36	140.6	0.0	65.4
80–84	141	0	141	800.3	0.0	357.2	46	0	46	261.1	0.0	116.5
85+	86	0	86	522.7	0.0	193.8	95	0	95	577.4	0.0	214.1
Total/Crude rate	1,635	0	1,635	191.9	0.0	94.8	244	0	244	28.6	0.0	14.2
AS Rate (Aust)				163.8	0.0	77.5				25.3	0.0	10.8
Confidence Interval (95%)				155.9 – 171.8	0.0 – 0.0	73.7 – 81.3				22.1 – 28.5	0.0 – 0.0	9.5 – 12.2
AS Rate (World)				106.1	0.0	50.7				12.3	0.0	5.4
Confidence Interval (95%)				101.3 – 111.0	0.0 – 0.0	48.4 – 53.1				11.0 – 13.6	0.0 – 0.0	4.8 – 6.0
Lifetime Risk				1 in 8	N/A	1 in 16				1 in 125	N/A	1 in 259
PYLL										428	0	428
% of all cancers				28.5	0.0	15.6				12.0	0.0	6.6
Trend 2013–2017 (per annum)				-1.7%	0.0%	-1.6%				-3.6%	0.0%	-2.9%

Table A2.39 – Cancer of the Testis

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	4	0	4	6.8	0.0	3.5	0	0	0	0.0	0.0	0.0
25–29	16	0	16	27.6	0.0	13.9	1	0	1	1.7	0.0	0.9
30–34	11	0	11	19.1	0.0	9.5	0	0	0	0.0	0.0	0.0
35–39	13	0	13	24.5	0.0	12.2	1	0	1	1.9	0.0	0.9
40–44	10	0	10	18.8	0.0	9.4	1	0	1	1.9	0.0	0.9
45–49	1	0	1	1.8	0.0	0.9	0	0	0	0.0	0.0	0.0
50–54	2	0	2	3.6	0.0	1.8	0	0	0	0.0	0.0	0.0
55–59	1	0	1	1.8	0.0	0.9	0	0	0	0.0	0.0	0.0
60–64	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
65–69	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
70–74	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
75–79	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
80–84	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
85+	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
Total/Crude rate	58	0	58	6.8	0.0	3.4	3	0	3	0.4	0.0	0.2
AS Rate (Aust)				7.4	0.0	3.7				0.4	0.0	0.2
Confidence Interval (95%)				5.5 – 9.3	0.0 – 0.0	2.7 – 4.6				0.0 – 0.8	0.0 – 0.0	0.0 – 0.4
AS Rate (World)				7.6	0.0	3.8				0.4	0.0	0.2
Confidence Interval (95%)				5.8 – 9.4	0.0 – 0.0	2.9 – 4.7				0.0 – 0.8	0.0 – 0.0	0.0 – 0.4
Lifetime Risk				1 in 193	N/A	1 in 385				1 in 3,637	N/A	1 in 7,273
PYLL										118	0	118
% of all cancers				1.0	0.0	0.6				0.1	0.0	0.1
Trend 2013–2017 (per annum)				0.2%	0.0%	0.0%				79.9%	0.0%	81.0%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.40 – Cancer of Other male genital organs												
South Australia												
Year – 2017												
	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	1	0	1	1.9	0.0	0.9	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
55–59	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
60–64	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
65–69	1	0	1	2.2	0.0	1.1	0	0	0	0.0	0.0	0.0
70–74	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
75–79	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
80–84	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
85+	2	0	2	12.2	0.0	4.5	0	0	0	0.0	0.0	0.0
Total/Crude rate	4	0	4	0.5	0.0	0.2	0	0	0	0.0	0.0	0.0
AS Rate (Aust)				0.4	0.0	0.2				0.0	0.0	0.0
Confidence Interval (95%)				0.0 – 0.9	0.0 – 0.0	0.0 – 0.4				0.0 – 0.0	0.0 – 0.0	0.0 – 0.0
AS Rate (World)				0.3	0.0	0.1				0.0	0.0	0.0
Confidence Interval (95%)				0.0 – 0.5	0.0 – 0.0	0.0 – 0.3				0.0 – 0.0	0.0 – 0.0	0.0 – 0.0
Lifetime Risk				1 in 4934	N/A	1 in 10005				N/A	N/A	N/A
PYLL										0	0	0
% of all cancers				0.1	0.0	0.0				0.0	0.0	0.0
Trend 2013–2017 (per annum)				14.3%	0.0%	15.4%				-25.0%	0.0%	-25.0%

Table A2.41 – Cancer of the Kidney												
South Australia												
Year – 2017												
	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	3	1	4	5.7	2.0	3.9	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	1	1	0.0	1.7	0.9	0	0	0	0.0	0.0	0.0
35–39	1	0	1	1.9	0.0	0.9	0	0	0	0.0	0.0	0.0
40–44	9	2	11	17.0	3.8	10.4	0	0	0	0.0	0.0	0.0
45–49	10	4	14	17.5	6.8	12.1	0	0	0	0.0	0.0	0.0
50–54	30	7	37	54.1	12.3	33.0	3	0	3	5.4	0.0	2.7
55–59	22	4	26	39.5	6.9	22.9	4	4	8	7.2	6.9	7.1
60–64	24	15	39	48.1	28.4	38.0	5	1	6	10.0	1.9	5.8
65–69	33	10	43	71.6	20.5	45.4	8	1	9	17.4	2.1	9.5
70–74	33	20	53	88.2	49.7	68.3	4	2	6	10.7	5.0	7.7
75–79	22	11	33	85.9	37.4	60.0	7	6	13	27.3	20.4	23.6
80–84	9	9	18	51.1	41.2	45.6	7	2	9	39.7	9.1	22.8
85+	10	7	17	60.8	25.1	38.3	6	10	16	36.5	35.8	36.1
Total/Crude rate	206	91	297	24.2	10.4	17.2	44	26	70	5.2	3.0	4.1
AS Rate (Aust)				21.7	8.5	14.9				4.6	2.1	3.3
Confidence Interval (95%)				18.7 – 24.7	6.7 – 10.3	13.2 – 16.6				3.2 – 5.9	1.3 – 2.9	2.5 – 4.0
AS Rate (World)				15.5	5.8	10.5				2.7	1.2	1.9
Confidence Interval (95%)				13.5 – 17.6	4.6 – 7.0	9.3 – 11.7				2.0 – 3.5	0.7 – 1.6	1.5 – 2.3
Lifetime Risk				1 in 59	1 in 152	1 in 85				1 in 395	1 in 1,263	1 in 610
PYLL										270	95	365
% of all cancers				3.6	1.9	2.8				2.2	1.6	1.9
Trend 2013–2017 (per annum)				-0.5%	-1.0%	-0.5%				-5.1%	4.0%	-2.4%

Table A2.42 – Cancer of the Renal pelvis, other and unspecified urinary organs												
South Australia												
Year – 2017												
	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	0	1	1	0.0	1.8	0.9	0	1	1	0.0	1.8	0.9
55–59	0	1	1	0.0	1.7	0.9	0	0	0	0.0	0.0	0.0
60–64	1	0	1	2.0	0.0	1.0	0	1	1	0.0	1.9	1.0
65–69	0	0	0	0.0	0.0	0.0	1	1	2	2.2	2.1	2.1
70–74	6	2	8	16.0	5.0	10.3	2	1	3	5.3	2.5	3.9
75–79	1	6	7	3.9	20.4	12.7	1	3	4	3.9	10.2	7.3
80–84	4	4	8	22.7	18.3	20.3	3	5	8	17.0	22.9	20.3
85+	3	7	10	18.2	25.1	22.5	3	5	8	18.2	17.9	18.0
Total/Crude rate	15	21	36	1.8	2.4	2.1	10	17	27	1.2	1.9	1.6
AS Rate (Aust)				1.5	1.7	1.6				1.0	1.4	1.2
Confidence Interval (95%)				0.7 – 2.3	1.0 – 2.4	1.1 – 2.2				0.4 – 1.7	0.7 – 2.1	0.8 – 1.7
AS Rate (World)				0.8	0.9	0.9				0.5	0.7	0.6
Confidence Interval (95%)				0.5 – 1.1	0.6 – 1.2	0.6 – 1.1				0.3 – 0.8	0.4 – 1.1	0.4 – 0.8
Lifetime Risk				1 in 1109	1 in 2364	1 in 1532				1 in 2,661	1 in 2,441	1 in 2,551
PYLL										13	45	58
% of all cancers				0.3	0.4	0.3				0.5	1.0	0.7
Trend 2013–2017 (per annum)				-14.1%	2.0%	-7.7%				-4.2%	1.3%	-2.2%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.43 – Cancer of the Bladder

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	2	0	2	3.5	0.0	1.7	1	0	1	1.7	0.0	0.9
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	1	1	0.0	1.9	0.9	0	0	0	0.0	0.0	0.0
45–49	4	0	4	7.0	0.0	3.5	1	1	2	1.8	1.7	1.7
50–54	9	1	10	16.2	1.8	8.9	1	0	1	1.8	0.0	0.9
55–59	4	2	6	7.2	3.5	5.3	2	2	4	3.6	3.5	3.5
60–64	20	3	23	40.1	5.7	22.4	4	2	6	8.0	3.8	5.8
65–69	18	8	26	39.1	16.4	27.4	8	5	13	17.4	10.3	13.7
70–74	28	7	35	74.9	17.4	45.1	11	2	13	29.4	5.0	16.8
75–79	43	7	50	167.9	23.8	90.9	7	4	11	27.3	13.6	20.0
80–84	33	11	44	187.3	50.3	111.5	16	4	20	90.8	18.3	50.7
85+	41	16	57	249.2	57.3	128.5	27	12	39	164.1	43.0	87.9
Total/Crude rate	202	56	258	23.7	6.4	15.0	78	32	110	9.2	3.7	6.4
AS Rate (Aust)				21.0	4.7	12.0				8.2	2.6	5.0
Confidence Interval (95%)				18.1 – 23.9	3.4 – 5.9	10.5 – 13.5				6.3 – 10.0	1.7 – 3.5	4.1 – 5.9
AS Rate (World)				11.9	2.6	6.9				4.2	1.4	2.7
Confidence Interval (95%)				10.4 – 13.4	2.0 – 3.3	6.1 – 7.7				3.3 – 5.0	0.9 – 1.9	2.2 – 3.1
Lifetime Risk				1 in 107	1 in 429	1 in 174				1 in 315	1 in 827	1 in 462
PYLL										265	130	395
% of all cancers				3.5	1.2	2.5				3.8	1.9	3.0
Trend 2013–2017 (per annum)				6.0%	0.6%	5.4%				0.8%	-3.6%	-0.3%

Table A2.44 – Cancer of the Eye

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	2	0	2	3.8	0.0	2.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	1	0	1	1.9	0.0	1.0	0	0	0	0.0	0.0	0.0
20–24	1	0	1	1.7	0.0	0.9	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	1	0	1	1.7	0.0	0.9	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	2	1	3	3.5	1.7	2.6	0	0	0	0.0	0.0	0.0
50–54	2	1	3	3.6	1.8	2.7	0	0	0	0.0	0.0	0.0
55–59	2	2	4	3.6	3.5	3.5	0	0	0	0.0	0.0	0.0
60–64	1	1	2	2.0	1.9	1.9	0	0	0	0.0	0.0	0.0
65–69	2	2	4	4.3	4.1	4.2	0	0	0	0.0	0.0	0.0
70–74	2	0	2	5.3	0.0	2.6	0	2	2	0.0	5.0	2.6
75–79	3	1	4	11.7	3.4	7.3	1	1	2	3.9	3.4	3.6
80–84	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
85+	1	0	1	6.1	0.0	2.3	0	1	1	0.0	3.6	2.3
Total/Crude rate	20	8	28	2.3	0.9	1.6	1	4	5	0.1	0.5	0.3
AS Rate (Aust)				2.2	0.8	1.5				0.1	0.3	0.2
Confidence Interval (95%)				1.2 – 3.1	0.2 – 1.4	0.9 – 2.0				0.0 – 0.3	0.0 – 0.6	0.0 – 0.4
AS Rate (World)				1.9	0.6	1.2				0.1	0.2	0.1
Confidence Interval (95%)				1.0 – 2.7	0.2 – 1.0	0.8 – 1.7				0.0 – 0.1	0.0 – 0.3	0.0 – 0.2
Lifetime Risk				1 in 635	1 in 1547	1 in 902				N/A	1 in 4,021	1 in 7,761
PYLL										0	5	5
% of all cancers				0.3	0.2	0.3				0.0	0.2	0.1
Trend 2013–2017 (per annum)				-2.0%	-10.8%	-6.5%				-16.5%	1.6%	-8.5%

Table A2.45 – Cancer of the Brain

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	2	0	2	3.8	0.0	2.0	0	0	0	0.0	0.0	0.0
5–9	1	1	2	1.9	2.0	1.9	0	1	1	0.0	2.0	1.0
10–14	2	0	2	3.9	0.0	2.0	1	0	1	2.0	0.0	1.0
15–19	3	0	3	5.7	0.0	2.9	1	0	1	1.9	0.0	1.0
20–24	2	2	4	3.4	3.6	3.5	0	0	0	0.0	0.0	0.0
25–29	2	0	2	3.5	0.0	1.7	1	0	1	1.7	0.0	0.9
30–34	1	4	5	1.7	6.9	4.3	1	0	1	1.7	0.0	0.9
35–39	1	0	1	1.9	0.0	0.9	1	1	2	1.9	1.9	1.9
40–44	3	2	5	5.7	3.8	4.7	2	0	2	3.8	0.0	1.9
45–49	5	4	9	8.8	6.8	7.8	5	4	9	8.8	6.8	7.8
50–54	8	5	13	14.4	8.8	11.6	4	0	4	7.2	0.0	3.6
55–59	8	5	13	14.4	8.7	11.5	3	7	10	5.4	12.1	8.8
60–64	9	6	15	18.0	11.4	14.6	6	4	10	12.0	7.6	9.7
65–69	5	10	15	10.8	20.5	15.8	9	6	15	19.5	12.3	15.8
70–74	17	9	26	45.5	22.4	33.5	9	8	17	24.1	19.9	21.9
75–79	8	4	12	31.2	13.6	21.8	6	5	11	23.4	17.0	20.0
80–84	7	3	10	39.7	13.7	25.3	7	5	12	39.7	22.9	30.4
85+	5	5	10	30.4	17.9	22.5	5	7	12	30.4	25.1	27.0
Total/Crude rate	89	60	149	10.4	6.9	8.6	61	48	109	7.2	5.5	6.3
AS Rate (Aust)				9.6	5.9	7.7				6.5	4.4	5.4
Confidence Interval (95%)				7.6 – 11.6	4.4 – 7.4	6.4 – 8.9				4.9 – 8.2	3.1 – 5.6	4.4 – 6.4
AS Rate (World)				7.5	4.5	5.9				4.6	3.0	3.8
Confidence Interval (95%)				5.8 – 9.1	3.3 – 5.6	4.9 – 7.0				3.4 – 5.8	2.1 – 3.9	3.0 – 4.5
Lifetime Risk				1 in 140	1 in 212	1 in 169				1 in 223	1 in 320	1 in 263
PYLL										758	453	1,210
% of all cancers				1.6	1.3	1.4				3.0	2.9	2.9
Trend 2013–2017 (per annum)				-1.4%	-3.9%	-2.2%				-5.0%	-3.4%	-4.1%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.46 – Cancer of the Cranial nerves, spinal cord, meninges etc.

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	1	0	1	1.9	0.0	1.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	1	0	1	1.7	0.0	0.9	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	1	0	1	1.9	0.0	0.9
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	0	0	0	0.0	0.0	0.0	0	1	1	0.0	1.8	0.9
55–59	1	0	1	1.8	0.0	0.9	0	0	0	0.0	0.0	0.0
60–64	0	0	0	0.0	0.0	0.0	0	1	1	0.0	1.9	1.0
65–69	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
70–74	0	0	0	0.0	0.0	0.0	1	0	1	2.7	0.0	1.3
75–79	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
80–84	1	1	2	5.7	4.6	5.1	1	1	2	5.7	4.6	5.1
85+	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
Total/Crude rate	4	1	5	0.5	0.1	0.3	3	3	6	0.4	0.3	0.3
AS Rate (Aust)				0.5	0.1	0.3				0.3	0.3	0.3
Confidence Interval (95%)				0.0 – 0.9	0.0 – 0.3	0.0 – 0.5				0.0 – 0.7	0.0 – 0.7	0.1 – 0.6
AS Rate (World)				0.4	0.0	0.2				0.2	0.2	0.2
Confidence Interval (95%)				0.0 – 0.9	0.0 – 0.1	0.0 – 0.5				0.0 – 0.5	0.0 – 0.4	0.1 – 0.4
Lifetime Risk				1 in 3715	N/A	1 in 7404				1 in 4,384	1 in 5,476	1 in 4,887
PYLL										40	35	75
% of all cancers				0.1	0.0	0.0				0.1	0.2	0.2
Trend 2013–2017 (per annum)				51.5%	-14.2%	14.9%				13.8%	163.7%	43.6%

Table A2.47 – Cancer of the Thyroid gland

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	1	1	0.0	2.0	1.0	0	0	0	0.0	0.0	0.0
10–14	1	1	2	2.0	2.1	2.0	0	0	0	0.0	0.0	0.0
15–19	0	1	1	0.0	2.0	1.0	0	0	0	0.0	0.0	0.0
20–24	1	2	3	1.7	3.6	2.6	0	0	0	0.0	0.0	0.0
25–29	4	3	7	6.9	5.2	6.1	0	0	0	0.0	0.0	0.0
30–34	3	9	12	5.2	15.4	10.3	1	0	1	1.7	0.0	0.9
35–39	1	7	8	1.9	13.1	7.5	0	0	0	0.0	0.0	0.0
40–44	9	11	20	17.0	20.8	18.9	0	0	0	0.0	0.0	0.0
45–49	2	9	11	3.5	15.4	9.5	0	0	0	0.0	0.0	0.0
50–54	4	14	18	7.2	24.6	16.0	1	0	1	1.8	0.0	0.9
55–59	6	6	12	10.8	10.4	10.6	0	0	0	0.0	0.0	0.0
60–64	8	15	23	16.0	28.4	22.4	0	1	1	0.0	1.9	1.0
65–69	4	8	12	8.7	16.4	12.7	1	0	1	2.2	0.0	1.1
70–74	4	9	13	10.7	22.4	16.8	1	3	4	2.7	7.5	5.2
75–79	2	7	9	7.8	23.8	16.4	0	4	4	0.0	13.6	7.3
80–84	3	5	8	17.0	22.9	20.3	0	0	0	0.0	0.0	0.0
85+	1	3	4	6.1	10.7	9.0	2	2	4	12.2	7.2	9.0
Total/Crude rate	53	111	164	6.2	12.7	9.5	6	10	16	0.7	1.1	0.9
AS Rate (Aust)				6.1	12.1	9.1				0.6	0.8	0.7
Confidence Interval (95%)				4.4 – 7.7	9.8 – 14.3	7.7 – 10.5				0.1 – 1.2	0.3 – 1.3	0.4 – 1.1
AS Rate (World)				5.0	10.1	7.6				0.4	0.5	0.5
Confidence Interval (95%)				3.7 – 6.3	8.2 – 12.0	6.4 – 8.7				0.1 – 0.8	0.2 – 0.7	0.2 – 0.7
Lifetime Risk				1 in 219	1 in 111	1 in 146				1 in 2,387	1 in 2,138	1 in 2,239
PYLL										75	20	95
% of all cancers				0.9	2.3	1.6				0.3	0.6	0.4
Trend 2013–2017 (per annum)				3.5%	5.0%	4.8%				1.8%	109.3%	22.1%

Table A2.48 – Cancer of Other endocrine glands

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	1	1	0.0	2.0	1.0	0	0	0	0.0	0.0	0.0
5–9	0	1	1	0.0	2.0	1.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	1	1	0.0	1.7	0.9	0	0	0	0.0	0.0	0.0
50–54	0	1	1	0.0	1.8	0.9	1	0	1	1.8	0.0	0.9
55–59	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
60–64	1	0	1	2.0	0.0	1.0	0	0	0	0.0	0.0	0.0
65–69	0	1	1	0.0	2.1	1.1	0	0	0	0.0	0.0	0.0
70–74	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
75–79	0	1	1	0.0	3.4	1.8	0	0	0	0.0	0.0	0.0
80–84	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
85+	0	0	0	0.0	0.0	0.0	0	1	1	0.0	3.6	2.3
Total/Crude rate	1	6	7	0.1	0.7	0.4	1	1	2	0.1	0.1	0.1
AS Rate (Aust)				0.1	0.7	0.4				0.1	0.1	0.1
Confidence Interval (95%)				0.0 – 0.3	0.1 – 1.2	0.1 – 0.7				0.0 – 0.4	0.0 – 0.2	0.0 – 0.2
AS Rate (World)				0.1	0.7	0.4				0.1	0.0	0.1
Confidence Interval (95%)				0.0 – 0.2	0.1 – 1.3	0.1 – 0.7				0.0 – 0.3	0.0 – 0.1	0.0 – 0.2
Lifetime Risk				1 in 9983	1 in 2107	1 in 3497				1 in 11,083	N/A	1 in 22,457
PYLL										23	0	23
% of all cancers				0.0	0.1	0.1				0.0	0.1	0.1
Trend 2013–2017 (per annum)				-13.4%	-7.6%	-10.6%				-2.9%	-21.6%	-15.5%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.49 – Cancer of Other and unspecified sites

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	1	0	1	1.9	0.0	1.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	2	0	2	3.5	0.0	1.7	2	0	2	3.5	0.0	1.7
35–39	3	2	5	5.7	3.7	4.7	0	1	1	0.0	1.9	0.9
40–44	3	1	4	5.7	1.9	3.8	1	1	2	1.9	1.9	1.9
45–49	5	3	8	8.8	5.1	6.9	2	0	2	3.5	0.0	1.7
50–54	12	7	19	21.7	12.3	16.9	4	4	8	7.2	7.0	7.1
55–59	13	7	20	23.4	12.1	17.6	11	4	15	19.8	6.9	13.2
60–64	16	9	25	32.1	17.0	24.3	8	10	18	16.0	18.9	17.5
65–69	17	12	29	36.9	24.6	30.6	14	4	18	30.4	8.2	19.0
70–74	12	18	30	32.1	44.8	38.7	16	11	27	42.8	27.4	34.8
75–79	24	20	44	93.7	68.0	80.0	17	11	28	66.4	37.4	50.9
80–84	22	19	41	124.9	86.9	103.9	14	16	30	79.5	73.2	76.0
85+	25	39	64	152.0	139.7	144.2	25	44	69	152.0	157.6	155.5
Total/Crude rate	155	137	292	18.2	15.7	16.9	114	106	220	13.4	12.2	12.8
AS Rate (Aust)				16.6	11.7	14.0				11.8	8.7	10.2
Confidence Interval (95%)				13.9 – 19.2	9.7 – 13.7	12.4 – 15.6				9.6 – 14.0	7.0 – 10.4	8.8 – 11.6
AS Rate (World)				10.4	6.9	8.6				7.0	4.7	5.8
Confidence Interval (95%)				8.9 – 12.0	5.8 – 8.1	7.6 – 9.6				5.8 – 8.1	3.8 – 5.6	5.0 – 6.5
Lifetime Risk				1 in 117	1 in 165	1 in 137				1 in 160	1 in 277	1 in 205
PYLL										700	413	1,113
% of all cancers				2.7	2.9	2.8				5.6	6.3	5.9
Trend 2013–2017 (per annum)				-3.8%	-0.5%	-2.3%				-2.5%	-1.8%	-1.8%

Table A2.50 – Non-Hodgkin lymphoma

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	1	0	1	1.9	0.0	1.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	1	0	1	1.9	0.0	1.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	1	2	3	1.7	3.5	2.6	1	0	1	1.7	0.0	0.9
30–34	2	1	3	3.5	1.7	2.6	0	0	0	0.0	0.0	0.0
35–39	8	1	9	15.1	1.9	8.5	1	0	1	1.9	0.0	0.9
40–44	8	5	13	15.1	9.5	12.3	0	1	1	0.0	1.9	0.9
45–49	14	4	18	24.5	6.8	15.6	1	0	1	1.8	0.0	0.9
50–54	11	19	30	19.9	33.4	26.7	3	3	6	5.4	5.3	5.3
55–59	21	17	38	37.7	29.4	33.5	3	3	6	5.4	5.2	5.3
60–64	29	17	46	58.1	32.2	44.8	8	4	12	16.0	7.6	11.7
65–69	57	29	86	123.7	59.6	90.7	10	6	16	21.7	12.3	16.9
70–74	41	14	55	109.6	34.8	70.9	12	7	19	32.1	17.4	24.5
75–79	42	29	71	164.0	98.6	129.0	7	11	18	27.3	37.4	32.7
80–84	26	11	37	147.6	50.3	93.7	7	10	17	39.7	45.7	43.1
85+	27	30	57	164.1	107.5	128.5	21	19	40	127.6	68.1	90.2
Total/Crude rate	289	179	468	33.9	20.5	27.1	74	64	138	8.7	7.3	8.0
AS Rate (Aust)				30.1	16.5	22.9				7.7	5.4	6.4
Confidence Interval (95%)				26.6 – 33.6	14.0 – 19.0	20.8 – 25.0				5.9 – 9.5	4.0 – 6.7	5.3 – 7.5
AS Rate (World)				20.1	11.1	15.4				4.4	3.1	3.7
Confidence Interval (95%)				17.9 – 22.4	9.4 – 12.7	14.0 – 16.8				3.4 – 5.4	2.3 – 3.8	3.1 – 4.3
Lifetime Risk				1 in 49	1 in 95	1 in 65				1 in 233	1 in 403	1 in 298
PYLL										438	265	703
% of all cancers				5.0	3.7	4.5				3.6	3.8	3.7
Trend 2013–2017 (per annum)				-2.1%	-4.1%	-2.8%				-2.9%	0.1%	-1.7%

Table A2.51 – Hodgkin lymphoma

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	1	1	0.0	2.1	1.0	0	0	0	0.0	0.0	0.0
15–19	4	1	5	7.5	2.0	4.8	0	0	0	0.0	0.0	0.0
20–24	2	3	5	3.4	5.3	4.3	0	0	0	0.0	0.0	0.0
25–29	1	2	3	1.7	3.5	2.6	0	0	0	0.0	0.0	0.0
30–34	1	0	1	1.7	0.0	0.9	0	0	0	0.0	0.0	0.0
35–39	1	1	2	1.9	1.9	1.9	0	0	0	0.0	0.0	0.0
40–44	2	1	3	3.8	1.9	2.8	0	0	0	0.0	0.0	0.0
45–49	2	3	5	3.5	5.1	4.3	0	0	0	0.0	0.0	0.0
50–54	1	1	2	1.8	1.8	1.8	1	0	1	1.8	0.0	0.9
55–59	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
60–64	4	3	7	8.0	5.7	6.8	0	0	0	0.0	0.0	0.0
65–69	3	0	3	6.5	0.0	3.2	0	0	0	0.0	0.0	0.0
70–74	1	2	3	2.7	5.0	3.9	0	1	1	0.0	2.5	1.3
75–79	1	1	2	3.9	3.4	3.6	0	0	0	0.0	0.0	0.0
80–84	5	0	5	28.4	0.0	12.7	3	0	3	17.0	0.0	7.6
85+	0	0	0	0.0	0.0	0.0	1	0	1	6.1	0.0	2.3
Total/Crude rate	28	19	47	3.3	2.2	2.7	5	1	6	0.6	0.1	0.3
AS Rate (Aust)				3.2	2.2	2.7				0.6	0.1	0.3
Confidence Interval (95%)				2.0 – 4.4	1.2 – 3.2	1.9 – 3.4				0.1 – 1.1	0.0 – 0.2	0.1 – 0.5
AS Rate (World)				2.7	2.1	2.4				0.3	0.1	0.2
Confidence Interval (95%)				1.7 – 3.8	1.1 – 3.1	1.7 – 3.1				0.1 – 0.5	0.0 – 0.2	0.0 – 0.3
Lifetime Risk				1 in 471	1 in 586	1 in 523				1 in 11,083	1 in 8,041	1 in 9,178
PYLL										23	3	25
% of all cancers				0.5	0.4	0.4				0.2	0.1	0.2
Trend 2013–2017 (per annum)				13.3%	-9.8%	-0.3%				43.0%	127.3%	59.6%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.52 – Other lymphomas												
South Australia												
Year – 2017												
	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	1	1	0.0	1.9	0.9	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
55–59	0	2	2	0.0	3.5	1.8	0	0	0	0.0	0.0	0.0
60–64	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
65–69	2	0	2	4.3	0.0	2.1	0	0	0	0.0	0.0	0.0
70–74	3	1	4	8.0	2.5	5.2	2	0	2	5.3	0.0	2.6
75–79	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
80–84	0	2	2	0.0	9.1	5.1	0	1	1	0.0	4.6	2.5
85+	0	3	3	0.0	10.7	6.8	2	3	5	12.2	10.7	11.3
Total/Crude rate	5	9	14	0.6	1.0	0.8	4	4	8	0.5	0.5	0.5
AS Rate (Aust)				0.4	0.8	0.7				0.4	0.3	0.3
Confidence Interval (95%)				0.1 – 0.8	0.3 – 1.3	0.3 – 1.0				0.0 – 0.8	0.0 – 0.6	0.1 – 0.6
AS Rate (World)				0.3	0.5	0.4				0.2	0.1	0.1
Confidence Interval (95%)				0.1 – 0.6	0.2 – 0.8	0.2 – 0.6				0.0 – 0.4	0.0 – 0.2	0.1 – 0.2
Lifetime Risk				1 in 1618	1 in 2558	1 in 2007				1 in 3,740	N/A	1 in 7,761
PYLL										5	0	5
% of all cancers				0.1	0.2	0.1				0.2	0.2	0.2
Trend 2013–2017 (per annum)				-11.8%	12.1%	-0.7%				-5.0%	-3.1%	-2.8%

Table A2.53 – Mast cell tumours												
South Australia												
Year – 2017												
	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
55–59	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
60–64	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
65–69	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
70–74	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
75–79	0	0	0	0.0	0.0	0.0	1	0	1	3.9	0.0	1.8
80–84	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
85+	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
Total/Crude rate	0	0	0	0.0	0.0	0.0	1	0	1	0.1	0.0	0.1
AS Rate (Aust)				0.0	0.0	0.0				0.1	0.0	0.0
Confidence Interval (95%)				0.0 – 0.0	0.0 – 0.0	0.0 – 0.0				0.0 – 0.3	0.0 – 0.0	0.0 – 0.1
AS Rate (World)				0.0	0.0	0.0				0.1	0.0	0.0
Confidence Interval (95%)				0.0 – 0.0	0.0 – 0.0	0.0 – 0.0				0.0 – 0.1	0.0 – 0.0	0.0 – 0.1
Lifetime Risk				N/A	N/A	N/A				N/A	N/A	N/A
PYLL										0	0	0
% of all cancers				0.0	0.0	0.0				0.0	0.0	0.0
Trend 2013–2017 (per annum)				-17.3%	0.0%	-15.5%				undefined	0.0%	undefined

Table A2.54 – Malignancy of histiocytes and accessory lymphoid cells												
South Australia												
Year – 2017												
	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	1	1	2	1.9	2.0	2.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	1	0	1	2.0	0.0	1.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	1	0	1	1.8	0.0	0.9	0	0	0	0.0	0.0	0.0
55–59	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
60–64	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
65–69	0	1	1	0.0	2.1	1.1	0	0	0	0.0	0.0	0.0
70–74	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
75–79	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
80–84	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
85+	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
Total/Crude rate	3	2	5	0.4	0.2	0.3	0	0	0	0.0	0.0	0.0
AS Rate (Aust)				0.4	0.2	0.3				0.0	0.0	0.0
Confidence Interval (95%)				0.0 – 0.8	0.0 – 0.5	0.0 – 0.6				0.0 – 0.0	0.0 – 0.0	0.0 – 0.0
AS Rate (World)				0.4	0.2	0.3				0.0	0.0	0.0
Confidence Interval (95%)				0.0 – 0.9	0.0 – 0.6	0.0 – 0.7				0.0 – 0.0	0.0 – 0.0	0.0 – 0.0
Lifetime Risk				1 in 3515	1 in 4913	1 in 4067				N/A	N/A	N/A
PYLL										0	0	0
% of all cancers				0.1	0.0	0.0				0.0	0.0	0.0
Trend 2013–2017 (per annum)				6.6%	45.6%	14.7%				19.6%	undefined	40.4%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.55 – Multiple myeloma/Plasma cell tumours

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	1	0	1	1.7	0.0	0.9	0	0	0	0.0	0.0	0.0
35–39	0	1	1	0.0	1.9	0.9	0	0	0	0.0	0.0	0.0
40–44	1	0	1	1.9	0.0	0.9	2	0	2	3.8	0.0	1.9
45–49	2	3	5	3.5	5.1	4.3	0	1	1	0.0	1.7	0.9
50–54	6	2	8	10.8	3.5	7.1	2	1	3	3.6	1.8	2.7
55–59	7	8	15	12.6	13.8	13.2	5	1	6	9.0	1.7	5.3
60–64	12	6	18	24.0	11.4	17.5	2	1	3	4.0	1.9	2.9
65–69	17	9	26	36.9	18.5	27.4	5	2	7	10.8	4.1	7.4
70–74	14	12	26	37.4	29.8	33.5	7	8	15	18.7	19.9	19.3
75–79	12	11	23	46.9	37.4	41.8	8	9	17	31.2	30.6	30.9
80–84	11	13	24	62.4	59.5	60.8	12	6	18	68.1	27.4	45.6
85+	12	4	16	72.9	14.3	36.1	8	7	15	48.6	25.1	33.8
Total/Crude rate	95	69	164	11.2	7.9	9.5	51	36	87	6.0	4.1	5.0
AS Rate (Aust)				9.8	6.3	7.9				5.3	3.0	4.1
Confidence Interval (95%)				7.8 – 11.8	4.8 – 7.8	6.7 – 9.1				3.9 – 6.8	2.0 – 4.0	3.2 – 4.9
AS Rate (World)				6.2	4.1	5.0				3.1	1.8	2.4
Confidence Interval (95%)				5.0 – 7.3	3.2 – 5.0	4.3 – 5.8				2.4 – 3.9	1.2 – 2.3	1.9 – 2.9
Lifetime Risk				1 in 156	1 in 238	1 in 189				1 in 401	1 in 644	1 in 496
PYLL										278	115	393
% of all cancers				1.7	1.4	1.6				2.5	2.1	2.3
Trend 2013–2017 (per annum)				3.8%	2.1%	3.0%				6.4%	5.1%	6.4%

Table A2.56 – Immunoproliferative neoplasms

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	1	1	2	1.8	1.8	1.8	0	0	0	0.0	0.0	0.0
55–59	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
60–64	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
65–69	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
70–74	1	0	1	2.7	0.0	1.3	0	0	0	0.0	0.0	0.0
75–79	3	0	3	11.7	0.0	5.5	0	0	0	0.0	0.0	0.0
80–84	1	0	1	5.7	0.0	2.5	0	0	0	0.0	0.0	0.0
85+	1	0	1	6.1	0.0	2.3	1	0	1	6.1	0.0	2.3
Total/Crude rate	7	1	8	0.8	0.1	0.5	1	0	1	0.1	0.0	0.1
AS Rate (Aust)				0.7	0.1	0.4				0.1	0.0	0.0
Confidence Interval (95%)				0.2 – 1.3	0.0 – 0.3	0.1 – 0.7				0.0 – 0.3	0.0 – 0.0	0.0 – 0.1
AS Rate (World)				0.4	0.1	0.2				0.0	0.0	0.0
Confidence Interval (95%)				0.2 – 0.7	0.0 – 0.3	0.1 – 0.4				0.0 – 0.1	0.0 – 0.0	0.0 – 0.0
Lifetime Risk				1 in 4466	1 in 11375	1 in 6515				N/A	N/A	N/A
PYLL										0	0	0
% of all cancers				0.1	0.0	0.1				0.0	0.0	0.0
Trend 2013–2017 (per annum)				9.2%	-17.6%	-7.4%				-19.0%	-26.6%	-22.1%

Table A2.57 – All leukaemias

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	4	8	12	7.6	16.1	11.8	0	0	0	0.0	0.0	0.0
5–9	3	3	6	5.6	5.9	5.7	0	1	1	0.0	2.0	1.0
10–14	2	1	3	3.9	2.1	3.0	0	0	0	0.0	0.0	0.0
15–19	4	0	4	7.5	0.0	3.9	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	1	1	0.0	1.7	0.9	1	0	1	1.7	0.0	0.9
30–34	1	2	3	1.7	3.4	2.6	0	0	0	0.0	0.0	0.0
35–39	2	3	5	3.8	5.6	4.7	0	0	0	0.0	0.0	0.0
40–44	2	2	4	3.8	3.8	3.8	0	1	1	0.0	1.9	0.9
45–49	6	8	14	10.5	13.7	12.1	2	4	6	3.5	6.8	5.2
50–54	9	3	12	16.2	5.3	10.7	2	2	4	3.6	3.5	3.6
55–59	18	6	24	32.3	10.4	21.2	3	2	5	5.4	3.5	4.4
60–64	22	7	29	44.1	13.3	28.2	5	1	6	10.0	1.9	5.8
65–69	25	17	42	54.2	34.9	44.3	8	2	10	17.4	4.1	10.6
70–74	23	10	33	61.5	24.9	42.5	10	6	16	26.7	14.9	20.6
75–79	23	13	36	89.8	44.2	65.4	15	5	20	58.6	17.0	36.3
80–84	20	7	27	113.5	32.0	68.4	15	13	28	85.1	59.5	70.9
85+	17	21	38	103.3	75.2	85.6	26	17	43	158.0	60.9	96.9
Total/Crude rate	181	112	293	21.2	12.8	17.0	87	54	141	10.2	6.2	8.2
AS Rate (Aust)				19.1	10.6	14.6				9.1	4.6	6.6
Confidence Interval (95%)				16.3 – 21.9	8.6 – 12.6	12.9 – 16.3				7.2 – 11.0	3.4 – 5.9	5.5 – 7.7
AS Rate (World)				13.4	8.2	10.7				4.9	2.7	3.7
Confidence Interval (95%)				11.4 – 15.4	6.5 – 10.0	9.3 – 12.0				3.9 – 5.8	1.9 – 3.5	3.1 – 4.3
Lifetime Risk				1 in 80	1 in 142	1 in 103				1 in 293	1 in 519	1 in 378
PYLL										348	333	680
% of all cancers				3.2	2.3	2.8				4.3	3.2	3.8
Trend 2013–2017 (per annum)				-3.5%	-1.4%	-2.4%				-0.7%	-0.7%	-0.6%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.58 – Polycythaemia vera												
South Australia												
Year – 2017												
	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	1	0	1	1.9	0.0	1.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	1	1	2	1.9	1.9	1.9	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	0	1	1	0.0	1.8	0.9	0	0	0	0.0	0.0	0.0
55–59	1	1	2	1.8	1.7	1.8	0	0	0	0.0	0.0	0.0
60–64	1	2	3	2.0	3.8	2.9	0	0	0	0.0	0.0	0.0
65–69	1	2	3	2.2	4.1	3.2	0	0	0	0.0	0.0	0.0
70–74	1	1	2	2.7	2.5	2.6	0	0	0	0.0	0.0	0.0
75–79	2	1	3	7.8	3.4	5.5	1	0	1	3.9	0.0	1.8
80–84	1	1	2	5.7	4.6	5.1	1	0	1	5.7	0.0	2.5
85+	2	0	2	12.2	0.0	4.5	2	0	2	12.2	0.0	4.5
Total/Crude rate	11	10	21	1.3	1.1	1.2	4	0	4	0.5	0.0	0.2
AS Rate (Aust)				1.2	1.0	1.1				0.4	0.0	0.2
Confidence Interval (95%)				0.5 – 1.9	0.4 – 1.6	0.6 – 1.5				0.0 – 0.9	0.0 – 0.0	0.0 – 0.4
AS Rate (World)				0.8	0.7	0.8				0.2	0.0	0.1
Confidence Interval (95%)				0.3 – 1.3	0.3 – 1.1	0.4 – 1.1				0.1 – 0.3	0.0 – 0.0	0.0 – 0.1
Lifetime Risk				1 in 1611	1 in 1269	1 in 1412				N/A	N/A	N/A
PYLL										0	0	0
% of all cancers				0.2	0.2	0.2				0.2	0.0	0.1
Trend 2013–2017 (per annum)				-3.8%	14.0%	1.3%				139.7%	-11.2%	13.1%

Table A2.59 – Myelodysplastic syndromes												
South Australia												
Year – 2017												
	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	1	0	1	1.9	0.0	0.9	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	0	2	2	0.0	3.5	1.8	0	0	0	0.0	0.0	0.0
55–59	2	1	3	3.6	1.7	2.6	0	0	0	0.0	0.0	0.0
60–64	6	1	7	12.0	1.9	6.8	3	0	3	6.0	0.0	2.9
65–69	5	5	10	10.8	10.3	10.6	3	1	4	6.5	2.1	4.2
70–74	8	4	12	21.4	9.9	15.5	3	2	5	8.0	5.0	6.4
75–79	8	10	18	31.2	34.0	32.7	11	7	18	43.0	23.8	32.7
80–84	11	4	15	62.4	18.3	38.0	8	4	12	45.4	18.3	30.4
85+	17	12	29	103.3	43.0	65.4	13	10	23	79.0	35.8	51.8
Total/Crude rate	58	39	97	6.8	4.5	5.6	41	24	65	4.8	2.8	3.8
AS Rate (Aust)				6.1	3.2	4.4				4.3	1.9	2.9
Confidence Interval (95%)				4.5 – 7.6	2.2 – 4.2	3.5 – 5.3				3.0 – 5.6	1.1 – 2.6	2.2 – 3.6
AS Rate (World)				3.2	1.8	2.4				2.1	0.9	1.5
Confidence Interval (95%)				2.4 – 3.9	1.3 – 2.3	2.0 – 2.9				1.6 – 2.7	0.6 – 1.2	1.2 – 1.7
Lifetime Risk				1 in 403	1 in 731	1 in 524				1 in 974	1 in 2,846	1 in 1,473
PYLL										68	13	80
% of all cancers				1.0	0.8	0.9				2.0	1.4	1.8
Trend 2013–2017 (per annum)				-2.6%	-1.3%	-2.2%				22.4%	21.8%	23.2%

Table A2.60 – Other chronic myeloproliferative and haematological disorders												
South Australia												
Year – 2017												
	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	1	0	1	1.7	0.0	0.9	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	1	1	0.0	1.9	0.9	0	0	0	0.0	0.0	0.0
45–49	0	2	2	0.0	3.4	1.7	0	0	0	0.0	0.0	0.0
50–54	0	1	1	0.0	1.8	0.9	0	0	0	0.0	0.0	0.0
55–59	0	0	0	0.0	0.0	0.0	1	0	1	1.8	0.0	0.9
60–64	4	0	4	8.0	0.0	3.9	2	0	2	4.0	0.0	1.9
65–69	5	4	9	10.8	8.2	9.5	1	2	3	2.2	4.1	3.2
70–74	10	3	13	26.7	7.5	16.8	1	0	1	2.7	0.0	1.3
75–79	8	3	11	31.2	10.2	20.0	2	4	6	7.8	13.6	10.9
80–84	3	4	7	17.0	18.3	17.7	2	1	3	11.4	4.6	7.6
85+	3	2	5	18.2	7.2	11.3	1	0	1	6.1	0.0	2.3
Total/Crude rate	34	20	54	4.0	2.3	3.1	10	7	17	1.2	0.8	1.0
AS Rate (Aust)				3.3	1.8	2.5				1.0	0.6	0.8
Confidence Interval (95%)				2.2 – 4.5	1.0 – 2.6	1.8 – 3.2				0.4 – 1.7	0.2 – 1.1	0.4 – 1.2
AS Rate (World)				2.1	1.2	1.6				0.6	0.4	0.5
Confidence Interval (95%)				1.4 – 2.7	0.7 – 1.7	1.2 – 2.0				0.3 – 1.0	0.1 – 0.6	0.3 – 0.7
Lifetime Risk				1 in 423	1 in 880	1 in 579				1 in 1,879	1 in 4,869	1 in 2,747
PYLL										53	15	68
% of all cancers				0.6	0.4	0.5				0.5	0.4	0.5
Trend 2013–2017 (per annum)				10.0%	-2.3%	3.7%				5.2%	18.9%	11.2%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.61 – All cancers												
South Australia												
Year – 2017												
	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	14	12	26	26.8	24.2	25.5	0	0	0	0.0	0.0	0.0
5–9	5	8	13	9.3	15.7	12.4	0	2	2	0.0	3.9	1.9
10–14	6	6	12	11.8	12.4	12.1	2	0	2	3.9	0.0	2.0
15–19	17	8	25	32.1	15.8	24.1	1	1	2	1.9	2.0	1.9
20–24	13	12	25	21.9	21.4	21.7	2	3	5	3.4	5.3	4.3
25–29	34	29	63	58.7	50.4	54.6	5	0	5	8.6	0.0	4.3
30–34	45	61	106	78.0	104.5	91.3	8	2	10	13.9	3.4	8.6
35–39	66	91	157	124.6	170.3	147.6	6	6	12	11.3	11.2	11.3
40–44	91	142	233	171.5	268.6	219.9	12	16	28	22.6	30.3	26.4
45–49	162	290	452	283.6	495.5	390.8	35	42	77	61.3	71.8	66.6
50–54	298	372	670	537.8	654.1	596.7	78	55	133	140.8	96.7	118.5
55–59	498	411	909	894.8	711.1	801.2	102	93	195	183.3	160.9	171.9
60–64	710	521	1,231	1,422.5	986.8	1,198.5	164	147	311	328.6	278.4	302.8
65–69	928	620	1,548	2,013.4	1,273.5	1,633.3	246	174	420	533.7	357.4	443.2
70–74	951	675	1,626	2,542.9	1,679.0	2,095.4	294	198	492	786.1	492.5	634.0
75–79	762	568	1,330	2,975.5	1,931.2	2,417.3	299	256	555	1,167.6	870.4	1,008.7
80–84	614	400	1,014	3,485.1	1,829.9	2,568.6	316	239	555	1,793.6	1,093.4	1,405.9
85+	519	555	1,074	3,154.6	1,988.1	2,420.7	468	441	909	2,844.6	1,579.7	2,048.8
Total/Crude rate	5,733	4,781	10,514	673.0	548.2	609.9	2,038	1,675	3,713	239.2	192.1	215.4
AS Rate (Aust)				594.0	452.3	516.6				211.8	143.6	173.4
Confidence Interval (95%)				578.5 – 609.5	439.3 – 465.4	506.6 – 526.5				202.6 – 221.1	36.6 – 150.6	67.8 – 179.0
AS Rate (World)				390.7	316.3	350.5				120.7	85.2	101.2
Confidence Interval (95%)				380.9 – 400.4	307.3 – 325.4	343.8 – 357.1				115.9 – 125.6	81.1 – 89.3	98.1 – 104.4
Lifetime Risk				1 in 3	1 in 4	1 in 3				1 in 10	1 in 14	1 in 12
PYLL										10,613	8,838	19,450
% of all cancers				100.0	100.0	100.0				100.0	100.0	100.0
Trend 2013–2017 (per annum)				-2.0%	-0.2%	-1.1%				-1.8%	-1.2%	-1.4%

Table A2.62 – Mesothelioma												
South Australia												
Year – 2017												
	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	1	0	1	1.9	0.0	0.9	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
55–59	4	1	5	7.2	1.7	4.4	2	2	4	3.6	3.5	3.5
60–64	6	1	7	12.0	1.9	6.8	4	0	4	8.0	0.0	3.9
65–69	3	2	5	6.5	4.1	5.3	2	1	3	4.3	2.1	3.2
70–74	8	1	9	21.4	2.5	11.6	4	1	5	10.7	2.5	6.4
75–79	7	2	9	27.3	6.8	16.4	9	2	11	35.1	6.8	20.0
80–84	9	2	11	51.1	9.1	27.9	9	3	12	51.1	13.7	30.4
85+	10	1	11	60.8	3.6	24.8	14	2	16	85.1	7.2	36.1
Total/Crude rate	48	10	58	5.6	1.1	3.4	44	11	55	5.2	1.3	3.2
AS Rate (Aust)				5.0	0.9	2.7				4.6	0.9	2.5
Confidence Interval (95%)				3.6 – 6.4	0.3 – 1.4	2.0 – 3.4				3.3 – 6.0	0.4 – 1.5	1.9 – 3.2
AS Rate (World)				2.8	0.5	1.6				2.3	0.5	1.3
Confidence Interval (95%)				2.1 – 3.5	0.2 – 0.8	1.2 – 2.0				1.7 – 2.9	0.3 – 0.8	1.0 – 1.6
Lifetime Risk				1 in 409	1 in 1957	1 in 689				1 in 751	1 in 2,500	1 in 1,175
PYLL										110	45	155
% of all cancers				0.8	0.2	0.6				2.2	0.7	1.5
Trend 2013–2017 (per annum)				-10.2%	-8.1%	-9.6%				-7.0%	6.6%	-5.0%

Table A2.63 – Kaposi sarcoma												
South Australia												
Year – 2017												
	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	1	0	1	1.9	0.0	0.9	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
55–59	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
60–64	0	1	1	0.0	1.9	1.0	0	0	0	0.0	0.0	0.0
65–69	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
70–74	1	0	1	2.7	0.0	1.3	0	0	0	0.0	0.0	0.0
75–79	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
80–84	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
85+	1	0	1	6.1	0.0	2.3	0	0	0	0.0	0.0	0.0
Total/Crude rate	3	1	4	0.4	0.1	0.2	0	0	0	0.0	0.0	0.0
AS Rate (Aust)				0.3	0.1	0.2				0.0	0.0	0.0
Confidence Interval (95%)				0.0 – 0.7	0.0 – 0.3	0.0 – 0.4				0.0 – 0.0	0.0 – 0.0	0.0 – 0.0
AS Rate (World)				0.2	0.1	0.1				0.0	0.0	0.0
Confidence Interval (95%)				0.0 – 0.5	0.0 – 0.2	0.0 – 0.3				0.0 – 0.0	0.0 – 0.0	0.0 – 0.0
Lifetime Risk				1 in 4384	1 in 10560	1 in 6246				N/A	N/A	N/A
PYLL										0	0	0
% of all cancers				0.1	0.0	0.0				0.0	0.0	0.0
Trend 2013–2017 (per annum)				-3.7%	20.5%	3.5%				0.0%	0.0%	0.0%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.64 – Acute lymphocytic leukaemia

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	1	6	7	1.9	12.1	6.9	0	0	0	0.0	0.0	0.0
5–9	3	2	5	5.6	3.9	4.8	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	2	0	2	3.8	0.0	1.9	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	1	1	2	1.7	1.7	1.7	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	1	1	0.0	1.7	0.9	0	0	0	0.0	0.0	0.0
50–54	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
55–59	0	1	1	0.0	1.7	0.9	0	1	1	0.0	1.7	0.9
60–64	2	0	2	4.0	0.0	1.9	0	0	0	0.0	0.0	0.0
65–69	0	2	2	0.0	4.1	2.1	1	0	1	2.2	0.0	1.1
70–74	1	0	1	2.7	0.0	1.3	0	1	1	0.0	2.5	1.3
75–79	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
80–84	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
85+	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
Total/Crude rate	10	13	23	1.2	1.5	1.3	1	2	3	0.1	0.2	0.2
AS Rate (Aust)				1.1	1.5	1.3				0.1	0.2	0.1
Confidence Interval (95%)				0.4 – 1.9	0.7 – 2.4	0.8 – 1.9				0.0 – 0.3	0.0 – 0.4	0.0 – 0.3
AS Rate (World)				1.3	1.8	1.6				0.1	0.1	0.1
Confidence Interval (95%)				0.4 – 2.2	0.8 – 2.9	0.9 – 2.3				0.0 – 0.2	0.0 – 0.3	0.0 – 0.2
Lifetime Risk				1 in 1017	1 in 792	1 in 894				1 in 9,219	1 in 4,743	1 in 6,202
PYLL										8	20	28
% of all cancers				0.2	0.3	0.2				0.0	0.1	0.1
Trend 2013–2017 (per annum)				-7.7%	14.3%	-0.7%				-10.7%	-10.9%	-10.9%

Table A2.65 – Chronic lymphocytic leukaemia

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	1	1	0.0	1.7	0.9	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	1	0	1	1.9	0.0	0.9	0	0	0	0.0	0.0	0.0
45–49	2	3	5	3.5	5.1	4.3	0	0	0	0.0	0.0	0.0
50–54	4	2	6	7.2	3.5	5.3	0	0	0	0.0	0.0	0.0
55–59	14	3	17	25.2	5.2	15.0	1	0	1	1.8	0.0	0.9
60–64	12	6	18	24.0	11.4	17.5	1	1	2	2.0	1.9	1.9
65–69	16	11	27	34.7	22.6	28.5	1	0	1	2.2	0.0	1.1
70–74	10	4	14	26.7	9.9	18.0	2	0	2	5.3	0.0	2.6
75–79	6	7	13	23.4	23.8	23.6	2	2	4	7.8	6.8	7.3
80–84	8	1	9	45.4	4.6	22.8	6	4	10	34.1	18.3	25.3
85+	6	12	18	36.5	43.0	40.6	9	6	15	54.7	21.5	33.8
Total/Crude rate	79	50	129	9.3	5.7	7.5	22	13	35	2.6	1.5	2.0
AS Rate (Aust)				8.2	4.4	6.2				2.3	1.0	1.6
Confidence Interval (95%)				6.4 – 10.0	3.2 – 5.6	5.1 – 7.3				1.4 – 3.3	0.5 – 1.6	1.1 – 2.1
AS Rate (World)				5.4	2.8	4.1				1.1	0.5	0.7
Confidence Interval (95%)				4.2 – 6.5	2.0 – 3.6	3.4 – 4.8				0.7 – 1.5	0.3 – 0.7	0.5 – 1.0
Lifetime Risk				1 in 163	1 in 337	1 in 221				1 in 1,768	1 in 10,560	1 in 3,096
PYLL										43	13	55
% of all cancers				1.4	1.0	1.2				1.1	0.8	0.9
Trend 2013–2017 (per annum)				-5.1%	-0.4%	-3.0%				8.1%	-6.2%	1.9%

Table A2.66 – Other and unspecified lymphoid leukaemia

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	1	6	7	1.9	12.1	6.9	0	0	0	0.0	0.0	0.0
5–9	3	2	5	5.6	3.9	4.8	0	1	1	0.0	2.0	1.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	3	0	3	5.7	0.0	2.9	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	1	1	2	1.7	1.7	1.7	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	1	1	0.0	1.7	0.9	0	0	0	0.0	0.0	0.0
50–54	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
55–59	0	1	1	0.0	1.7	0.9	0	1	1	0.0	1.7	0.9
60–64	2	0	2	4.0	0.0	1.9	0	0	0	0.0	0.0	0.0
65–69	1	2	3	2.2	4.1	3.2	1	0	1	2.2	0.0	1.1
70–74	2	1	3	5.3	2.5	3.9	0	1	1	0.0	2.5	1.3
75–79	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
80–84	1	0	1	5.7	0.0	2.5	1	1	2	5.7	4.6	5.1
85+	0	0	0	0.0	0.0	0.0	0	1	1	0.0	3.6	2.3
Total/Crude rate	14	14	28	1.6	1.6	1.6	2	5	7	0.2	0.5	0.3
AS Rate (Aust)				1.6	1.6	1.6				0.2	0.5	0.3
Confidence Interval (95%)				0.7 – 2.4	0.8 – 2.5	1.0 – 2.2				0.0 – 0.5	0.0 – 0.9	0.1 – 0.6
AS Rate (World)				1.6	1.9	1.8				0.1	0.4	0.2
Confidence Interval (95%)				0.7 – 2.6	0.8 – 3.0	1.0 – 2.5				0.0 – 0.3	0.0 – 0.8	0.0 – 0.5
Lifetime Risk				1 in 758	1 in 721	1 in 742				1 in 9,219	1 in 3,240	1 in 4,787
PYLL										8	88	95
% of all cancers				0.2	0.3	0.3				0.1	0.3	0.2
Trend 2013–2017 (per annum)				-6.4%	5.6%	-2.3%				-15.5%	3.6%	-7.2%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.67 – Acute myeloid leukaemia

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	1	1	0.0	2.0	1.0	0	0	0	0.0	0.0	0.0
5–9	0	1	1	0.0	2.0	1.0	0	0	0	0.0	0.0	0.0
10–14	1	1	2	2.0	2.1	2.0	0	0	0	0.0	0.0	0.0
15–19	1	0	1	1.9	0.0	1.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	1	1	0.0	1.7	0.9	1	0	1	1.7	0.0	0.9
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	2	2	4	3.8	3.7	3.8	0	0	0	0.0	0.0	0.0
40–44	0	1	1	0.0	1.9	0.9	0	1	1	0.0	1.9	0.9
45–49	2	2	4	3.5	3.4	3.5	1	4	5	1.8	6.8	4.3
50–54	3	0	3	5.4	0.0	2.7	1	2	3	1.8	3.5	2.7
55–59	1	2	3	1.8	3.5	2.6	2	0	2	3.6	0.0	1.8
60–64	5	1	6	10.0	1.9	5.8	3	0	3	6.0	0.0	2.9
65–69	7	1	8	15.2	2.1	8.4	4	2	6	8.7	4.1	6.3
70–74	7	4	11	18.7	9.9	14.2	8	5	13	21.4	12.4	16.8
75–79	9	3	12	35.1	10.2	21.8	10	3	13	39.0	10.2	23.6
80–84	4	6	10	22.7	27.4	25.3	7	8	15	39.7	36.6	38.0
85+	5	5	10	30.4	17.9	22.5	11	6	17	66.9	21.5	38.3
Total/Crude rate	47	31	78	5.5	3.6	4.5	48	31	79	5.6	3.6	4.6
AS Rate (Aust)				4.9	3.0	3.9				5.0	2.8	3.7
Confidence Interval (95%)				3.5 – 6.3	1.9 – 4.1	3.0 – 4.8				3.5 – 6.4	1.8 – 3.8	2.9 – 4.6
AS Rate (World)				3.3	2.3	2.8				2.8	1.7	2.2
Confidence Interval (95%)				2.4 – 4.3	1.4 – 3.2	2.1 – 3.4				2.1 – 3.5	1.1 – 2.4	1.7 – 2.7
Lifetime Risk				1 in 322	1 in 586	1 in 420				1 in 445	1 in 695	1 in 547
PYLL										220	215	435
% of all cancers				0.8	0.6	0.7				2.4	1.9	2.1
Trend 2013–2017 (per annum)				-5.6%	-3.4%	-4.7%				0.7%	-0.2%	-0.1%

Table A2.68 – Chronic myeloid leukaemia

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	1	1	0.0	1.9	0.9	0	0	0	0.0	0.0	0.0
40–44	0	1	1	0.0	1.9	0.9	0	0	0	0.0	0.0	0.0
45–49	2	2	4	3.5	3.4	3.5	0	0	0	0.0	0.0	0.0
50–54	2	1	3	3.6	1.8	2.7	1	0	1	1.8	0.0	0.9
55–59	1	0	1	1.8	0.0	0.9	0	1	1	0.0	1.7	0.9
60–64	2	0	2	4.0	0.0	1.9	1	0	1	2.0	0.0	1.0
65–69	0	3	3	0.0	6.2	3.2	1	0	1	2.2	0.0	1.1
70–74	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
75–79	2	1	3	7.8	3.4	5.5	0	0	0	0.0	0.0	0.0
80–84	3	0	3	17.0	0.0	7.6	0	0	0	0.0	0.0	0.0
85+	1	0	1	6.1	0.0	2.3	0	0	0	0.0	0.0	0.0
Total/Crude rate	13	9	22	1.5	1.0	1.3	3	1	4	0.4	0.1	0.2
AS Rate (Aust)				1.5	1.0	1.2				0.3	0.1	0.2
Confidence Interval (95%)				0.7 – 2.3	0.3 – 1.6	0.7 – 1.7				0.0 – 0.7	0.0 – 0.3	0.0 – 0.4
AS Rate (World)				0.9	0.8	0.9				0.2	0.1	0.2
Confidence Interval (95%)				0.5 – 1.4	0.3 – 1.3	0.5 – 1.2				0.0 – 0.5	0.0 – 0.2	0.0 – 0.3
Lifetime Risk				1 in 1549	1 in 1325	1 in 1428				1 in 3,346	1 in 11,561	1 in 5,263
PYLL										43	18	60
% of all cancers				0.2	0.2	0.2				0.1	0.1	0.1
Trend 2013–2017 (per annum)				3.9%	-6.7%	-2.1%				-10.4%	-4.5%	-7.5%

Table A2.69 – Other and unspecified myeloid leukaemia

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
55–59	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
60–64	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
65–69	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
70–74	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
75–79	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
80–84	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
85+	1	1	2	6.1	3.6	4.5	1	1	2	6.1	3.6	4.5
Total/Crude rate	1	1	2	0.1	0.1	0.1	1	1	2	0.1	0.1	0.1
AS Rate (Aust)				0.1	0.1	0.1				0.1	0.1	0.1
Confidence Interval (95%)				0.0 – 0.3	0.0 – 0.2	0.0 – 0.2				0.0 – 0.3	0.0 – 0.2	0.0 – 0.2
AS Rate (World)				0.0	0.0	0.0				0.0	0.0	0.0
Confidence Interval (95%)				0.0 – 0.1	0.0 – 0.1	0.0 – 0.1				0.0 – 0.1	0.0 – 0.1	0.0 – 0.1
Lifetime Risk				N/A	N/A	N/A				N/A	N/A	N/A
PYLL										0	0	0
% of all cancers				0.0	0.0	0.0				0.0	0.1	0.1
Trend 2013–2017 (per annum)				-2.5%	undefined	29.1%				-8.6%	undefined	11.0%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.70 – Other specified leukaemias

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	1	0	1	1.8	0.0	0.9
50–54	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
55–59	2	0	2	3.6	0.0	1.8	0	0	0	0.0	0.0	0.0
60–64	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
65–69	1	0	1	2.2	0.0	1.1	1	0	1	2.2	0.0	1.1
70–74	3	1	4	8.0	2.5	5.2	0	0	0	0.0	0.0	0.0
75–79	5	2	7	19.5	6.8	12.7	2	0	2	7.8	0.0	3.6
80–84	2	0	2	11.4	0.0	5.1	0	0	0	0.0	0.0	0.0
85+	4	1	5	24.3	3.6	11.3	4	0	4	24.3	0.0	9.0
Total/Crude rate	17	4	21	2.0	0.5	1.2	8	0	8	0.9	0.0	0.5
AS Rate (Aust)				1.7	0.3	0.9				0.8	0.0	0.4
Confidence Interval (95%)				0.9 – 2.5	0.0 – 0.6	0.5 – 1.3				0.3 – 1.4	0.0 – 0.0	0.1 – 0.6
AS Rate (World)				0.9	0.2	0.5				0.4	0.0	0.2
Confidence Interval (95%)				0.6 – 1.3	0.0 – 0.3	0.3 – 0.7				0.1 – 0.7	0.0 – 0.0	0.1 – 0.3
Lifetime Risk				1 in 1451	1 in 8041	1 in 2509				1 in 5,102	N/A	1 in 10,418
PYLL										35	0	35
% of all cancers				0.3	0.1	0.2				0.4	0.0	0.2
Trend 2013–2017 (per annum)				0.3%	-2.2%	-0.1%				-6.6%	-2.4%	-5.2%

Table A2.71 – Leukaemias NOS

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	1	0	1	1.9	0.0	0.9	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
55–59	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
60–64	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
65–69	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
70–74	1	0	1	2.7	0.0	1.3	0	0	0	0.0	0.0	0.0
75–79	1	0	1	3.9	0.0	1.8	1	0	1	3.9	0.0	1.8
80–84	2	0	2	11.4	0.0	5.1	1	0	1	5.7	0.0	2.5
85+	0	2	2	0.0	7.2	4.5	1	3	4	6.1	10.7	9.0
Total/Crude rate	5	2	7	0.6	0.2	0.4	3	3	6	0.4	0.3	0.3
AS Rate (Aust)				0.5	0.1	0.3				0.3	0.2	0.3
Confidence Interval (95%)				0.1 – 1.0	0.0 – 0.3	0.1 – 0.6				0.0 – 0.7	0.0 – 0.4	0.1 – 0.5
AS Rate (World)				0.3	0.0	0.2				0.1	0.1	0.1
Confidence Interval (95%)				0.1 – 0.6	0.0 – 0.1	0.1 – 0.3				0.0 – 0.3	0.0 – 0.1	0.0 – 0.2
Lifetime Risk				1 in 4388	N/A	1 in 8959				N/A	N/A	N/A
PYLL										0	0	0
% of all cancers				0.1	0.0	0.1				0.1	0.2	0.2
Trend 2013–2017 (per annum)				27.7%	-11.1%	3.5%				0.8%	21.5%	8.2%

Table A2.72 – Cancer of the Lip, and skin of lip (non-melanoma)

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	3	0	3	5.2	0.0	2.6	0	0	0	0.0	0.0	0.0
35–39	5	0	5	9.4	0.0	4.7	0	0	0	0.0	0.0	0.0
40–44	6	0	6	11.3	0.0	5.7	0	0	0	0.0	0.0	0.0
45–49	1	0	1	1.8	0.0	0.9	0	0	0	0.0	0.0	0.0
50–54	7	1	8	12.6	1.8	7.1	0	0	0	0.0	0.0	0.0
55–59	9	1	10	16.2	1.7	8.8	0	0	0	0.0	0.0	0.0
60–64	4	2	6	8.0	3.8	5.8	0	1	1	0.0	1.9	1.0
65–69	8	4	12	17.4	8.2	12.7	1	0	1	2.2	0.0	1.1
70–74	9	4	13	24.1	9.9	16.8	0	0	0	0.0	0.0	0.0
75–79	6	4	10	23.4	13.6	18.2	0	1	1	0.0	3.4	1.8
80–84	5	7	12	28.4	32.0	30.4	0	0	0	0.0	0.0	0.0
85+	6	5	11	36.5	17.9	24.8	0	0	0	0.0	0.0	0.0
Total/Crude rate	69	28	97	8.1	3.2	5.6	1	2	3	0.1	0.2	0.2
AS Rate (Aust)				7.5	2.4	4.9				0.1	0.2	0.1
Confidence Interval (95%)				5.7 – 9.3	1.5 – 3.3	3.9 – 5.9				0.0 – 0.3	0.0 – 0.5	0.0 – 0.3
AS Rate (World)				5.5	1.4	3.4				0.1	0.1	0.1
Confidence Interval (95%)				4.3 – 6.8	0.9 – 1.9	2.8 – 4.1				0.0 – 0.2	0.0 – 0.3	0.0 – 0.2
Lifetime Risk				1 in 189	1 in 787	1 in 308				1 in 9,219	1 in 10,560	1 in 9,859
PYLL										8	13	20
% of all cancers				1.2	0.6	0.9				0.0	0.1	0.1
Trend 2013–2017 (per annum)				-9.0%	-13.8%	-10.5%				127.8%	96.7%	89.1%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.73 – Melanoma of lip												
South Australia												
Year – 2017												
	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
55–59	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
60–64	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
65–69	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
70–74	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
75–79	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
80–84	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
85+	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
Total/Crude rate	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
AS Rate (Aust)				0.0	0.0	0.0				0.0	0.0	0.0
Confidence Interval (95%)				0.0 – 0.0	0.0 – 0.0	0.0 – 0.0				0.0 – 0.0	0.0 – 0.0	0.0 – 0.0
AS Rate (World)				0.0	0.0	0.0				0.0	0.0	0.0
Confidence Interval (95%)				0.0 – 0.0	0.0 – 0.0	0.0 – 0.0				0.0 – 0.0	0.0 – 0.0	0.0 – 0.0
Lifetime Risk				N/A	N/A	N/A				N/A	N/A	N/A
PYLL										0	0	0
% of all cancers				0.0	0.0	0.0				0.0	0.0	0.0
Trend 2013–2017 (per annum)				-16.7%	0.0%	-0.4%				0.0%	0.0%	0.0%

Table A2.74 – Melanoma of eyelid, including canthus												
South Australia												
Year – 2017												
	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
55–59	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
60–64	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
65–69	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
70–74	1	1	2	2.7	2.5	2.6	0	0	0	0.0	0.0	0.0
75–79	0	1	1	0.0	3.4	1.8	0	0	0	0.0	0.0	0.0
80–84	1	0	1	5.7	0.0	2.5	0	1	1	0.0	4.6	2.5
85+	0	2	2	0.0	7.2	4.5	0	0	0	0.0	0.0	0.0
Total/Crude rate	2	4	6	0.2	0.5	0.3	0	1	1	0.0	0.1	0.1
AS Rate (Aust)				0.2	0.3	0.3				0.0	0.1	0.1
Confidence Interval (95%)				0.0 – 0.5	0.0 – 0.6	0.1 – 0.5				0.0 – 0.0	0.0 – 0.3	0.0 – 0.1
AS Rate (World)				0.1	0.1	0.1				0.0	0.0	0.0
Confidence Interval (95%)				0.0 – 0.2	0.0 – 0.3	0.0 – 0.2				0.0 – 0.0	0.0 – 0.1	0.0 – 0.0
Lifetime Risk				1 in 7480	1 in 8041	1 in 7761				N/A	N/A	N/A
PYLL										0	0	0
% of all cancers				0.0	0.1	0.1				0.0	0.1	0.0
Trend 2013–2017 (per annum)				63.7%	3.1%	15.6%				0.0%	undefined	undefined

Table A2.75 – Melanoma of ear												
South Australia												
Year – 2017												
	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	1	0	1	1.7	0.0	0.9	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	1	0	1	1.9	0.0	0.9	0	0	0	0.0	0.0	0.0
45–49	1	1	2	1.8	1.7	1.7	0	1	1	0.0	1.7	0.9
50–54	1	1	2	1.8	1.8	1.8	0	0	0	0.0	0.0	0.0
55–59	1	0	1	1.8	0.0	0.9	0	0	0	0.0	0.0	0.0
60–64	0	2	2	0.0	3.8	1.9	0	0	0	0.0	0.0	0.0
65–69	3	1	4	6.5	2.1	4.2	0	0	0	0.0	0.0	0.0
70–74	3	0	3	8.0	0.0	3.9	2	0	2	5.3	0.0	2.6
75–79	1	0	1	3.9	0.0	1.8	0	0	0	0.0	0.0	0.0
80–84	3	1	4	17.0	4.6	10.1	0	0	0	0.0	0.0	0.0
85+	1	0	1	6.1	0.0	2.3	0	0	0	0.0	0.0	0.0
Total/Crude rate	16	6	22	1.9	0.7	1.3	2	1	3	0.2	0.1	0.2
AS Rate (Aust)				1.7	0.6	1.1				0.2	0.1	0.1
Confidence Interval (95%)				0.9 – 2.5	0.1 – 1.1	0.6 – 1.6				0.0 – 0.4	0.0 – 0.4	0.0 – 0.3
AS Rate (World)				1.2	0.4	0.8				0.1	0.1	0.1
Confidence Interval (95%)				0.6 – 1.7	0.1 – 0.8	0.5 – 1.1				0.0 – 0.3	0.0 – 0.3	0.0 – 0.2
Lifetime Risk				1 in 852	1 in 2149	1 in 1232				1 in 3,740	1 in 11,707	1 in 5,811
PYLL										5	28	33
% of all cancers				0.3	0.1	0.2				0.1	0.1	0.1
Trend 2013–2017 (per annum)				-9.2%	-4.2%	-8.2%				-5.5%	197.6%	10.7%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.76 – Melanoma of other and unspecified parts of face												
South Australia												
Year – 2017												
	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	1	0	1	1.7	0.0	0.9	0	0	0	0.0	0.0	0.0
30–34	1	1	2	1.7	1.7	1.7	0	0	0	0.0	0.0	0.0
35–39	2	0	2	3.8	0.0	1.9	0	0	0	0.0	0.0	0.0
40–44	0	2	2	0.0	3.8	1.9	0	0	0	0.0	0.0	0.0
45–49	1	1	2	1.8	1.7	1.7	0	0	0	0.0	0.0	0.0
50–54	1	2	3	1.8	3.5	2.7	0	0	0	0.0	0.0	0.0
55–59	2	0	2	3.6	0.0	1.8	0	0	0	0.0	0.0	0.0
60–64	4	5	9	8.0	9.5	8.8	0	0	0	0.0	0.0	0.0
65–69	6	2	8	13.0	4.1	8.4	1	0	1	2.2	0.0	1.1
70–74	9	4	13	24.1	9.9	16.8	2	0	2	5.3	0.0	2.6
75–79	6	6	12	23.4	20.4	21.8	0	0	0	0.0	0.0	0.0
80–84	10	5	15	56.8	22.9	38.0	2	0	2	11.4	0.0	5.1
85+	11	10	21	66.9	35.8	47.3	1	1	2	6.1	3.6	4.5
Total/Crude rate	54	38	92	6.3	4.4	5.3	6	1	7	0.7	0.1	0.4
AS Rate (Aust)				5.7	3.4	4.4				0.6	0.1	0.3
Confidence Interval (95%)				4.1 – 7.2	2.3 – 4.5	3.5 – 5.3				0.1 – 1.1	0.0 – 0.2	0.1 – 0.5
AS Rate (World)				3.4	2.1	2.7				0.3	0.0	0.2
Confidence Interval (95%)				2.5 – 4.2	1.4 – 2.8	2.1 – 3.2				0.1 – 0.5	0.0 – 0.1	0.1 – 0.3
Lifetime Risk				1 in 337	1 in 584	1 in 431				1 in 2,661	N/A	1 in 5,506
PYLL										13	0	13
% of all cancers				0.9	0.8	0.9				0.3	0.1	0.2
Trend 2013–2017 (per annum)				4.2%	7.3%	5.7%				-13.0%	-26.3%	-19.2%

Table A2.77 – Melanoma of scalp and neck												
South Australia												
Year – 2017												
	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	1	0	1	1.7	0.0	0.9	0	0	0	0.0	0.0	0.0
30–34	1	0	1	1.7	0.0	0.9	0	0	0	0.0	0.0	0.0
35–39	4	0	4	7.6	0.0	3.8	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	1	2	3	1.8	3.4	2.6	0	0	0	0.0	0.0	0.0
50–54	2	1	3	3.6	1.8	2.7	0	0	0	0.0	0.0	0.0
55–59	1	0	1	1.8	0.0	0.9	0	0	0	0.0	0.0	0.0
60–64	4	0	4	8.0	0.0	3.9	0	0	0	0.0	0.0	0.0
65–69	8	7	15	17.4	14.4	15.8	2	0	2	4.3	0.0	2.1
70–74	7	4	11	18.7	9.9	14.2	1	0	1	2.7	0.0	1.3
75–79	3	1	4	11.7	3.4	7.3	0	0	0	0.0	0.0	0.0
80–84	4	0	4	22.7	0.0	10.1	1	0	1	5.7	0.0	2.5
85+	7	2	9	42.5	7.2	20.3	2	2	4	12.2	7.2	9.0
Total/Crude rate	43	17	60	5.0	1.9	3.5	6	2	8	0.7	0.2	0.5
AS Rate (Aust)				4.6	1.5	2.9				0.6	0.1	0.3
Confidence Interval (95%)				3.2 – 5.9	0.8 – 2.2	2.2 – 3.6				0.1 – 1.1	0.0 – 0.3	0.1 – 0.6
AS Rate (World)				3.1	1.0	2.0				0.3	0.0	0.2
Confidence Interval (95%)				2.2 – 4.0	0.5 – 1.6	1.5 – 2.5				0.1 – 0.5	0.0 – 0.1	0.1 – 0.3
Lifetime Risk				1 in 322	1 in 678	1 in 440				1 in 2,852	N/A	1 in 5,885
PYLL										18	0	18
% of all cancers				0.8	0.4	0.6				0.3	0.1	0.2
Trend 2013–2017 (per annum)				-8.6%	4.6%	-5.7%				-4.8%	-20.5%	-9.4%

Table A2.78 – Melanoma of trunk												
South Australia												
Year – 2017												
	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	2	2	4	3.5	3.4	3.4	0	0	0	0.0	0.0	0.0
35–39	3	3	6	5.7	5.6	5.6	0	0	0	0.0	0.0	0.0
40–44	7	6	13	13.2	11.3	12.3	1	0	1	1.9	0.0	0.9
45–49	14	6	20	24.5	10.3	17.3	0	0	0	0.0	0.0	0.0
50–54	17	4	21	30.7	7.0	18.7	0	0	0	0.0	0.0	0.0
55–59	22	5	27	39.5	8.7	23.8	0	0	0	0.0	0.0	0.0
60–64	18	10	28	36.1	18.9	27.3	1	0	1	2.0	0.0	1.0
65–69	28	9	37	60.7	18.5	39.0	2	0	2	4.3	0.0	2.1
70–74	16	13	29	42.8	32.3	37.4	3	0	3	8.0	0.0	3.9
75–79	11	8	19	43.0	27.2	34.5	3	0	3	11.7	0.0	5.5
80–84	13	3	16	73.8	13.7	40.5	2	1	3	11.4	4.6	7.6
85+	9	5	14	54.7	17.9	31.6	2	0	2	12.2	0.0	4.5
Total/Crude rate	160	74	234	18.8	8.5	13.6	14	1	15	1.6	0.1	0.9
AS Rate (Aust)				17.2	7.3	12.0				1.4	0.1	0.7
Confidence Interval (95%)				14.5 – 19.9	5.6 – 9.0	10.4 – 13.6				0.7 – 2.2	0.0 – 0.3	0.3 – 1.1
AS Rate (World)				12.2	5.4	8.7				0.9	0.0	0.4
Confidence Interval (95%)				10.4 – 14.1	4.2 – 6.6	7.6 – 9.8				0.4 – 1.3	0.0 – 0.1	0.2 – 0.6
Lifetime Risk				1 in 78	1 in 173	1 in 109				1 in 1,231	N/A	1 in 2,534
PYLL										68	0	68
% of all cancers				2.8	1.5	2.2				0.7	0.1	0.4
Trend 2013–2017 (per annum)				-0.4%	5.5%	1.4%				-3.3%	8.0%	-2.1%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.79 – Melanoma of upper limb, including shoulder

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	1	1	0.0	1.8	0.9	0	0	0	0.0	0.0	0.0
25–29	1	1	2	1.7	1.7	1.7	0	0	0	0.0	0.0	0.0
30–34	3	1	4	5.2	1.7	3.4	0	0	0	0.0	0.0	0.0
35–39	1	3	4	1.9	5.6	3.8	0	0	0	0.0	0.0	0.0
40–44	4	5	9	7.5	9.5	8.5	0	0	0	0.0	0.0	0.0
45–49	5	6	11	8.8	10.3	9.5	0	0	0	0.0	0.0	0.0
50–54	6	9	15	10.8	15.8	13.4	0	0	0	0.0	0.0	0.0
55–59	8	7	15	14.4	12.1	13.2	0	0	0	0.0	0.0	0.0
60–64	13	15	28	26.0	28.4	27.3	1	0	1	2.0	0.0	1.0
65–69	22	12	34	47.7	24.6	35.9	1	1	2	2.2	2.1	2.1
70–74	17	11	28	45.5	27.4	36.1	0	0	0	0.0	0.0	0.0
75–79	18	10	28	70.3	34.0	50.9	1	0	1	3.9	0.0	1.8
80–84	12	7	19	68.1	32.0	48.1	1	0	1	5.7	0.0	2.5
85+	10	12	22	60.8	43.0	49.6	1	0	1	6.1	0.0	2.3
Total/Crude rate	120	100	220	14.1	11.5	12.8	5	1	6	0.6	0.1	0.3
AS Rate (Aust)				12.5	9.7	11.0				0.5	0.1	0.3
Confidence Interval (95%)				10.2 – 14.8	7.8 – 11.7	9.5 – 12.4				0.1 – 1.0	0.0 – 0.3	0.1 – 0.5
AS Rate (World)				8.4	6.9	7.6				0.3	0.1	0.2
Confidence Interval (95%)				6.9 – 9.8	5.5 – 8.3	6.6 – 8.6				0.1 – 0.5	0.0 – 0.2	0.0 – 0.3
Lifetime Risk				1 in 118	1 in 144	1 in 131				1 in 4,793	1 in 9,737	1 in 6,486
PYLL										20	8	28
% of all cancers				2.1	2.1	2.1				0.2	0.1	0.2
Trend 2013–2017 (per annum)				3.4%	-0.1%	1.6%				-16.2%	-8.7%	-14.4%

Table A2.80 – Melanoma of lower limb, including hip

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	1	0	1	1.7	0.0	0.9	0	0	0	0.0	0.0	0.0
25–29	0	1	1	0.0	1.7	0.9	0	0	0	0.0	0.0	0.0
30–34	3	2	5	5.2	3.4	4.3	0	0	0	0.0	0.0	0.0
35–39	2	5	7	3.8	9.4	6.6	0	0	0	0.0	0.0	0.0
40–44	1	1	2	1.9	1.9	1.9	0	0	0	0.0	0.0	0.0
45–49	3	7	10	5.3	12.0	8.6	0	0	0	0.0	0.0	0.0
50–54	3	8	11	5.4	14.1	9.8	0	0	0	0.0	0.0	0.0
55–59	8	10	18	14.4	17.3	15.9	0	0	0	0.0	0.0	0.0
60–64	5	8	13	10.0	15.2	12.7	1	1	2	2.0	1.9	1.9
65–69	5	7	12	10.8	14.4	12.7	2	1	3	4.3	2.1	3.2
70–74	10	12	22	26.7	29.8	28.4	0	0	0	0.0	0.0	0.0
75–79	6	11	17	23.4	37.4	30.9	1	1	2	3.9	3.4	3.6
80–84	4	6	10	22.7	27.4	25.3	1	0	1	5.7	0.0	2.5
85+	1	3	4	6.1	10.7	9.0	2	3	5	12.2	10.7	11.3
Total/Crude rate	52	81	133	6.1	9.3	7.7	7	6	13	0.8	0.7	0.8
AS Rate (Aust)				5.5	8.1	6.8				0.7	0.5	0.6
Confidence Interval (95%)				4.0 – 7.0	6.3 – 9.8	5.6 – 8.0				0.2 – 1.3	0.1 – 0.9	0.3 – 0.9
AS Rate (World)				4.1	6.0	5.1				0.4	0.2	0.3
Confidence Interval (95%)				3.0 – 5.1	4.7 – 7.3	4.2 – 5.9				0.1 – 0.7	0.0 – 0.5	0.1 – 0.5
Lifetime Risk				1 in 235	1 in 168	1 in 196				1 in 3,154	1 in 5,066	1 in 3,912
PYLL										28	20	48
% of all cancers				0.9	1.7	1.3				0.3	0.4	0.4
Trend 2013–2017 (per annum)				-4.2%	-3.5%	-3.8%				-6.2%	-14.1%	-11.2%

Table A2.81 – Melanoma of other site

South Australia Year – 2017	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
55–59	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
60–64	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
65–69	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
70–74	1	0	1	2.7	0.0	1.3	0	0	0	0.0	0.0	0.0
75–79	1	0	1	3.9	0.0	1.8	0	0	0	0.0	0.0	0.0
80–84	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
85+	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
Total/Crude rate	2	0	2	0.2	0.0	0.1	0	0	0	0.0	0.0	0.0
AS Rate (Aust)				0.2	0.0	0.1				0.0	0.0	0.0
Confidence Interval (95%)				0.0 – 0.4	0.0 – 0.0	0.0 – 0.2				0.0 – 0.0	0.0 – 0.0	0.0 – 0.0
AS Rate (World)				0.1	0.0	0.1				0.0	0.0	0.0
Confidence Interval (95%)				0.0 – 0.2	0.0 – 0.0	0.0 – 0.1				0.0 – 0.0	0.0 – 0.0	0.0 – 0.0
Lifetime Risk				1 in 7480	N/A	1 in 15521				N/A	N/A	N/A
PYLL										0	0	0
% of all cancers				0.0	0.0	0.0				0.0	0.0	0.0
Trend 2013–2017 (per annum)				279.1%	0.0%	239.6%				0.0%	0.0%	0.0%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.82 – Melanoma, site unspecified												
South Australia												
Year – 2017												
	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	1	1	0.0	1.9	0.9	0	0	0	0.0	0.0	0.0
45–49	0	1	1	0.0	1.7	0.9	1	0	1	1.8	0.0	0.9
50–54	0	1	1	0.0	1.8	0.9	0	0	0	0.0	0.0	0.0
55–59	1	0	1	1.8	0.0	0.9	0	0	0	0.0	0.0	0.0
60–64	0	1	1	0.0	1.9	1.0	0	0	0	0.0	0.0	0.0
65–69	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
70–74	0	0	0	0.0	0.0	0.0	2	0	2	5.3	0.0	2.6
75–79	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
80–84	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
85+	0	1	1	0.0	3.6	2.3	0	0	0	0.0	0.0	0.0
Total/Crude rate	1	5	6	0.1	0.6	0.3	3	0	3	0.4	0.0	0.2
AS Rate (Aust)				0.1	0.5	0.3				0.3	0.0	0.1
Confidence Interval (95%)				0.0 – 0.3	0.1 – 1.0	0.1 – 0.6				0.0 – 0.6	0.0 – 0.0	0.0 – 0.3
AS Rate (World)				0.1	0.4	0.3				0.2	0.0	0.1
Confidence Interval (95%)				0.0 – 0.2	0.0 – 0.8	0.0 – 0.5				0.0 – 0.5	0.0 – 0.0	0.0 – 0.2
Lifetime Risk				1 in 11131	1 in 2758	1 in 4392				1 in 2,818	N/A	1 in 5,811
PYLL										33	0	33
% of all cancers				0.0	0.1	0.1				0.1	0.0	0.1
Trend 2013–2017 (per annum)				-21.6%	20.6%	-11.4%				-20.7%	-18.5%	-20.3%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Appendix 3 Quality Measures

Table A3.1 (males) and A3.2 (females) display a series of commonly used data quality indices as defined by the Cancer Incidence in Five Continents Vol. X.

Table A3.1 Indices of data quality – male cancers, 2017

MALES							
ICD-O-3	Site	Inc	Mort	M/I%	HV%	MV%	DCO%
C00	Lip	39	0	0	100	100	0.0
C01 C02	Tongue	46	8	17	98	100	0.0
C09 C10	Oropharynx	52	12	23	88	92	8.3
C16	Stomach	128	70	55	95	98	0.0
C18-C20	Colon and rectum	605	224	37	96	96	0.9
C22	Liver and intrahepatic bile ducts	122	86	70	52	53	4.7
C23 C24	Gallbladder and bile ducts	33	27	82	73	82	3.7
C25	Pancreas	132	108	82	62	78	4.6
C33 C34	Trachea, bronchus and lung	524	430	82	68	85	2.3
C38	Heart, mediastinum and pleura	48	45	94	73	85	0.0
C44._ + M872-879	Melanoma of skin	450	43	10	100	100	0.0
C61.9	Prostate	1,635	244	15	98	98	0.8
C62	Testis	58	3	5	100	100	0.0
C64	Kidney	206	44	21	89	90	9.1
C67	Bladder	202	78	39	92	94	2.6
C71	Brain	89	61	69	78	78	0.0
C73	Thyroid gland	53	6	11	98	100	0.0
C26 C39 C42 C76 C77 C80	Other and unspecified primary	155	114	74	69	76	8.8
M9591 9597 967-972 9735 9737 9738	Non-Hodgkin lymphoma	289	74	26	84	91	1.4
M965-966	Hodgkin lymphoma	28	5	18	100	100	0.0
M9731-9734	Multiple myeloma/Plasma cell tumours	95	51	54	81	95	2.0
M980-994	All leukaemias	181	87	48	56	71	0.0
M998 999	Myelodysplastic syndromes	58	41	71	76	93	0.0
All cancers		5,733	2,038	36	88	92	2.2

Inc: incidence, Mort: mortality, M/I%: Mortality incidence ratio, HV%: histologic verification proportion: MV%: microscopic verification proportion, DCO%: Death certificate only notification proportion

Table A3.2 Indices of data quality – female cancers, 2017

FEMALES							
ICD-O-3	Site	Inc	Mort	M/I%	HV%	MV%	DCO%
C00	Lip	12	0	0	100	100	0.0
C01 C02	Tongue	31	7	23	97	97	0.0
C09 C10	Oropharynx	9	2	22	89	100	0.0
C16	Stomach	56	40	71	89	89	0.0
C18-C20	Colon and rectum	576	183	32	95	95	2.2
C22	Liver and intrahepatic bile ducts	48	36	75	48	48	5.6
C23 C24	Gallbladder and bile ducts	50	40	80	64	72	0.0
C25	Pancreas	144	131	91	59	74	0.8
C33 C34	Trachea, bronchus and lung	470	306	65	66	82	4.6
C38	Heart, mediastinum and pleura	11	9	82	82	82	0.0
C44._ + M872-879	Melanoma of skin	325	13	4	100	100	0.0
C50	Female breast	1,396	208	15	99	99	2.9
C51	Vulva	37	7	19	97	97	0.0
C53	Cervix uteri	63	26	41	94	97	3.8
C54 C55	Body of the uterus	229	50	22	97	98	0.0
C56.9	Ovary	96	65	68	78	91	1.5
C64	Kidney	91	26	29	19	21	0.0
C67	Bladder	56	32	57	89	91	0.0
C71	Brain	60	48	80	80	80	2.1
C73	Thyroid gland	111	10	9	94	98	0.0
C26 C39 C42 C76 C77 C80	Other and unspecified primary	137	106	77	58	65	0.0
M9591 9597 967-972 9735 9737 9738	Non-Hodgkin lymphoma	179	64	36	80	86	0.0
M965-966	Hodgkin lymphoma	19	1	5	100	100	0.0
M9731-9734	Multiple myeloma/Plasma cell tumours	69	36	52	86	93	0.0
M980-994	All leukaemias	112	54	48	45	55	1.9
M998 999	Myelodysplastic syndromes	39	24	62	72	92	0.0
All cancers		4,781	1,675	35	87	91	3.6

Inc: incidence, Mort: mortality, M/I%: Mortality incidence ratio, HV%: histologic verification proportion: MV%: microscopic verification proportion, DCO%: Death certificate only notification proportion

Mortality-to-Incidence (M:I) ratio

Compares the number of deaths due to a specific type of cancer over a specific period of time with the number of new cases of that type of cancer registered during the same period. M:I values greater than expected lead to a suspicion of incompleteness (incident cases missed). Cancers with a higher M:I ratio tend to have a poorer survival.

The overall M:I ratio for males was 36% and for females was 35%.

Death Certificate Only (DCO%)

Cases for which no other information than a death certificate has been used, despite a thorough trace-back procedure. An elevated DCO% is indicative of inadequate case finding procedures.

The overall DCO% for males was 2.2% and for females was 3.6%.

Microscopic verification (MV%)

The percentage of cases diagnosed on the basis of microscopic verification. This includes all histologically verified cases, in addition to cases where cytology specimens were examined and also haematological malignancies - where the diagnosis was made on a full blood count (without a bone marrow biopsy).

The overall MV% for males was 92% and for females was 91%.

Histologic verification (HV%)

The percentage of cases diagnosed on the basis of histologic verification.

The overall HV% for males was 88% and for females was 87%.

For more information

South Australian Cancer Registry
Wellbeing SA
PO Box 6 Rundle Mall, Adelaide
South Australia 5000 Australia
Telephone: (08) 8226 0787
www.sahealth.sa.gov.au



<https://creativecommons.org/licenses>



Government
of South Australia